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 5 
Abstract	
	
	
Osteopontin	 (OPN)	 has	 been	 reported	 as	 one	 of	 the	 most	 overexpressed	
molecules	in	PTC.	OPN	is	a	secreted	extracellular	matrix	(ECM)	protein	that	is	encoded	
by	the	highly	conserved	SPP1	gene;	its	expression	levels	were	reported	to	be	increased	
in	several	types	of	human	cancers,	such	as	prostate	carcinoma,	melanoma,	and	ovary,	
lung	and	gastric	carcinoma.	OPN	primary	transcript	is	subjected	to	alternative	splicing,	
generating	three	OPN	splicing	variants	(OPN-SV):	the	full-length	OPNa	and	the	shorter	
variants	OPNb	and	OPNc	(lacking	exons	5	and	4,	respectively).	The	three	OPN-SV	have	
been	 shown	 to	 play	 specific	 roles	 in	 different	 types	 of	 tumours	 and,	 to	 date,	 their	
functions	 in	 TC	 remain	 to	 be	 determined.	 Thyroid	 cancer	 (TC)	 is	 the	most	 prevalent	
endocrine	 malignancy,	 and	 the	 fifth	 most	 frequent	 cancer	 in	 women.	 Thyroid	 is	
composed	 by	 follicular	 cells	 and	 by	 parafollicular	 or	 C-cells.	 The	majority	 of	 TCs	 are	
derived	 from	 follicular	 cells,	 being	 differentiated	 thyroid	 cancer	 (DTC),	 comprising	
papillary	 thyroid	 cancer	 (PTC)	 and	 follicular	 thyroid	 cancer	 (FTC),	 the	most	 common	
subtypes	 and	 accounting	 for	 90–95%	 of	 all	 cases.	 Parafollicular	 cells	 give	 rise	 to	
medullary	thyroid	cancer	(MTC).	TCs	frequently	present	aberrant	expression	of	different	
gene	products	that	may	be	related	to	cancer	progression.	
In	the	first	part	we	analysed	the	expression	profile	of	total	OPN	and	OPN-SV	in	
TC	 derived	 from	 follicular	 cells,	 the	 correlation	 of	 such	 expression	 with	
clinicopathological	 and	 molecular	 features,	 and	 the	 functional	 roles	 of	 OPN-SV	 in	
follicular	tumour-derived	cells.	We	showed	that	tOPN	and	OPNa	are	overexpressed	in	
classic	papillary	thyroid	carcinoma	(cPTC)	in	comparison	to	adjacent	thyroid,	adenoma	
and	 follicular	 variant	 of	 papillary	 thyroid	 carcinoma	 (fvPTC)	 tissues.	 In	 cPTC,	 OPNa	
overexpression	 is	 associated	with	 larger	 tumour	 size,	 vascular	 invasion,	 extrathyroid	
extension	 and	BRAFV600E	mutation.	We	 found	 that	 TC	 cell	 lines	overexpressing	OPNa	
exhibited	increased	proliferation,	migration,	motility	and	in	vivo	invasion.	Conditioned	
medium	 secreted	 from	 cells	 overexpressing	 OPNa	 induce	 MMP2	 and	 MMP9	
metalloproteinases	activity.	Taking	together	all	the	data	we	suggested	that	OPNa	serve	
as	a	cancer	promoter	factor	in	follicular	cell	derived	via	the	regulation	of	MMPs	activity.	
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In	 the	 second	part	we	explored	 the	 contributions	of	OPN	 in	 the	 formation	of	
psammoma	 bodies	 (PB).	 PB	 are	 concentric	 lamellated	 calcified	 structures,	 observed	
almost	 exclusively	 in	 cPTCs	 (about	 50%	 of	 all	 PTC	 cases),	 their	 clinicopathological	
significance	remains	unclarified.	The	presence	of	PB	 in	PTC	has	been	associated	with	
younger	patients	and	lymph	node	metastasis.	We	found	that	overexpression	of	OPNa	
was	 significantly	 associated	 with	 presence	 of	 PB	 in	 PTC	 samples.	 Fitting	 with	 these	
results	we	observed	furthermore	that	OPNa	overexpression	promotes	calcification	and	
substantial	collagen	synthesis	in	thyroid	cancer	cell	lines.	
In	the	last	part	of	the	thesis	we	focused	on	exploring	the	expression	profile	of	
total	OPN	(all	variants)	and	OPN-SV	in	MTC	(tumours	derived	from	parafollicular	cells)	
and	we	evaluated	if	OPN	expression	was	associated	with	clinicopathological	data	and	
we	also	assessed	the	role	of	OPN-SV	in	a	parafollicular-	tumour	derived	cell	line	(TT).	We	
observed	that	OPN	 is	expressed	 in	MTCs	and	that	such	expression	 is	associated	with	
smaller	 tumour	 size,	 less	 invasive	 features	 and	 overexpression	 of	 nuclear	 PTEN.	We	
reported	for	the	first	time	the	OPN	expression	in	the	specialised	neuroendocrine	cells	of	
the	thyroid,	and	showed	that	such	expression	was	more	marked	in	normal	C-cell	and	
hyperplastic	C-cells	that	in	MTCs	thus	supporting	this	assumption	that	OPNa	may	play	a	
role	 in	 C-cell	 differentiation.	 In	 accordance	 with	 the	 data	 obtained	 in	 the	
clinicopathological	study	we	observed	that	TT	cells	overexpressing	OPNa	variant	show	
reduced	 proliferation	 and	 viability,	 suggesting	 that	 OPN	 may	 contribute	 to	 prevent	
tumour	progression.		
In	conclusion,	in	this	thesis	we	explore	some	of	the	roles	that	the	matricellular	
protein	 OPN	 can	 have	 in	 endocrine	 and	 neuroendocrine	 thyroid	 cells	 and	 their	
respective	 tumours.	We	show	that	OPNa	 is	 the	most	prominent	OPN	variant	 in	both	
endocrine	and	neuroendocrine	 tumour	models.	We	also	 show	that	OPNa	appears	 to	
play	opposite	role	in	the	two	models:	in	parafollicular-cell	derived	tumours	OPNa	acts	
as	a	differentiation	marker	whereas	 in	 follicular-cell	derived	 tumours	OPNa	acts	as	a	
contributor	for	cancer	progression.	We	also	show	that	OPNa	may	have	a	strong	effect	
in	 the	 calcification	 process	 in	 PTCs,	 participating	 on	 PB	 formation.	 Summing	 of,	 our	
findings	highlight	OPNa	variant	as	a	major	TC	biomarker,	and	provide	an	interesting	basis	
for	exploring	several	possibilities	with	regard	to	the	etiopathogenesis	and	therapy	of	the	
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two	main	types	of	TC.	From	a	practical	standpoint	our	findings	support	the	assumption	
that	OPNa	may	serve	as	a	therapy	target	in	PTC.		
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Resumo	
	
A OPN é uma proteína da matriz extracelular segregada por vários tipos celulares 
e codificada por um gene altamente conservado (SPP1); os seus níveis de expressão estão 
aumentados em vários tipos de cancros humanos, tais como os carcinomas da próstata, 
ovário, pulmão e estomago e o melanoma. O transcrito primário da OPN é submetido a 
splicing alternativo, gerando três variantes da OPN (OPN-SV): OPNa que corresponde à 
variante completa, e as variantes mais curtas OPNb e OPNc que faltam os exãos 5 e 4, 
respetivamente. O carcinoma da tireoide (CT) é a neoplasia maligna endócrina mais 
prevalente, e o quinto cancro mais frequente nas mulheres. A tireoide é composta por 
células parafoliculares, ou células C, e por células foliculares. A maioria dos CTs são 
derivados das células foliculares, sendo o carcinoma diferenciado da tireoide (CDT), que 
compreende o carcinoma papilar (CPT) e o carcinoma folicular (CFT), os subtipos mais 
comuns correspondendo a 90-95% de todos os casos. As células parafoliculares dão 
origem ao carcinoma medular da tireoide (CMT). CTs apresentam frequentemente 
expressão aberrante –normalmente sobre-expressão- de produtos de genes diferentes, 
havendo evidencia de que essas alterações de expressão podem estar relacionadas com a 
progressão dos cancros. A osteopontina (OPN) foi apontada como uma das moléculas 
mais sobre-expressas em CPT. Vários estudos demonstraram que as três OPN-SV podem 
desempenhar funções específicas em diferentes tipos de tumores, mas eram 
desconhecidas as suas funções em CTs quando esta Tese foi iniciada. 
Na primeira parte desta Tese, analisámos o perfil de expressão da OPN total e das 
OPN-SV em CT derivados de células foliculares, a correlação dessa expressão com 
características clínicas e moleculares, e os papéis funcionais das OPN-SV em linhas 
celulares de origem folicular. Mostrámos que a OPN total e OPNa estão sobre-expressas 
nas formas convencionais do carcinoma papilar da tireoide (cCPT) em comparação com 
a tireoide adjacente, adenoma e variante folicular de carcinoma papilar da tireoide 
(fvCPT). Nos cCPTs, a sobre-expressão da OPNa está associada com tumores maiores, 
invasão vascular, extensão extratireoideia e mutação do BRAFV600E. Mostrámos também 
que linhas celulares de CT com sobre-expressão de OPNa tinham proliferação, migração, 
motilidade e invasão in vivo substancialmente aumentadas. O meio condicionado por 
células de linhas que sobre-expressam a OPNa e a segregam induzem atividade 
aumentada das metaloproteinases MMP2 e MMP9. Em conjunto os nossos resultados 
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sugerem que a OPNa se comporta como um promotor neoplásico nos carcinomas 
derivados de células foliculares através da uma ação em MMPs. 
Na segunda parte explorámos as contribuições da OPN na formação dos corpos 
psamomatosos (PB). Os PB são estruturas calcificadas lamelares concêntricas observadas 
quase exclusivamente nas formas clássicas de CPTs. Embora sejam encontrados em cerca 
de 50% de todos os casos de CPTs, o seu significado clínico-patológico permanece não 
esclarecido. A presença de PB em CPTs foi associada a doentes mais jovens e a 
metástases em gânglios linfáticos. Observamos que a sobre-expressão de transcritos da 
OPNa se associava significativamente à presença de PB em amostras de CPTs. 
Demonstrámos também que a OPNa tem uma forte capacidade para promover a síntese 
de colagénio e a calcificação em linhas celulares de carcinoma da tireoide. 
Na última parte desta Tese, explorámos o perfil de expressão da OPN total (todas 
as variantes) e das OPN-SV em CMT avaliando as relações dessa expressão com os dados 
clínico-patológicos. Também avaliámos o papel das OPN-SV numa linha celular derivada 
de MTC (TT). Neste trabalho, demonstrámos que a OPN é expressa em CTMs e que essa 
expressão se associa com tumores pequenos, menos invasores e mostrando sobre-
expressão nuclear do PTEN. Mostramos pela primeira vez a expressão da OPN em células 
neuroendócrinas especializados da tireoide (células C) e observamos que essa expressão 
era mais elevada em células C “normais” e células C hiperplásicas do que em MTCs. 
Estes achados lavaram-nos a concluir que a OPNa deverá desempenhar um papel na 
diferenciação das células C. Além disso, mostrámos que as células TT que sobre-
expressam a variante OPNa têm proliferação e viabilidade diminuídas, sugerindo que a 
OPN poderá contribuir para prevenir a progressão dos MTCs. 
Em conclusão, nesta Tese explorámos alguns dos diversos papéis que a proteína 
matricelular OPN desempenha em células de tireoide endócrinas e neuroendócrinas e nos 
tumores deles derivados. Mostrámos que a OPNa é a variante mais proeminente em 
ambos os modelos tumorais MTC e PTC. Além disso, mostrámos que OPNa desempenha 
aparentemente um papel oposto em carcinomas com origem em células C (MTC) e em 
carcinomas com origem em células foliculares (PTC e FTC). Nas células parafoliculares 
a OPNa serve como um marcador de diferenciação enquanto nas células foliculares a 
OPNa parece contribuir para a progressão das neoplasias. Finalmente, demonstrámos que 
a OPNa tem um forte efeito no processo de calcificação em cCPTs, participando na 
formação dos PB. Em resumo, os nossos resultados identificam a variante OPNa como 
um biomarcador de CT, e fornecem uma base interessante para explorar várias 
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possibilidades com relação à etiopatogenia e terapia dos dois principais tipos de CTs. De 
um ponto de vista prático os nossos resultados suportam a hipótese de que a OPNa pode 
servir como um alvo de terapia em CPT. 
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Chapter	1	–	Introduction	
	
	
1.1	Osteopontin	
	
1.1.1	Osteopontin	(OPN)	
	
	
OPN	was	first	 identified	and	described	by	Senger	et	al.	 in	1979,	as	a	secreted	
transformation-specific	phosphoprotein	[1].	Ten	years	later,	OPN	was	rediscovered	by	
molecular	cloning	of	 the	transformation-associated	gene	2ar	 [2].	Together	with	OPN,	
but	independently,	was	identified	a	bone	sialoprotein	(BSP),	as	a	major	sialoprotein	in	
bone	 extracellular	 matrix	 (ECM)	 [3-5].	 Both	 proteins	 were	 initially	 named	 bone	
sialoprotein	1	(BSP	1)	and	bone	sialoprotein	2	(BSP	2)	[3].	The	name	osteopontin	was	
introduced	 to	 reflect	 the	 capacity	 of	 the	 protein	 to	 bridge	 hydroxyapatite	 crystals	
through	RGD	and	polyaspartic	acid	motifs	discovered	 in	the	primary	sequence	of	 the	
protein	[6].	The	term	“osteo”	means	bone	and	the	term	“pontin”	is	a	latin	word	derived	
from	“pons”	that	means	bridge.	Nonetheless,	the	same	protein	was	then	described	as	a	
putative	lymphokine	produced	by	activated	lymphocytes	and	macrophages	and	called	
Eta-1	 (early	T-	 lymphocyte	activation	gene	 I)	 [7],	and	thus	a	more	general	pattern	of	
expression	for	OPN	was	emerging.	Subsequently,	was	introduced	as	an	alternative	name	
“secreted	phosphoprotein”	(SPP1),	to	reflect	a	broader	functional	role	of	this	protein.	
Nevertheless,	 the	name	osteopontin	 has	 largely	 been	 retained,	 and	was	 kept	 as	 the	
nomenclature	used	for	the	human	gene	[8].		
Hence,	OPN	belongs	to	the	SIBLING	family	of	proteins.	SIBLING	(Small	Integrin-
Binding	Ligand	N-linked	Glycoproteins)	proteins	are	a	family	of	glycoproteins	that	are	
encoded	by	a	gene	cluster	on	chromosomes	4	and	5	in	humans	and	mice,	respectively,	
and	play	important	roles	in	mineralization	[9].	
	
	
1.1.2	Structure	and	post-translational	modification	(PTM)	
	
OPN	is	expressed	by	a	single-copy	gene	as	a	34-kDa	nascent	protein	composed	
of	 300	 amino	 acid	 residues.	 Its	molecular	weight	 is	 44	 to	 66	 KDa	 depending	 on	 the	
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species	and	cell	types	[10].	The	human	gene	contains	7	exons,	spanning	1.1kb.	OPN	is	a	
high	negatively	charged	protein,	being	hydrophilic	and	acidic	in	nature.	It	is	also	rich	in	
aspartic	and	glutamic	acid	and	serine,	and	contains	a	polyaspartic	acid	motif,	through	
which	the	protein	can	bind	to	hydroxyapatite	and	calcium	ions,	and	a	RGD	sequence	
which	can	mediate	cell	attachment	[11],	shown	in	Figure	1.		
OPN	contain	distinct	secondary	structure	elements	with	reduced	conformational	
edibility	and	displays	distinct	tertiary	contacts	that	encompass	binding	sites	 for	avb3	
integrin	and	heparin	[12].	Additionally,	OPN	can	be	cleaved	by	thrombin,	exposing	the	
cryptic	C-terminal	a4b1	and	a9b1	integrin-binding	motif	(SVVYGLR)	[13].		
OPN	 is	 extensively	 post-translationally	 modified.	 It	 has	 multiple	 Ser	 and	 Thr	
phosphorylation	sites,	as	well	as	sites	for	N-	and	O-linked	glycosylation.	Thus,	a	variety	
of	phosphorylation,	glycosylation,	sulphation	and	proteolytic	processing	occurs.	These	
modifications	have	significant	effects	on	the	structure	and	biological	properties	of	the	
protein,	generating	different	OPN	functional	variants,	presenting	tissue	specificity	and	
functional	 versatility	 [14,	 15].	 For	 instance,	 normal	 rat	 kidney	 cells	 secrete	 both	
phosphorylated	and	non-phosphorylated	variants	of	OPN,	which	diverge	in	glycosylation	
patterns	and	physiological	properties	 [16].	Phosphorylation	 is	one	of	 the	PTMs	most	
studied	and	has	been	shown	 to	be	very	 important	 for	a	diversity	of	 functions	of	 the	
protein.	Therefore,	Shiraga	et	al.,	[17]	showed	that	the	regulatory	roles	of	OPN	in	normal	
and	pathological	mineralization	are	highly	dependent	on	the	phosphorylation	status	of	
the	 protein.	 Yet,	 dephosphorylation	 of	 OPN	 interfere	 with	 its	 ability	 to	 inhibit	
hydroxyapatite	formation	[18],	whereas	OPN	phosphorylation	is	necessary	for	inhibition	
of	 calcium	 oxalate	 crystallization	 in	 urine	 [19]	 and	 calcification	 of	 vascular	 smooth	
muscle	cells	[20].	OPN	has	also	been	shown	to	promote	trophoblastic	cell	migration	in	a	
process	that	is	dependent	on	protein	phosphorylation	levels	[21].		
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Figure	 1:	 OPN	 molecular	 structure	 and	 interactions.	 OPN	 binds	 to	 integrins,	
transmembrane	and	dimeric	proteins,	consisting	of	alfa	and	beta	subunits.	It	has	several	
cell	 interacting	 domains	 that	 facilitate	 integrin	 binding	 in	 different	 cell	 types:	 an	
arginine–glycine–aspartic	 acid	 (RGD)	 cell	 binding	 sequence,	which	 interacts	with	 cell	
surface	 integrins	 αvß3,	 αvß1,	 αvß5,	 and	 α8ß1;	 a	 serine–valine–valine–tyrosine–
glutamate–leucine–arginine	 (SVVYGLR)-containing	domain,	 located	between	 the	RGD	
sequence	and	the	thrombin	cleavage	site,	which	interacts	with	α9ß1,	α4ß1,	and	α4ß7;	
a	ELVTDFTDLPAT	domain	is	also	reported	to	bind	to	α4ß1;	a	calcium	binding	site	and	
two	 heparin	 binding	 domains	 also	 exist:	 the	 heparin	 binding	 domains	 bind	 to	 CD44	
receptor.	 Furthermore,	 OPN	 can	 be	 cleaved	 by	 at	 least	 two	 classes	 of	 proteases:	
thrombin	 and	 matrix	 metalloproteases	 (MMPs).	 In	 vitro,	 fragments	 generated	 by	
cleavage	 expose	 new	 active	 domains	 that	may	 impart	 new	 activities.	 Adapted	 from:	
Musso	G	et	al.,	2013.	Cell. 
	
	
1.1.3	Alternative	splicing		
	
By	definition	alternative	splicing	 is	 the	process	by	which	pre-mRNA	molecules	
are	spliced	in	distinct	ways,	and	this	process	 is	 important	for	normal	development	to	
create	diversity	of	proteins	in	complex	organisms	[22].	Also,	alternative	splicing	has	been	
found	 to	 be	 associated	 with	 cancer	 and	 other	 diseases	 such	 as	 Frasier	 syndrome,	
Parkinson’s	disease,	cystic	fibrosis,	retinitis	pigmentosa,	spinal	muscular	atrophy,	and	
myotonic	dystrophy	[23,	24].	In	pathological	conditions	may	occur	aberrant	splicing	of	
pre-mRNA,	which	can	be	ultimately	caused	by	errors	in	RNA	splicing	or	in	its	regulation.	
Additionally,	 splice	 variants	 can	 be	 produced	 by	 disruption	 of	 splicing	 patterns,	 and	
these	splice	variants	(SV)	can	have	different	functions	[25].	OPN	is	encoded	by	a	single	
copy	gene,	although	can	be	expressed	in	a	number	of	different	variants,	that	differ	as	a	
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result	 of	 alternative	 translation	 [26],	 alternative	 splicing	 [10],	 but	 also	mainly	 in	 the	
extent	 of	 PTMs	 [27].	 The	 human	 OPN	 mRNA	 is	 subjected	 to	 alternative	 splicing,	
generating	three	spliced	variants	(OPN-SV).	OPNa	is	the	full	length	variant,	OPNb	lacks	
exon	5	and	OPNc	lacks	exon	4,	as	shown	in	Figure	2.		
The	first	description	of	OPN-SV	was	reported	by	Saitoh	Y	et	al.	in	1995	[28],	in	
glioma	cells.	Since	 this	date,	many	other	papers	have	been	published,	describing	 the	
expression	patterns	and	the	roles	of	OPN-SV	in	different	cell	contexts,	notably	in	cancer	
cells.	Tissue	specific-expression	and	functional	roles	are	the	main	features	of	these	OPN-
SV,	and,	nevertheless,	each	OPN-SV	can	act	as	a	single	OPN-SV	or	 in	concert,	or	they	
may	 even	 have	 opposite	 roles	 in	 the	 same	 cell	 type.	 Acting	 as	 a	 single	 OPN-SV,	 for	
instance,	 in	 ovarian	 and	 breast	 tumour	 cells,	 OPNc	 activates	 tumour-progression	
features	[29,	30].	As	examples	of	OPN-SV	that	acts	in	concert,	OPNb	and	OPNc	exerts	
several	pro-tumorigenic	roles,	through	activating	different	steps	of	tumour	progression	
in	 prostate	 cancer	 cells	 [31].	 Also,	 in	 human	 glioma	 cells,	 OPNa	 and	 OPNc	 activate	
invasion	 [32].	 In	 mesothelioma	 cells,	 OPNa,	 OPNb	 and	 OPNc	 demonstrate	 different	
activities	in	cell	proliferation,	wound	closure	and	invasion	assays,	being	OPNa	and	OPNb	
the	pro-tumorigenic	variants	 [33].	 In	other	 tumour	 types,	different	OPN-SV	can	have	
different	 functions	 or	 show	 opposite	 roles,	 activating	 different	 aspects	 of	 tumour	
progression.	 In	 lung	cancer	cells,	OPNb	affect	proliferation,	while	OPNc	expression	 is	
correlated	with	tumour-cell	invasion	[34].	Other	studies	have	demonstrated	that	OPNa	
is	overexpressed	in	lung	cancer	and	stimulates	several	tumorigenic	features,	whereas	
OPNb	has	fewer	effects	than	OPNa.	Even	in	this	tumour	type,	OPNc	inhibits	proliferation	
and	other	important	cancer	hallmarks,	such	as	angiogenesis	and	VEGF	secretion	[35,	36].	
In	hepatocellular	carcinoma	(HCC)	cells,	OPN-SV	effects	depend	on	the	cell	line	tested.	
Tumour	tissues	predominantly	express	OPNa	and	OPNb,	whereas	normal	liver	tissues	
mainly	 express	OPNc	 [37].	Other	 investigators	 have	 demonstrated	 that	 in	HCC	 cells,	
increased	 expression	 of	 OPNc	 is	 associated	 with	 cellular	 invasion	 and	 appears	 to	
correlate	with	metastatic	potential	[38].		
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Figure	2:	Structural	features	of	OPN-SV.	OPNa,	OPNb	and	OPNc,	are	known.	These	three	
splice	variants	contain	identical	domains	[aspartate,	arginine-glycine-aspartate,	Ser-Val-
Val-Tyr-Gly-Leu-Arg	 (SVVYGLR),	 thrombin	 cleavage,	 calcium	 binding	 and	 heparin	
binding],	which	are	linked	together	through	several	linkers.	These	variants	distinguish	
themselves	by	having	a	variable	length	between	signal	peptide	and	aspartate	domain	
linker.	RGD:	Arginine-glycine-aspartate.	Adapted	from:	Cao	et	al.,	2012.	
	
									
1.1.4	Intra	and	extra-cellular	OPN	
	
Concerning	location	of	OPN,	although	it	has	been	mainly	studied	as	a	secreted	or	
extracellular	protein,	some	OPN	molecules	are	not	secreted,	remaining	inside	the	cells.	
Therefore,	it	has	been	shown	that	OPN	can	be	found	both	in	the	cytoplasm	and	in	the	
nucleus	 [26].	 Many	 studies	 have	 demonstrated	 that	 intracellular	 OPN	 (iOPN)	 has	
biological	 functions	 distinct	 from	 extracellular	 OPN	 (eOPN).	 Further,	 it	 has	 been	
proposed	that	iOPN	and	eOPN	can	also	act	together	[26,	39].	Mouse	iOPN	and	eOPN	
variants	 represent	 alternative	 translational	 products	 of	 a	 single	 full-length	 OPN	
transcript.	Translation	of	eOPN	is	initiated	from	the	50	canonical	AUG	start	site,	whereas	
translation	 of	 the	 iOPN	 variant	 is	 initiated	 from	 a	 downstream	 non-AUG	 codon.	
Downstream	translation	of	 iOPN	 is	accompanied	by	deletion	of	 the	N-terminal	16-aa	
signal	sequence,	allowing	the	shortened	protein	products	to	remain	in	the	cytoplasm,	
but	not	 in	 secretory	vesicles	 [26,	39].	However,	 the	molecular	mechanisms	by	which	
iOPN	and	eOPN	have	been	generated	in	human	cells	have	not	been	described	and	none	
iOPN	SV,	in	any	other	species,	has	been	reported.	Regarding	their	mechanism	of	action,	
it	was	reported	that	similarly	to	eOPN,	 iOPN	variants	can	also	be	associated	to	CD44	
complex	[40].		
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Overall,	among	the	different	variants	of	OPN,	the	extracellular	human	OPN-SV	
are	the	ones	that	have	been	widely	studied	in	different	cell	contexts,	and	their	role	in	
cell	physiology,	notably	in	cancer	cells,	has	been	extensively	investigated	[33,	41,	42].	
		
1.1.5	Regulation		
	
OPN	up-regulation	 is	modulated	by	a	diversity	of	 factors,	 including	hormones	
(steroids,	 retinoic	 acid,	 glucocorticosteroids	 and	 1,25-dihydroxy	 vitamin	 D3),	
inflammatory	cytokines	and	growth	&	differentiation	factors,	such	as	epidermal	growth	
factor	(EGF),	platelet-derived	growth	factor	and	transforming	growth	factor-Beta	(TGF-
β).	These	 factors	 influence	gene	transcriptional	 rates,	mRNA	processing,	stability	and	
protein	translation,	as	well	as	PTMs	maturation	[43].		
Additionally,	 OPN	 can	 be	 down-regulated	 by	 bisphosphonates	 in	 bone	 and	
kidney	[44,	45].	Yet,	OPN	expression	can	be	suppressed	in	vascular	smooth	muscle	cells	
by	 cGMP-dependent	 protein	 kinase,	 which	 is	 a	 mediator	 of	 nitric	 oxide	 and	 cGMP	
signalling	[46].				
	
1.1.6	Functions		
	
OPN	 is	 a	 multifunctional	 molecule	 that	 is	 involved	 in	 both	 physiological	 and	
pathophysiological	processes.	As	the	biological	function	of	OPN	can	be	regulated	at	both	
post-transcriptional	 and	 post-translational	 levels,	 OPN	 from	 various	 cellular	 sources	
might	have	diverse	structural	characteristics	that	are	reflected	in	its	various	processes	
[47,	48],	 including	bone	remodelling;	calcification	 (inhibition	of	urinary	crystallization	
and	cardiovascular	calcification);	immune	response	(macrophage	cytokine	production,	
T	cell	activation,	stimulation	of	Th1	response);	inflammation	(both	acute	and	chronic);	
regulation	of	cell	adhesion	migration;	cell	survival;	oncogenesis	and	cancer	progression;	
angiogenesis;	 inhibition	of	 apoptosis;	 diseases	 such	as	 restenosis,	 arterial	 neointimal	
hypeplasia,	artherosclerosis	and	myocardial	necrosis	[49].	OPN	has	also	been	recognized	
as	 an	 important	 luminal	 regulator,	 due	 to	 its	 expression	 by	 epithelial	 cells	 covering	
luminal	cavities	capable	of	active	secretion	and	absorption	of	nutrients	[45].		
Studies	 in	OPN-knockout	mice	have	suggested	 the	existence	of	 structural	and	
functional	differences	between	 tumour-	derived	OPN	and	 the	OPN	 isoforms	 that	are	
 19 
relevant	for	host	defences.	There	is	evidence	suggesting	that	tumour-	derived	OPN	is	
unique	(i.e.	structurally	different	from	OPN	derived	from	untransformed	cells)	and	lacks	
important	 domains.	 Thus,	 expression	 of	 structurally	 altered	OPN	by	 cancer	 cells	 can	
represent	a	mechanism	of	immune	evasion	[50].	
1.1.7	Mechanisms	of	action	
	
Is	 widely	 known	 that	 OPN	 act	 by	 binding	 to	 cell	 surface	 receptors,	 such	 as	
integrins	and	CD44	(Figure	3),	being	integrins	the	main	receptors	used	by	OPN	to	cell	
adhesion.	OPN	bind	to	different	cell	types	by	both	αv	(β1,	β3,	β5)	and	(α4,	α8,	α9)	β1	
integrin	 chains.	 The	 interaction	 of	 OPN	with	 integrin	 is	mediated	 by	 the	 RGD	motif	
(although	not	 limited	 to)	and	on	a	high	 integrin	 receptor	activation	state.	Therefore,	
OPN	also	interacts	with	αvβ1	and	α4β1	integrins	through	the	sequence	SVVYGLR,	which	
is	 thought	 to	be	exposed	upon	putative	 thrombin	 cleavage,	 adjacent	 to,	 but	distinct	
from,	the	RGD	motif	[51,	52].	The	amino-	and	carboxy-terminal	parts	of	OPN	non-GRGDS	
(Gly-Arg-Gly-Asp-Ser)	region	also	mediate	cell	attachment.	The	αvβ3	integrin,	which	can	
be	 regulated	 by	 OPN,	 is	 believed	 to	 be	 primarily	 responsible	 for	 the	 adhesion	 and	
migratory	properties	[53].		
OPN	can	also	bind	intra	or	extracellularly	to	CD44	and	its	various	isoforms,	which	
is	the	main	cell	surface	receptor	for	hyaluronate.	CD44	is	expressed	in	a	variety	of	cells	
such	as	osteoclasts,	osteoblast,	osteocytes,	epithelial	cells,	endothelial	cells,	fibroblasts	
and	smooth	muscle	cells	[54].	The	binding	of	OPN	to	CD44	activate	signalling	pathways,	
such	as	PLC-g/	PKC/PI	3-kinase,	leading	to	cell	motility	and	survival	[49].		
Previous	 reports	 showed	 that	 the	 interaction	 of	 OPN	 and	 CD44	 enhances	
formation	of	foci,	 invasion	and	tumorigenesis	in	H-Ras-V12-transformed	cells	through	
the	Rac-mediated	pathway,	and	these	effects	were	abolished	upon	treatment	with	a	
CD44	blocking	antibody	[55].	The	OPN	and	CD44	interactions	can	further	be	mediated	
through	integrins,	as	there	is	some	evidence	that	OPN	binding	by	CD44	variants	and	b-
containing	integrins	could	cooperate	to	promote	cell	spreading	and	migration	[56].		
Regarding	the	activation	of	signalling	pathways	by	OPN-SV,	many	reports	have	
emerged	 describing	 the	 roles	 of	 OPN-SV	 on	 activating	 different	 aspects	 of	 tumour	
progression.	 In	glioma	cells,	 for	 instance,	OPNa	and	OPNc	 induce	cellular	 invasion	by	
binding	αvβ3	integrin,	activating	PI3K/AKT/NF-kB	pathway	[32].	In	ovarian	and	prostate	
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cancer	 tumour	 cells,	 several	 aspects	 of	 tumour	 progression	 are	 activated	 by	 OPNc	
overexpression,	also	being	modulated	by	PI3K/AKT	signalling	pathway	[30,	31,	57].	 In	
HCC	 cell	 lines,	OPN-SV	 can	differentially	modulate	 its	migratory	activity,	 probably	by	
differentially	 activating	 signalling	 pathways	 involved	 in	 tumour	 metastasis,	 such	 as	
urokinase-type	plasminogen	activator	 (uPA)	 and	p42/p44	MAP	kinase.	 In	 these	 cells,	
OPNa	and	OPNb	increased	the	levels	of	uPA,	whereas	OPNc	did	not	promote	this	effect.	
Yet,	 OPNa	 and	 OPNb,	 but	 not	 OPNc,	 were	 able	 to	 increase	 the	 phosphorylation	 of	
ERK1/2	in	hepatocarcinoma	cellular	cell	lines.	Together,	these	data	suggest	that	OPNa	
and	OPNb	are	 involved	 in	 the	activation	of	 integrin	 signalling,	but	 that	OPNc	 cannot	
activate	this	pathway	[37].	Besides,	 in	head	and	neck	cancer	cells,	 the	RGD	region	of	
OPNa	and	OPNb	variants	inhibited	apoptosis	by	inducing	NF-kappaB	activation	and	FAK	
phosphorylation	[58].		
	
Figure	3:	Activated	OPN	signalling	pathways	by	binding	to	CD44	and	integrin	receptors.	
OPN	can	initiate	Arg–Gly–Asp	(RGD)-dependent	and	RGD-independent	interactions	with	
several	integrins	(such	as	 v 3	and	 9 1,	respectively).	OPN	can	also	interact	with	the	
CD44	family	of	receptors.	Some	of	these	complexes	are	able	to	mediate	the	following	
functions:	 cell	 survival	 through	 phospholipase	 C- 	 (PLC )–protein	 kinase	 C	 (PKC)–
phosphatidylinositol	3-kinase	(PI3K)–Akt	pathway	activation	that	leads	to	anti-apoptotic	
signals	in	tumour	cells.	OPN-induced	Akt	phosphorylation	can	be	blocked	by	the	tumour	
suppressor	 PTEN	 (phosphatase	 and	 tensin	homologue).	However,	PTEN	 is	 frequently	
mutated	 and	 thus	 rendered	 inactive	 in	 cancer	 cells	 such	 as	 melanoma	 and	 glioma.	
Moreover,	motility	through	the	activation	of	the	canonical	 v 3	integrin	pathway	where	
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both	nuclear	factor-inducing	kinase	(NIK)–ERK	(extracellular	signal-related	kinase)	and	
MEKK1	 (also	known	as	mitogen-activated	protein	kinase	kinase	kinase	1)	 (MAP3K1)–
JNK1	 (also	 known	 as	 MAPK8)	 signalling	 promote	 cell	 migration	 by	 activating	 AP1-
dependent	 gene	 expression.	 Upon	 binding	 to	 v 3,	 OPN	 also	 stimulates	 epidermal	
growth	factor	receptor	(EGFR)	transactivation,	ERK	phosphorylation	and	AP1	activation.	
Adapted	from:	Bellahcène	et	al.,	2008	(Nature	Reviews	Cancer).	
		
	
1.1.8	OPN	in	normal	tissues	
	
In	 human,	 OPN	 is	 one	 of	 the	 most	 abundant	 non-collagenous,	 non-specific	
protein	in	bone.	It	is	expressed	in	a	variety	of	tissues	such	as	bone,	bone	marrow	derived	
gland	cells,	cartilage,	dentine,	cementum,	kidney,	brain,	vascular	tissues,	epithelial	cells	
of	the	gastrointestinal,	urinary	and	reproductive	tracts,	the	gall	bladder,	pancreas,	lung	
bronchi,	 lactating	 breast,	 salivary	 glands,	 sweat	 ducts	 as	 well	 as	 in	 activated	
macrophages	and	lymphocytes.	Furthermore,	OPN	is	found	in	biological	fluids,	such	as	
milk,	urine,	blood	and	seminal	fluid	[59].	Because	OPN	was	mainly	found	to	be	expressed	
in	the	luminal	surfaces	of	these	tissues,	some	authors	suggested	that	OPN	might	have	a	
protective	role	in	interactions	between	epithelial	surfaces	and	the	external	environment	
[60].	For	instance,	it	was	described	that	OPN	is	likely	to	have	a	physiologic	role	in	milk	
[61].	
	Cell	 growth,	 differentiation,	 and	 a	 high	 degree	 of	 tissue	 remodelling	 occurs	
during	 the	 different	 stages	 of	 the	mammary	 gland.	 During	 pregnancy	 and	 lactation,	
these	processes	ensure	the	establishment	of	the	spatial	relations	between	stromal	and	
epithelial	 cells,	 and	 the	 organization	 of	 the	 latter	 into	 a	 branched	 tree	 of	 ducts	 and	
terminal	alveoli.	The	highly	metabolic	active	epithelial	cells	 lining	 the	ducts	 rest	on	a	
basal	membrane	of	collagen	and	other	ECM	proteins,	and	signals	from	the	ECM	to	the	
cells	 are	 important	 for	 cell	 differentiation	 and	 milk	 secretion	 [62].	 Studies	 on	 the	
expression	and	regulation	of	OPN	in	the	mammary	glands	has	been	described	by	several	
investigators.	Experiments	showed	that	mammary	epithelial	cells	that	had	the	levels	of	
OPN	 down-regulated	 by	 antisense	 mRNA,	 showed	 an	 increase	 in	 matrix	
metalloproteinase	MMP-2.	Possibly,	MMP-2	and	OPN	compete	for	binding	to	integrins	
in	the	cells,	and	OPN	binding	can	 induce	normal	cell	differentiation,	whereas	MMP-2	
binding	induces	tissue	degradation	[60].		
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1.1.9	OPN	in	cancer	
	
Cancer	 is	a	multifactorial	pathological	disease,	emerging	 from	deregulation	of	
one	 or	 more	 cellular	 phenomena,	 resulting	 from	 accumulation	 of	 aberrant	 genetic	
and/or	epigenetic	alterations	[63].	The	cancer	environment	is	comprised	of	tumour	cells	
as	well	as	a	wide	network	of	stromal	and	vascular	cells	that	participates	in	the	cellular	
and	molecular	 events	necessary	 for	 invasion	 and	metastasis.	Hence,	 cancer	 cells	 are	
regulated	not	only	by	autonomous	signalling	pathways,	but	also	by	contextual	molecular	
interactions	received	from	tumour-associated	stroma	[64].		
OPN	is	a	multifunctional	matricellular	protein	and	its	capacity	to	bind	to	receptor	
complexes	and	activate	different	signalling	pathways	leading	to	a	variety	of	effects	such	
as	 cell	 survival,	 proliferation,	 migration	 and	 invasion,	 have	 been	 clinically	 and	
functionally	associated	with	many	types	of	cancers	[65].	It	has	been	well	stablished	that	
OPN	 is	 important	 for	 tumour	 initiation	and	 invasion	 in	 liver,	 gastric,	 colorectal,	 lung,	
ovary	and	prostate	cancer	[66,	67].		
Moreover,	OPN	may	induce	changes	in	the	expression	of	many	genes,	resulting	
in	 proteins	 that	 can	 contribute	 to	 altered	 cell	 behaviour,	 including	 migration	 and	
invasion,	an	effect	promoted	by	interactions	of	OPN	with	cell	surface	receptors.	These	
effects	of	OPN	may	vary	between	cell	types,	depending	for	example	on	which	integrins	
are	expressed	and	which	signal	pathways	can	be	activated.	There	is	convincing	evidence	
that	soluble	OPN,	in	several	situations,	help	cells	to	survive	a	situation	which	would	be	
lethal	[60].	Notably,	this	survival	signalling	is	mediated	by	receptors	that	are	generally	
considered	 to	 be	 receptors	 for	 ECM	 components.	 It	 has	 been	 suggested	 that	 OPN	
delivers	an	anti-apoptotic	"ECM-like"	signal	via	multiple	ligand-receptor	interactions	to	
both	 adherent	 and	 non-adherent	 cells	 [68].	 Multiple	 and	 complex	 mechanisms	 are	
involved	in	OPN	roles	 in	cancer,	not	only	 interactions	with	cell	surface	receptors,	but	
also	proteases	and	growth	factor/receptor	pathways	[60].	
		A	huge	amount	of	studies	has	indicated	that	OPN	is	highly	expressed	in	several	
malignancies,	 including	 cancer.	 Abundant	 secreted	 OPN	 act	 as	 a	 marker	 for	
osteosarcoma,	glioblastoma,	prostate	and	breast	cancer,	squamous	cell	carcinoma	and	
melanoma	 [69].	 Additionally,	 OPN	 might	 also	 contribute	 to	 cancer	 progression	 by	
regulating	 the	 tumour-surveillance	mechanism	and	 inhibiting	 apoptosis	 of	 neoplastic	
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cells	 [70].	 In	 cancer,	 the	 mechanisms	 through	 which	 OPN	 exerts	 its	 effect	 are	
incompletely	 understood.	 Recent	 studies	 pointed	 to	 a	 link	 between	 OPN	 and	 the	
epithelial-mesenchymal	 transition	 (EMT),	 appearing	 to	 be	 a	 significant	 molecular	
explanation	for	how	OPN	influences	cancer	development	[71].		
	
	
1.1.10	OPN	and	calcification	
	
OPN	is	known	as	a	“molecule	for	all	seasons”	because	of	its	multifunctional	roles.	
Apart	 from	 its	 functions	 related	 to	 cell	 survival,	 migration,	 proliferation,	 invasion,	
metabolic	regulation,	inflammation,	etc;	many	studies	have	reported	the	importance	of	
OPN	in	bone	microenvironment	[72].	Accordingly,	OPN	is	involved	in	bone	remodelling	
and	mineralization.	In	healthy	bone	tissues,	OPN	is	expressed	by	both	osteoclasts	and	
osteoblasts,	 which	 are	 responsible	 for	 bone	 remodelling.	 During	 physiological	 bone	
mineralization,	 osteoclast-derived	OPN	 inhibits	 the	 formation	 of	 hydroxyapatite	 [73,	
74].	Additionally,	in	teeth,	OPN	in	the	cement	layer	may	be	utilized	for	osteoblast	cell	
adhesion,	or	to	guide	early	calcification	events	at	this	tissue	junction.	The	expression	of	
iOPN,	together	with	CD44,	in	proliferating	osteogenic	cells	seems	to	be	correlated	with	
cell	 motility.	 Yet,	 OPN	 expressed	 during	 cement	 layer	 formation	 possibly	 regulate	
hydroxyapatite	crystal	growth,	which	would	be	consistent	with	the	demonstrated	ability	
of	phosphorylated	OPN	as	a	potent	regulator	of	hydroxyapatite	crystal	growth	[73-75].	
	Moreover,	 in	 the	 urinary	 tract,	 OPN	 was	 demonstrated	 to	 be	 related	 with	
defence	against	renal	stones	formation,	mostly	composed	by	calcium	oxalate.	OPN	is	
then	synthesized	within	the	kidney	and	secreted	into	the	urine	by	epithelial	cells	[76,	
77].	OPN	can	inhibit	the	nucleation,	growth	and	aggregation	of	calcium	oxalate	crystals	
in	 vitro	 and	directly	 inhibits	 the	binding	of	 calcium	oxalate	 crystals	 to	 cultured	 renal	
epithelial	cells	[78].	Currently,	the	exact	molecular	mechanisms	by	which	OPN	exerts	its	
many	inhibitory	effects	in	unclear,	although	it	is	known	that	phosphorylation	of	the	OPN	
molecule	is	critically	important	[19,	20].	
The	functional	diversity	of	OPN	in	bone	formation	and	remodelling	appears	as	
fundamental	 roles	 of	 this	 protein	 in	 host	 defences	 and	 tissue	 repair.	 The	 bone	
remodelling	sequences	have	many	features	of	repair	processes	involving	inflammatory	
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responses.	Thus,	a	primarily	role	seems	to	be	to	facilitate	organism	recovery	after	injury	
or	infection,	which	generally	causes	an	increase	in	its	expression.	OPN	stimulates	cellular	
signalling	pathways	via	various	receptors	found	on	most	cell	types,	including	the	cells	of	
mineralized	 tissues.	 It	 can	 regulate	cell	proliferation	and	phagocytic	activity,	and	can	
both	promote	and	participate	on	cell	migration.	Moreover,	modulation	of	immune	and	
inflammatory	 responses	 by	 OPN	 is	 reflected	 on	 the	 formation	 and	 activity	 of	
macrophages	and	also	osteoclasts.	As	an	ECM	component,	it	can	regulate	mineral	crystal	
formation	and	growth,	and	can	form	supramolecular	structures	by	covalent	interactions	
with	other	matrix	macromolecules	[14].		
Although	many	 studies	 have	 reported	 the	 altered	 expression	of	OPN	 in	 bone	
tumours,	the	mechanisms	by	which	OPN	overexpression	are	related	with	calcification	in	
different	pathologies	and	in	tumour	microenvironment,	is	still	poorly	understood.	For	
instance,	 the	up-regulation	of	OPN	 is	also	 found	 in	regions	of	dystrophic	calcification	
such	as	that	associated	with	degenerative	and	atheromatous	vascular	disease	[79,	80].		
The	mechanism	underlying	the	formation	of	calcifications	in	PTC	is	incompletely	
known.	Underwood	[81]	believe	that	the	psammoma	bodies	(PB)	represent	a	process	of	
dystrophic	 calcification,	 in	which	 the	 deposition	 occurs	 locally	 in	 nonviable	 or	 dying	
tissues	with	normal	serum	levels	of	calcium,	in	the	absence	of	derangements	of	calcium	
metabolism.	Cameron	and	Mc	Cluggage	[82]	however,	hypothesized	that	PB	formation	
is	the	result	of	a	factor	secreted	locally	by	the	tumour	cells,	rather	than	the	widely	held	
theory	 that	 their	 formation	 is	 secondary	 to	 necrosis,	 with	 subsequent	 dystrophic	
calcification	within	a	papillary	neoplasm.	However,	Kozlovskii	et	al.	[83]	in	serous	ovary	
adenocarcinoma	 (where	 PB	 are	 also	 frequent)	 suggested	 that	 PB	 were	 formed	
intracellularly,	 resulting	 in	 cell	 death	 and	 release	 of	 small	 PB.	 Tsuchida	et	 al.	 [84]	 in	
meningioma	described	 formation	of	precursors	of	PB	extracellularly,	 due	 to	 collagen	
production	 by	 meningothelial	 cells.	 Despite	 the	 lack	 of	 a	 consensus	 regarding	 the	
mechanisms	by	which	PB	are	formed,	literature	data	indicate	that	OPN	may	be	involved	
in	 these	 processes.	 Tunio	 et	 al.	 [85]	 observed	 PTC	 cells	 overexpressing	 OPN	mRNA	
around	PB.	In	addition,	the	localization	of	OPN	protein	expression	was	also	consistent	
with	that	of	PB.	The	authors	further	reported	that	the	OPN	transcript-expressing	cells	
were	 identified	 as	 CD68+	 macrophages.	 In	 a	 more	 recent	 study,	 OPN	 expression	
presented	a	significantly	association	with	the	presence	of	PB	in	PTC	samples,	together	
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with	the	expression	of	the	bone	sialoprotein	(BSP).	The	authors	advanced	that	the	strong	
correlation	between	BSP,	OPN	and	PTC	suggest	a	role	for	BSP	and	OPN	on	calcification	
and	PTC	tumour	progression	[86].		
	
	
1.1.11	OPN	in	bone	metastases	
	
Concerning	 bone	 metastases,	 OPN	 expression	 has	 been	 detected	 in	 both	
osteoclasts	and	metastatic	tumour	cells	[87].	Kang	et	al.	[88]	showed	that	breast	cancer	
cells	 spreading	 to	bone	had	 increased	OPN	expression	and	 identified	OPN	 in	 a	bone	
metastasis	gene	signature.	Consistent	with	this	finding,	Nemoto	et	al.	[89]	reported	that	
melanoma	cells	with	down-regulated	OPN	have	 lower	 incidence	of	bone	metastases.	
Moreover,	 OPN	 expression	 may	 differ	 between	 bone	 metastases	 with	 a	 more	
osteolytic	versus	osteoblastic	pattern	of	involvement	[90].	For	example,	tumour	cells	in	
bone	 metastases	 from	 breast	 cancer	 (mixed	 osteolytic	 and	 osteoblastic/sclerotic	
pattern)	 have	 strong	 OPN	 expression,	 compared	 to	 lower	 OPN	 expression	 in	 bone	
metastases	from	prostate	carcinomas	(more	osteoblastic/sclerotic	pattern)	[90].	
A	 number	 of	 studies	 have	 demonstrated	 that	 OPN	may	 be	 involved	 in	 early	
tumour	 cell	 colonization	 into	 the	 bone	 [91].	 Yoneda	 et	 al.	 [92]	 showed	 that	 the	
interaction	between	tumour	cells	and	bone	marrow	endothelial	cells	may	be	an	early	
step	 in	bone	metastasis	 formation.	Breast	 tumour	cells	without	OPN	have	decreased	
ability	 to	 bind	 bone	marrow	 endothelial	 cells	 [91,	 93].	 OPN	 expression	 by	 prostatic	
tumour	cells	is	also	induced	because	of	physical	contact	with	bone	marrow	stromal	cells	
[94].	Once	contact	among	cancer	cells,	bone	marrow	stromal	cells	and	bone	marrow	
endothelial	cells	is	important	for	both	survival	and	proliferation,	OPN	expression	may	be	
important	for	cancer	metastatic	growth	in	bone	microenvironment.	OPN	also	helps	to	
regulate	 osteoclast	 activation	 and	 adhesion	 to	 the	 bone	 surface,	 activating	 the	
mechanism	of	bone	resorption,	which	aids	on	bone	metastasis	formation	[87,	95,	96].	
Thus,	OPN	expressed	in	tumour	cells	that	have	spread	to	bone,	as	well	as	in	a	number	
of	cell	types	in	the	bone	itself,	may	play	a	functional	role	on	helping	cancer	cells	survival	
and	growth	within	the	bone	microenvironment.		
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1.1.12	OPN	in	thyroid	cancer	
	
OPN	was	first	described	to	be	overexpressed	in	human	TC	by	Brown	et	al.	in	1994	
[97],	 in	a	study	that	evaluated	OPN	expression	and	distribution	in	human	carcinomas	
when	 compared	 to	 corresponding	 normal	 tissues.	 In	 this	 report,	 by	 using	 in	 situ	
hybridization,	OPN	transcript	was	demonstrated	to	be	expressed	in	macrophages	closely	
associated	with	 tumour	 cells,	which	 contained	 no	 detectable	OPN	mRNA	expression	
[59].	In	1998	the	expression	of	OPN	was	associated	with	the	presence	of	PB	in	human	
papillary	thyroid	cancer	(PTC),	and	these	cells	were	identified	as	CD68+	macrophages.	
The	authors	concluded	that	OPN	produced	by	macrophages	may	play	a	significant	role	
in	 the	 development	 of	 PB	 in	 PTCs	 [85].	 In	 2003,	 OPN	 was	 demonstrated	 to	 be	 up-
regulated	by	thyrotropin	(TSH)	hormone	and	iodine	in	cultured	human	thyroid	follicles,	
using	a	cDNA	microarray	experiment	[98].	Later,	in	a	more	complex	study,	Castellone	et	
al.	[99]	showed	that	OPN	is	a	transcriptional	target	of	RET/PTC-	in	PCCl3	thyroid	follicular	
rat	cell	 line.	They	also	demonstrated	that	OPN	overexpression	increased	proliferation	
and	 invasion	of	RET/PTC-transformed	PCCL3	cell	 line.	After	 that,	Guarino	et	al.	 [100]	
reported	 overexpression	 of	 OPN	 in	 a	 much	 large	 series	 of	 human	 PTCs,	 and	 such	
overexpression	was	correlated	with	the	presence	of	lymph	node	metastases	and	tumour	
size.	They	also	showed	that	the	treatment	of	human	PTC	cell	line	with	recombinant	OPN	
also	enhanced	cell	invasiveness.	Briese	et	al.	[101]	analysed	OPN	expression	patterns	in	
thyroid	carcinomas	and	they	observed	OPN	overexpression	 in	PTC	and	 in	MTC	tissue	
samples.	 Further	 work	 associated	 OPN	 up-regulation	 to	 the	 occurrence	 of	
microcalcification	and	lymph	node	metastasis,	suggesting	a	possible	role	of	OPN	in	PTC	
calcifications	[86,	102].	Recently,	Kang	KH	[103]	showed	an	association	between	OPN	
up-regulation,	BRAFV600E	mutation	and	lymph	node	metastasis	in	PTC	samples.	
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1.2	Tumour	microenvironment		
	
1.2.1	Extracellular	Matrix	(EMC)	and	tumour	microenvironment	(TME)		
	
The	ECM	is	the	non-cellular	component,	a	collection	of	extracellular	molecules	
secreted	by	cells	in	all	organs	and	tissues,	providing	essential	physical	scaffolding	for	the	
cellular	constituents	and	supplying	crucial	biochemical	and	biomechanical	structure	to	
support	 tissue	 morphogenesis,	 differentiation	 and	 homeostasis	 [104].	 The	 ECM	
macromolecules	 are	 assembled	 into	 three-dimensional	 structures	 and	 regulate	 cell	
growth,	motility	and	survival	by	binding	specific	cell	surface	receptors	such	as	integrins,	
syndecans	and	discoidin	[105,	106].	Additionally,	the	ECM	is	also	important	to	maintain	
growth	 factors	and	cytokines	availability,	and	also	 regulates	hydration	and	pH	of	 the	
local	 microenvironment	 [107].	 Yet,	 it	 is	 known	 that	 interactions	 between	 specific	
collagens	 and	 glycoproteins	 with	 cell	 receptors	 is	 important	 to	 control	 cellular	
cytoskeleton,	differentiation	and	gene	expression.	Moreover,	physical	forces,	generated	
by	cellular	interactions	with	the	ECM	can	in	turn	influence	proliferation	and	migration	
in	normal	tissues,	but	are	currently	in	the	spotlight	with	respect	to	tumour	stroma	and	
progression	[108].	In	2011,	Hanahan	and	Weinberg	[63]	revisited	the	hallmarks	of	cancer	
adding	 two	 emerging	 features:	 dysregulation	 of	 cellular	 metabolism	 and	 evasion	 of	
immune	 destruction.	 Importantly,	 the	 ECM	 regulates	 many	 of	 the	 same	 cellular	
responses	that	characterize	these	cancer	hallmarks.		
ECM	has	been	widely	described	as	an	essential	component	of	a	typical	tumour	
microenvironment	 (TME),	which	also	 comprise	many	other	essential	elements	 in	 the	
stroma	 including	 fibroblast,	 myofibroblasts,	 neuroendocrine	 cells,	 adipose	 cells,	
immune	 and	 inflammatory	 cells,	 the	 blood	 and	 lymphatic	 vascular	 networks	 [109].	
Microenvironment	 and	 tumour	 cells	 mutually	 influence	 each	 other	 during	 tumour	
initiation	and	progression	[110].	Therefore,	TME	is	a	crucial	factor	for	the	faith	of	any	
cancer.	Recent	reports	have	indicated	that	the	TME	can	dictate	aberrant	tissue	function	
and	play	a	critical	role	in	the	subsequent	development	of	more	advanced	and	refractory	
malignancies	[111].	Moreover,	fibres	of	ECM	proteins	such	as	collagens	seems	to	have	
an	important	role	in	tumour	progression,	building	migration	tracks	for	the	tumour	cells.	
At	the	same	time,	the	ECM	can	function	as	a	barrier	blocking,	e.g.,	the	penetration	of	
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immune	cells	into	the	tumour,	or	it	can	create	a	high	interstitial	fluid	pressure	preventing	
the	perfusion	of	drugs,	which	facilitates	chemoresistance	[107].	
The	degradation	and	 remodelling	of	 the	ECM	are	 some	of	 the	essential	 steps	
involved	in	cell	migration	and	tumour	progression,	being	such	steps	critically	dependent	
on	 the	 proteolytic	 activity	 generated	 by	 metalloproteinases	 (MMPs)	 and	 the	
plasminogen-activator–plasmin	 system	 [49].	 The	 MMP	 enzymes	 are	 ECM-degrading	
molecules	that	play	a	crucial	role	in	embryogenesis,	tissue	remodelling,	 inflammation	
and	angiogenesis	[112].	MMP2	and	MMP9	(also	called	gelatinase	A	and	B)	are	important	
contributors	 to	 the	 process	 of	 invasion,	 tumour	 growth	 and	 metastasis	 [113].	 Both	
MMP2	 and	 MMP9	 efficiently	 degrade	 native	 type	 IV	 and	 V	 collagens,	 fibronectin,	
ectactin	and	elastin.	Several	studies	have	shown	a	correlation	between	MMP2	activation	
and	metastatic	potential	and	have	suggested	that	MMP2	might	act	as	a	useful	marker	
for	the	prognosis	or	diagnosis	of	various	cancers	[114].		
	
1.2.2	Osteopontin	in	ECM	
	
It	has	long	been	known	that	OPN	can	be	produced	by	a	diversity	of	cells	that	are	
present	 in	 the	 TME,	 including	 tumour,	macrophages	 and	 stromal	 cells;	 however,	 its	
several	contributions	to	tumour	growth,	progression	and	the	TME	are	still	incompletely	
understood.	 Studies	 of	 genetically	 manipulated	 animal	 models	 and	 the	 use	 of	
transformed	cell	lines	have	revealed	important	clues	about	the	role	of	OPN	in	the	TME	
[91].	
As	aforementioned,	OPN	can	be	expressed	both	by	tumour	cells	and	by	many	
other	cells	 that	compose	 the	TME.	For	 instance,	Tuck	et	al.	 [115]	 reported	 that	OPN	
transcript	 and	 protein	 were	 detected	 in	 tumour	 cells	 and	 in	 tumour	 infiltrating	
inflammatory	cells	in	a	cohort	of	lymph	node	negative	breast	cancer	patients.	Similarly,	
Wang-Rodriguez	et	al.	[116],	observed	OPN	cytoplasmic	staining	in	breast	cancer	cells	
and	 OPN	 expression	 in	 tumour-infiltrating	 inflammatory	 cells,	 whereas	 stromal	
fibroblasts	 and	 endothelial	 cells	 were	 negative	 for	 OPN	 expression.	 Another	 study	
demonstrated	that	in	pulmonary	artery	sarcomas,	tumour	cells	as	well	as	macrophages	
and	ECM	were	positive	for	OPN	expression,	being	tumour	cell	staining	most	frequent	at	
cell	surface	and	at	sites	of	invasion	[117].	In	cutaneous	squamous	cell	carcinoma	Chang	
et	al.	 [118]	 found	that	 in	most	cases,	OPN	was	expressed	 in	cancer	cells	and	 in	ECM	
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adjacent	to	the	tumour,	but	not	in	other	stromal	regions.	Conversely,	in	some	tumour	
types,	OPN	expression	was	found	primarily	in	macrophages	and	stromal	cells,	and	less	
frequently	in	the	tumour	cells	themselves,	as	in	oesophageal	adenocarcinoma	[119].		
Thus,	is	not	clear	whether	tumour-derived	OPN	is	incorporated	into	the	ECM.	In	
some	 tissues,	 such	 as	 bone,	 OPN	 is	 an	 established	 component	 of	 the	 ECM	 and	 is	
important	in	cell	attachment	[120].	Although	OPN	has	been	found	in	the	ECM	of	several	
cancer	types	by	 immunohistochemistry	[117,	121,	122],	 it	has	been	discussed	that	at	
least	in	some	instances,	tumour-derived	OPN	may	be	more	soluble	and	not	incorporated	
into	the	ECM	[123].	Hence,	it	is	undefined	whether	it	is	tumour-	or	stromal-derived	OPN	
(or	 both)	 that	 can	 be	 incorporated	 into	 the	 ECM	 and	 affect	 tumour	 growth	 and	
progression.	Although	some	evidences	point	that	differences	in	OPN	variants	and	PTMs	
may	affect	different	OPN	functions	[124,	125],	there	is	very	scant	data	in	literature	on	
how	tumour-derived	OPN	may	differ	 from	stroma-derived	OPN,	either	structurally	or	
functionally.		
So	 far,	 it	 is	 also	 observed	 that	 OPN	 cellular	 staining	 patterns	 may	 change	
according	 to	 tumour	 stage.	 For	 instance,	 in	 colon	 carcinomas,	 well-differentiated	
tumours	 show	 OPN	 immunostaining	 at	 the	 apical	 cell	 surface,	 while	 poorly	
differentiated	 tumours	 OPN	 is	 expressed	 on	 the	 basal	 cell	 surface,	 at	 the	 stromal	
interface	[97].		
Finally,	Figure	4	shows	how	OPN	can	contribute	to	a	diversity	of	steps	in	tumour	
progression	and	metastases.	OPN	is	likely	to	regulate	key-molecules	in	order	to	facilitate	
matrix	degradation,	cell	migration	and	invasion,	then	culminating	on	the	establishment	
of	tumour	metastasis.		
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Figure	4:	Model	depicting	the	role	of	OPN	in	the	regulation	and	activation	MMPs	during	
tumour	progression	and	metastasis.	Cancer	metastasis	is	a	highly	complicated	process	
that	involves	cell	motility,	invasion,	angiogenesis,	intravasation	of	tumour	cells	into	the	
blood	stream	and	subsequent	extravasation,	followed	by	colonization	of	tumour	cells	at	
secondary	 sites.	 The	 invasion	 involves	 translocation	 of	 neoplastic	 cells	 across	 tissue	
boundaries	and	through	the	extracellular	matrix	barrier.	This	process	requires	cellular	
adhesion	and	local	proteolysis,	leading	to	migration	of	neoplastic	cells.	Adapted	from:	
Rangaswami	et	al.,	2006.	Trends	in	cell	biology.	
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1.3	Thyroid	Cancer		
	
	
Thyroid	cancer	 (TC)	 is	 the	most	common	endocrine	cancer,	and	 its	 incidence	has	
continuously	increased	in	the	last	three	decades	all	over	the	world	[126].		
Most	of	the	thyroid	cancers	derive	from	follicular	cells	and	a	minority	from	C-cells.	
Based	on	recent	data,	TC	is	the	fifth	most	common	cancer	in	women	[127].	In	Portugal,	
a	significant,	rapid	and	continued	increase	in	incidence	has	been	observed	for	both	sexes	
[128].	In	the	USA,	approximately	1.0%	–	1.5%	of	all	new	cancers	diagnosed	each	year	
corresponds	to	TC	[129].	Only	in	few	countries	(Norway	and	Sweden)	TC	incidence	has	
decreased	[130].		
This	significant	increase	in	TC	incidence	has	been	largely	attributed	to	the	increasing	
use	of	ultrasonography	and	other	imaging	techniques,	although	environmental	factors	
may	also	be	 important.	 It	was	 found	many	years	ago	that	small	papillary	carcinomas	
were	a	common	finding	at	autopsy,	reaching	a	frequency	of	36%	[131],	suggesting	that	
there	 is	 a	 large	 reservoir	 of	 small	 papillary	 carcinomas	 that	 do	 not	 present	 clinically	
during	 life,	 but	 can	 be	 uncovered	 by	 ultrasonography	 or	 other	 screening	 techniques	
[126].	A	epidemiological	study	in	Portugal,	refers	that	the	significant	increased	incidence	
is	predominantly	observed	among	women	from	the	North	of	the	country	[128].	
On	the	other	hand,	mortality	rates	from	TC	has	minimally	changed	over	the	past	
five	decades.	TC	present	a	broad	range	of	clinical	behaviours—	in	most	cases	indolent	
tumours	with	low	mortality,	and	rarely,	very	aggressive	malignancies,	as	anaplastic	TC.	
The	challenge	faced	by	physicians	who	treat	TCs	is	to	balance	the	therapeutic	approach	
so	that	patients	with	lower	risk	disease	or	benign	thyroid	nodules	are	not	over	treated.	
At	the	same	time,	they	need	to	recognise	those	patients	with	more	advanced	or	high-
risk	disease,	who	need	a	more	aggressive	treatment	approach.	Therefore,	undertaking	
a	 proper	 diagnostic	work-	 up	 before	 treatment	 is	 started,	 is	 crucial	 to	 appropriately	
tailor	therapy.		
Tumours	originated	by	follicular	cells	can	go	through	follicular	adenomas	(FTA),	
a	benign	encapsulated	follicular	lesion,	to	well-differentiated	carcinomas	(WDTC),	such	
as	papillary	carcinoma	(PTC)	and	follicular	carcinoma	(FTC)	and	finally,	they	can	develop	
into	poorly	differentiated	thyroid	carcinoma	(PDTC)	and	in	anaplastic	carcinoma	(ATC	-	
also	called	as	undifferentiated	cancer)	as	shown	on	Figure	5.	The	concept	of	stepwise	
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progression	 from	 a	 pre-existing	 WDTC	 to	 PDTC	 and	 ATC	 is	 supported	 by	 clinical,	
epidemiologic,	 pathologic	 and	 molecular	 evidence	 (studies	 of	 comparative	 genomic	
hybridization,	loss	of	heterozygosity,	genetic	and	epigenetic	alterations).	Yet,	the	PDTC	
and	 ATC	 can	 be	 originated	 independently	 from	 pre-existing	 papillary	 or	 follicular	
carcinomas	and	may	apparently	arise	de	novo	[132-135].		
Additionally,	 parafollicular	 cells	 can	 develop	 into	 the	 medullary	 thyroid	
carcinoma	(MTC).		
	
	
	
Figure	 5:	 Schematic	 model	 of	 thyroid	 cancer	 progression.	 This	 model	 is	 based	 on	
histological	and	clinical	features	as	well	as	on	the	degree	of	tumour	differentiation.	The	
WDTC	 cell	 may	 give	 rise	 to	 both	 benign	 and	 malignant	 tumours.	 Additionally,	 the	
differentiated	 thyroid	 follicles	 can	 also	 give	 rise	 to	 well-differentiated	 papillary	 or	
follicular	carcinomas,	PDTC,	and	anaplastic	carcinoma.	The	parafollicular	cells	may	give	
rise	to	C-cell	hyperplasia,	and	then	to	MTC.		
		
	
	
1.3.1	Well-differentiated	thyroid	cancer	
	
1.3.1.1	Clinical	Presentation	
	
	
Among	 thyroid	 tumours,	 the	well-differentiated	carcinomas	are	 the	ones	 that	
presents	the	best	overall	prognosis.	They	are	the	most	common	tumours,	accounting	
for	more	than	95%	of	cases	and	include	three	main	entities:	papillary	thyroid	carcinoma	
(PTC),	follicular	thyroid	carcinoma	(FTC)	and	Hürthle	cell	carcinoma	(HCC).	
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PTC	 is	 the	 most	 common	 subtype	 and	 carries	 the	 best	 overall	 prognosis.	
Metastases	 most	 commonly	 involve	 cervical	 lymph	 nodes	 and,	 less	 commonly,	 the	
lungs.	Microscopically,	PTC	are	characterized	by	the	presence	of	papillary	areas,	showing	
evidence	 of	 follicular	 cell	 differentiation,	 being	 characterized	 by	 distinctive	 nuclear	
features	[136],	such	as	large	and	clear	nuclei,	containing	cytoplasmatic	inclusions	and	
grooves	[137].	PTC	is	also	associated	with	the	presence	of	psammoma	bodies	(PB),	which	
can	appear	as	microcalcifications	on	ultrasonography	in	up	to	50%	of	patients.	Due	to	
their	well-differentiated	nature,	PTC	cells	often	retain	their	ability	to	concentrate	iodine	
and	occasionally	produce	thyroid	hormones	[138-140].	They	also	produce	and	secrete	
thyroglobulin	(Tg)	and	can	express	thyrotropin	receptors	on	their	surfaces	[141].	PTCs	
that	are	composed	 totally	or	 in	part	by	papillae	besides	 the	aforementioned	nuclear	
features,	are	classified	as	classic	variant	of	PTC	(cPTC),	comprising	the	most	 frequent	
histotype.	
The	second	most	common	histotype	of	PTC	is	the	follicular	variant	(fvPTC),	with	
an	increasing	frequency,	comprising	about	20-30	%	of	all	PTCs.	It	is	composed	exclusively	
or	 almost	 exclusively	 of	 follicles	 lined	 by	 cells	 showing	 nuclear	 features	 of	 papillary	
carcinoma.	Well-formed	papillae	should	not	be	observed	in	fvPTCs	[136,	142-144].	This	
variant	 commonly	 presents	 as	 infiltrative	 (or	 nonencapsulated)	 and	 as	 a	 well	
circumscribed	 or	 noninvasive	 encapsulated	 follicular	 variant	 of	 papillary	 thyroid	
carcinoma	(EFVPTC),	and	as	a	result	of	encapsulation	and	follicular	architecture,	it	may	
be	 mistaken	 for	 follicular	 adenoma	 or	 follicular	 carcinoma.	 Although	 fvPTC	 is	
distinguished	 from	 follicular	 adenoma	and	 carcinoma	by	 its	 characteristic	 “papillary”	
nucleus,	nuclear	features	are	often	subtler	than	that	of	cPTC,	making	this	variant	one	of	
the	most	controversial	entities	of	surgical	pathology,	largely	due	to	the	lack	of	consensus	
on	when	to	(or	not	to)	diagnose	the	nuclear	features	of	papillary	carcinoma	[143-146].	
The	 EFVPTC	 has	 an	 indolent	 behaviour	 and	 is	 genetically	 distinct	 from	 infiltrative	
tumours.	Yet,	most	patients	with	EFVPTC	continue	to	be	treated	similarly	to	those	with	
conventional	 PTC.	Recently,	Nikiforov	et	 al.	 [147]	 proposed	 that	 noninvasive	 EFVPTC	
having	a	very	low	risk	of	adverse	outcome	should	be	termed	as	“noninvasive	follicular	
thyroid	 neoplasms	 with	 papillary-like	 nuclear	 features”	 (NIFTP).	 This	 reclassification	
intends	 to	 affect	 a	 large	 population	 of	 patients	 worldwide	 to	 achieve	 a	 significant	
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reduction	 in	psychological	and	clinical	consequences	associated	with	the	diagnosis	of	
cancer.	
The	EFVPTC	 rarely	metastasises	 to	 lymph	nodes,	present	only	 in	 about	5%	of	
cases.	 The	 infiltrative/diffuse	 fvPTC	 tumours	 harbour	 more	 often	 lymph	 node	
metastasis,	which	are	reported	in	around	65%	of	cases.	The	prognosis	of	these	tumours	
is	 similar	 to	 the	 cPTC	 [148].	 There	 are	 several	 other	 histological	 subtypes	 of	 PTC	
described,	besides	the	cPTC	and	the	fvPTC,	but	with	low	incidence.	They	always	present	
the	 characteristic	 nuclei,	 therefore	 the	 variants	 of	 PTC	 differ	 in	 their	 morphologic	
organization	and	background	[136].		
The	 FTC	 is	 an	 unusual	 tumour	 comprising	 approximately	 5	 –	 10%	 of	 thyroid	
malignancies	 in	 nonendemic	 goiter	 areas	 of	 the	 world	 [149].	 The	 identification	 of	
capsular	 or	 vascular	 invasion	 differentiates	 FTC	 from	 follicular	 adenoma.	
Macroscopically,	 FTC	 tends	 to	 comprise	 solitary	 tumours	 of	 varying	 sizes	 with	 thick	
fibrous	capsules	that	have	a	tan	cut	surface.	FTC	is	considered	a	more	aggressive	WDTC	
when	 compared	 to	 PTC	 [150].	 Several	 prognostic	 features	 that	 decrease	 the	 overall	
survival	of	FTC	include	age,	tumour	size,	distant	metastasis,	extrathyroid	extension	and	
histologic	type.	In	high	risk	groups	(age	>	45	years,	stage	>	T1,	distant	metastasis,	high	
histologic	grade),	the	10-year	survival	rate	can	be	as	low	as	56%	[151].	The	two	main	
subgroups	of	FTC	are	the	minimally	invasive	and	the	widely	invasive.	Minimally	invasive	
FTCs	have	been	shown	in	several	studies	to	have	a	more	favourable	prognosis	[151-154].	
FTC	has	a	higher	rate	of	haematogenous	spread	than	PTC.	It	is	important	to	the	surgeon	
to	recognize	it	at	the	time	of	diagnosis	of	FTC,	once	10%	to	15%	of	cases	present	distant	
metastasis	[155-157].		
HCC	 can	 be	 considered	 a	 subtype	 of	 FTC,	 accounting	 for	 3-4%	 of	 TC	 and	 is	
pathologically	characterized	by	the	presence	of	cells	 rich	 in	mitochondria	 (Hürthle	or	
oncocytic	cells).	The	Hürthle	cell’s	rich	mitochondrial	content	makes	HCCs	appear	brown	
on	their	cut	surface.		
	
1.3.1.2	Genetic	Alterations		
	
The	 BRAFV600E	 mutation	 is	 the	 most	 common	 genetic	 mutation	 detected	 in	
patients	with	TC	and	occur	in	approximately	50-70%	of	patients	with	PTC	[158].	Genomic	
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rearrangements	also	occur	often	in	TC	leading	to	expression	of	novel	fusion	oncogenes	
that	 are	 present	 in	 many	 TC.	 PAX8–peroxisome	 proliferator-	 activated	 receptor	 γ	
(PPARγ)	 translocation	occurs	 in	more	 than	30%	of	 FTC	 cases	 [159],	 and	 the	RET-PTC	
translocations	 targeting	 the	 RET	 oncogene	 occur	 in	 about	 20%	 of	 PTC	 cases	 [160].	
Additionally,	mutations	in	the	promoter	of	telomerase	(pTERT)	have	been	identified	in	
all	types	of	TC,	in	particular	in	more	aggressive	subsets	of	TC	[161].		
	
1.3.1.3	Assessment	and	Treatment	
	
The	assessment	of	a	thyroid	nodule	is	made	primarily	by	ultrasonography,	and	
depending	on	such	sonographic	appearances,	patient	undergo	(or	not)	to	fine-needle	
aspiration	(FNA).	2015	ATA	guidelines	recommend	biopsy	only	for	nodules	larger	than	1	
cm.	 For	 the	 classification	 of	 the	 FNA,	 the	 Bethesda	 system	 for	 reporting	 thyroid	
cytopathology	 includes	 six	 diagnostic	 categories	 [162]	 that	 goes	 from	 benign	 to	
malignant	nodules	(which	generally	need	surgery).		
Concerning	the	treatment,	PTC	greater	than	2	cm	(T2)	is	best	managed	by	total	
thyroidectomy.	Thyroid	lobectomy	and	isthmectomy	may	be	adequate	for	unifocal	PTC	
less	than	1	cm	in	patients	without	negative	prognostic	factors.	Central	compartment	and	
possible	 lateral	 neck	 dissections	 should	 be	 performed	 when	 nodal	 metastases	 are	
present	 in	 the	 respective	 nodal	 basins.	 Post-operatively,	 radioactive	 iodine	 (RAI)	
ablation	 with	 131I	 followed	 by	 thyroid	 stimulating	 hormone	 (TSH)	 suppression	 is	
indicated	 in	 certain	patients	 to	 improve	 loco-regional	 control	 and	 reduce	 recurrence	
[163].		
FTC	 is	 diagnosed	 microscopically	 through	 the	 identification	 of	 capsular	 or	
vascular	 invasion.	 Finally,	 the	 microscopically	 diagnosis	 of	 HCC	 is	 made	 through	
identification	of	capsular	or	vascular	invasion,	similar	to	that	of	FTC,	and	the	presence	
of	Hürthle	cells.	Although	HCC	rarely	presents	lymph	node	metastases,	it	has	the	highest	
incidence	 of	 distant	metastasis	 of	 all	 the	WDTC.	 Approximately	 34%	 of	 patients	will	
develop	distant	metastasis	at	some	time	during	their	illness	[164].	It	also	has	a	higher	
rate	of	refractoriness	to	radio-iodine	therapy	compared	to	PTC	and	FTC	[156,	165].	
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1.3.2	Medullary	thyroid	carcinoma	
 
1.3.2.1	C-cell	pre-neoplastic	lesion		
	
	
C-Cell	 hyperplasia	 (CCH)	 was	 first	 described	 in	 the	 early	 1970's	 [166-168]	 in	
asymptomatic	 relatives	 of	 patients	 with	MTC.	 CCH	 is	 characterized	 by	 an	 abnormal	
increased	number	of	C	cells	(parafollicular	cells)	within	the	thyroid	gland.		
Such	hyperplasia	can	be	further	classified	as	physiological	(reactive)	or	neoplastic	
[169].	 The	 reactive	 CCH	 corresponds	 to	 proliferation	 of	 calcitonin-producing	 cells	 in	
response	to	different	physiological	and/or	pathological	endocrine	stimuli	(e.g.,	thyroid-
stimulating	hormone	overstimulation,	hypercalcemia,	and	paracrine	factors)	[170,	171].	
Reactive	CCH	has	no	malignant	potential	and	can	be	observed	in	association	with	many	
other	 thyroid	diseases	 (including	WDTC)	 [169,	172].	On	 the	 contrary,	neoplastic	CCH	
should	 be	 considered	 as	 a	 pre-neoplastic	 stage	 in	 the	 spectrum	 of	 C-cell	 disease,	
ultimately	leading	to	the	development	of	the	MTC.	In	particular,	the	progression	from	
CCH	to	MTC	is	a	well-defined	event	in	the	hereditary	setting,	including	isolated	familial	
MTC	and	multiple	endocrine	neoplasia	type	2	(MEN2)	syndromes	[171,	173,	174].	
Neoplastic	CCH	is	considered	as	a	pre-neoplastic	condition,	commonly	observed	
in	patients	with	germ-line	mutations	in	the	RET	oncogene	(commonly	in	families	with	a	
history	of	hereditary	MTC,	 i.e.	 familial	MTC	or	multiple	endocrine	neoplasia	types	 IIA	
and	IIB)	[174,	175].	In	sporadic	cases,	the	role	of	CCH	in	carcinogenesis	is	controversial.	
In	 such	cases,	CCH	has	been	considered	as	a	different	state	 in	C-cell	pathology	 [176,	
177].	
Frequently,	 the	 diagnosis	 of	 CCH	 may	 fail,	 first	 because	 of	 the	 very	 low	
proportion	of	C-cells	in	thyroid,	and	secondly	due	to	its	particular	form	of	distribution	
throughout	the	thyroid	parenchyma	(its	density	is	higher	in	the	upper	two-thirds	of	the	
thyroid	lobes,	with	the	highest	concentration	found	in	the	junction	zone	between	the	
upper	and	middle	thirds	of	each	lobe	[178,	179]);	therefore,	the	partial	examination	of	
the	thyroid	gland	may	lead	to	non-representative	material,	causing	diagnosis	difficulties	
[178,	179].		
Since	C-cells	are	widely	recognized	for	 its	ability	to	secrete	calcitonin,	prior	to	
surgery,	the	CCH	diagnosis	should	be	suspected	in	the	presence	of	hypercalcitoninemia.	
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Apart	 from	 MTC,	 CCH	 is	 the	 most	 common	 feature	 found	 in	 patients	 with	
hypercalcitoninemia,	especially	in	the	absence	of	suspect	thyroid	nodules	(which	could	
indicate	 the	 presence	 of	 MTC)	 [180,	 181].	 Overall,	 total	 thyroidectomy	 (which	 is	
currently	the	preferred	surgical	approach	in	the	majority	of	thyroid	diseases,	including	
MTC),	is	an	adequate	treatment	and	achieves	cure,	even	in	patients	with	neoplastic	CCH.	
However,	for	patients	with	pure	CCH,	cervical	lymph	node	dissection	is	not	performed	
[182].	
 
	
1.3.2.2	Clinical	Presentation	
	
MTC	is	a	rare	thyroid	malignancy	(accounting	for	1–2%	of	all	TCs)	[183].	Derived	
from	C-cells,	MTC	is	associated	with	a	higher	incidence	of	distant	metastasis	and	poorer	
prognosis	compared	with	the	more	frequent	well-differentiated	papillary	and	follicular	
thyroid	carcinomas	[184,	185].	This	malignancy	is	often	found	as	a	single	nodule	in	the	
thyroid	 in	 patients	 between	 forty	 and	 sixty	 years	 old	 [186].	 Occasionally,	 neck	
lymphadenopathy	 is	 the	 first	 manifestation,	 because	 the	 disease	 frequently	
metastasises	 to	 cervical	 lymph	 nodes,	 being	 that	 70%	 of	 the	 patients	 presenting	
palpable	MTC	have	evidence	of	cervical	metastases	at	surgery	[187].			
Due	 to	 the	 typical	 distribution	of	C-cells	 throughout	 the	 thyroid	parenchyma,	
mentioned	in	the	previous	section,	the	tumour	is	typically	located	at	the	junction	of	the	
upper	 third	 and	 the	 lower	 two-thirds	 of	 the	 thyroid	 lobes.	 25%	 of	 MTCs	 occur	 as	
hereditary	 forms,	 the	 majority	 of	 which	 occur	 as	 part	 of	 the	 multiple	 endocrine	
neoplasia	(MEN)	2	syndromes	[188].		
	
	1.3.2.3	Genetic	Alterations	
	
The	most	frequent	mutations	in	MTC	occur	in	the	RET	proto-oncogene,	whereas	
a	small	proportion	presents	sporadic	RAS	mutations.	RET	mutations	can	be	somatic	or	
germline	events	exhibiting	autosomal	dominant	 inheritance	 [186,	189].	RET	 germline	
mutations	can	predispose	patients	to	early	development	of	MTC	as	a	component	of	the	
MEN	2A	and	2B	syndromes.	As	such,	patients	who	present	MTC	at	young	age	are	likely	
to	have	hereditary	disease.		
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Somatic	mutations	of	the	RET	proto-oncogene	have	been	identified	in	25-33%	of	
sporadic	MTC,	and	may	be	associated	with	a	poor	outcome	compared	with	 sporadic	
tumours	without	RET	mutation	[190,	191].	Besides	mutations	in	different	codons	of	RET	
gene,	small	deletions	of	the	RET	gene	have	also	been	identified	in	a	few	cases.	
Because	1–7%	of	patients	presenting	apparently	 sporadic	MTC	are	 carriers	of	
germline	RET	mutations	[186],	assessment	for	a	heritable	RET	germline	mutation	should	
be	recommended	to	all	patients	presenting	MTC,	regardless	of	their	family	history	or	
age.		
	
	
	1.3.2.4	Assessment	and	Treatment	
	
Surgery	 is	 the	 only	 curative	 treatment	 for	 MTC;	 however,	 few	 patients	 with	
clinically	apparent	nodal	metastases	at	diagnosis	achieve	undetectable	tumour	markers.	
Imaging	and	diagnosis	before	 surgery	are	 crucial	 to	 indicate	 the	appropriate	 surgical	
intervention,	 as	 with	 differentiated	 thyroid	 cancer.	 Ultrasonography	 and	 tumour	
markers	(calcitonin	and	carcinoembryonic	antigen)	measurement	are	made	in	patients	
with	preoperative	diagnosis	of	MTC.		
Such	cases	in	which	the	tumour	markers	are	undetectable	and	present	normal	
imaging	after	surgery	should	continue	to	be	followed	up	annually;	those	with	persistent	
tumour	markers	need	to	be	followed	up	more	closely	for	progression.	Calcitonin	and	
carcinoembryonic	 antigen	 doubling	 times	 are	 useful	 measures,	 because	 they	 are	
predictive	of	outcomes	and	aggressive	tumour	behaviour	[192].	Patients	with	calcitonin	
and	carcinoembryonic	antigen	doubling	times	within	6	months	have	a	shorter	overall	
survival.	 Concerning	 chemotherapy,	 treatment	 with	 dacarbazine,	 5-fluorouracil	 and	
doxorubicin	(alone	or	in	combination)	has	shown	very	limited	efficacy,	achieving	only	
partial	responses	in	the	range	of	10	e	20%	and	of	short	duration	[193-195].	A	variety	of	
kinase	inhibitors	are	currently	under	evaluation	and	preliminary	results	are	promising.	
They	include	motesanib	diphosphate,	vandetanib,	sorafenib	and	sunitinib.	Preliminary	
results	showed	partial	responses	in	6-20%	of	patients,	and	stable	disease	in	47-87%	of	
patients	with	tolerable	and	manageable	toxicities	[196-198].		
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Chapter	2	–Aims	
 
 
 
With this thesis we intended to address the role of the total osteopontin (tOPN) 
and its variants (OPNa, OPNb and OPNc) in the two main histotypes thyroid carcinoma 
(TC). As mentioned above, OPN is a matricellular protein overexpressed in many types 
of cancers where it correlates with poor survival. OPN effects in tumour progression have 
been associated with its ability to induce ECM invasion and migration. Proteolysis and 
remodelling of the ECM represent early events modulating cancer cell invasion through 
the surrounding stroma, and OPN has been implicated in such processes. OPN has been 
shown to be overexpressed in TC being, similarly to what was reported in other tumour 
models, associated with guarded prognosis. Although some key molecular functions have 
been attributed to OPN in the invasion and progression of the thyroid tumours, little is 
known about the role of OPN in TC, in particular in what concerns the differential effect 
of OPN splice variants and the putative differences between the distinct TC histotypes. 
 
Our aims were: 
 
1) To evaluate the expression profile of tOPN, OPNa, OPNb and OPNc in TC 
tissues and to compare with their expression in samples from non-tumour at thyroid 
tissues and benign tumours; 
 
2) To evaluate the relationship between tOPN expression profile and its variants 
with the clinicopathological data and genetic alterations of the two main types of TC; 
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3) To evaluate the functions of the OPN variants (OPNa, OPNb and OPNc) in TC 
cell lines and its relationship with their tumourigenic capacities, including the analysis of 
activity and profile of MMPs expression; 
 
4) To evaluate the relationship between the expression of OPN and its variants 
with aspects of ECM remodelling, including the role of OPN in collagen deposition and 
the formation of dystrophic calcifications including psammoma bodies. 
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Chapter	3	–	Paper	I	-	Osteopontin-a	splice	variant	is	overexpressed	
in	papillary	thyroid	carcinoma	and	modulates	invasive	behavior		
	
This	 chapter	 appears	 as	 an	article	with	 the	 same	 title	published	 in	 the	 “Oncotarget”	
Ferreira	LB	et	al.	(2016)	7,	52003-52013	
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ABSTRACT
Osteopontin (OPN) is a matricellular protein overexpressed in cancer cells 
and modulates tumorigenesis and metastasis, including in thyroid cancer (TC). The 
contribution of each OPN splice variant (OPN-SV), named OPNa, OPNb and OPNc, in 
TC is currently unknown. This study evaluates the expression of total OPN (tOPN) 
and OPN-SV in TC tissues and cell lines, their correlation with clinicopathological, 
molecular features and their functional roles. We showed that tOPN and OPNa are 
overexpressed in classic papillary thyroid carcinoma (cPTC) in relation to adjacent 
thyroid, adenoma and follicular variant of papillary thyroid carcinoma (fvPTC) 
tissues. In cPTC, OPNa overexpression is associated with larger tumor size, vascular 
invasion, extrathyroid extension and BRAFV600E mutation. We found that TC cell lines 
overexpressing OPNa exhibited increased proliferation, migration, motility and in vivo 
invasion. Conditioned medium secreted from cells overexpressing OPNa induce MMP2 
and MMP9 metalloproteinases activity. In summary, we described the expression 
pattern of OPN-SV in cPTC samples and the key role of OPNa expression on activating 
TC tumor progression features. Our findings highlight OPNa variant as TC biomarker, 
besides being a putative target for cPTC therapeutic approaches.
INTRODUCTION
Thyroid cancer (TC) is the most common endocrine 
malignancy, being the fifth most frequent cancer in women 
[1]. TC incidence rates have been increasing in the last 
three decades all over the world [2]. The reason for the 
raised incidence of TCs remains controversial. While some 
studies point to improved diagnostic approaches [3, 4], 
others indicate that it may be correlated to environmental 
and lifestyle changes [5-8].
The majority of TCs are derived from follicular 
cells, being differentiated thyroid cancer (DTC), 
comprising papillary thyroid cancer (PTC) and follicular 
thyroid cancer (FTC), the most common subtypes and 
accounting for 90–95% of all cases [9]. Within PTCs, 
which encompass more than 80% of TCs, classical type 
               Research Paper
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of PTC (cPTC) corresponds to around 50% of the cases, 
whereas follicular variant PTC (fvPTC) corresponds to 
about 40% of all PTCs [10].
Despite the overall good prognosis of DTCs, a 
subset of DTC patients follows a more aggressive disease 
course, developing recurrent or metastatic disease [11]. 
The early identification of this cases is one of the most 
challenging tasks in thyroid oncology.
Osteopontin (OPN) is a secreted extracellular matrix 
(ECM) protein encoded by the highly conserved SPP1 gene 
[12]. Previous studies have found that total OPN (tOPN) 
is overexpressed in TCs [13-17], similarly as reported in 
other tumor models, being correlated with poor survival 
[17]. tOPN effects in tumor progression has been associated 
with its ability to induce ECM invasion and migration 
[18]. Proteolysis and remodeling of the ECM represent 
early events modulating cancer cell invasion through the 
surrounding stroma [19, 20], and OPN has been implicated 
in such processes [21, 22].
OPN primary transcript is subjected to alternative 
splicing, generating three OPN splicing variants (OPN-
SV): the full-length OPNa and the shorter variants OPNb 
and OPNc (lacking exons 5 and 4, respectively) [23]. 
Recent studies have shown that OPN-SV are differentially 
expressed and may exhibit functional differences in 
normal tissue and their respective tumors [24]. For 
instance [25], in hepatocellular carcinoma (HCC), tumor 
tissues predominantly expressed OPNa and OPNb, while 
normal liver tissues mainly expressed OPNc. In this tumor 
model, OPNa and OPNb induced Hep3B cell migration, 
while OPNc had no significant effect. However, in SK-
Hep1 cells OPNc suppressed the migratory activity, while 
OPNa induced no significant changes [25]. Our group 
previously demonstrated that OPNc, but not OPNa and 
OPNb, is specifically expressed in ovarian cancer samples. 
Furthermore, OPNc overexpression in OvCar-3 cells 
activates proliferation, migration, invasion and colony 
formation, as well as tumor formation in nude mice [26].
Based on these data, we then hypothesized that specific 
OPN-SV could be putative biomarkers in TCs. We here 
investigated the expression patterns and putative biological 
roles of tOPN and OPN-SV in DTC tumor progression.
RESULTS
tOPN protein is overexpressed in cPTC and 
is associated with vascular invasion and 
extrathyroid extension
In thyroid tumor tissues (Figure 1A-1H), tOPN 
staining was mainly localized in the cytoplasm of 
TC cells, although a few samples also showed focal 
membrane staining (Figure 1G and 1H). Total OPN protein 
expression was observed in 27 of 44 cPTCs (61.4%), in 6 
of 16 fvPTCs (37.6%) and in 6 of 10 FTCs (60%). In the 
cPTC, staining intensity was faint in 31.8%, moderate in 
20.5% and strong in 9.1% of the cases (Table 1). Staining 
score of the positive cases was moderate to high in the 
majority of the cases (Table 1). Representative sections 
of tOPN staining scores from 0 to 7 are also depicted in 
Figure 1. Tissues adjacent to thyroid tumor areas were 
virtually negative for tOPN staining (Figure 1I and 1J).
Of note, cPTC samples displaying vascular invasion 
exhibited higher tOPN staining scores than tumors 
without vascular invasion (Table 2). Tumors displaying 
extrathyroid extension had higher average tOPN staining 
score than tumors without this feature, although not 
attaining statistical significance (Table 2). cPTC samples 
containing hyaline stroma exhibited higher tOPN staining 
score than tumors without stroma (p = 0.01) (Table 2). In 
cPTC samples, no significant associations were observed 
between tOPN staining scores and patient’ gender or age, 
tumor size, capsular invasion, lymph node metastasis, 
thyroiditis, RET/PTC translocation, BRAFV600E, RAS and 
TERT mutations. Moreover, no significant associations 
were observed between tOPN staining score and any 
clinicopathological or molecular features in FTC (data not 
show). With regard to tOPN protein expression in well and 
poorly circumscribed fvPTC cases, there is a difference 
in the tOPN staining score media, although not attaining 
statistical significance (Supplementary Table S1).
OPNa is the predominant OPN-SV expressed 
in cPTC tissues and thyroid cell lines and is 
associated to invasiveness
Since we had observed a higher tOPN protein 
expression in cPTC and a significant association with 
invasive features, we then evaluated the mRNA expression 
patterns of each OPN-SV (OPNa, OPNb or OPNc) and of 
tOPN, in an attempt to evaluate their relative contributions 
to cell invasiveness. The comparison of tOPN and each 
OPN-SV expression levels among distinct thyroid tissue 
samples showed that tOPN is overexpressed in relation 
to each OPN-SV (Supplementary Figure S1). It is worth 
to mention, that tOPN expression corresponds to the sum 
of all OPN-SV. Among the three OPN-SV, OPNa has the 
highest expression levels in all thyroid tissues (Figure 2A 
and Supplementary Figure S1).
cPTC samples express higher levels of tOPN, OPNa 
and OPNb, when compared to adjacent thyroid, adenoma 
and FTC samples (p < 0.05) (Figure 2A; 2B and 2C). 
OPNc variant has the lowest expression levels and is only 
significantly overexpressed in cPTC samples in relation 
to adenoma and fvPTC samples (Figure 2D). These data 
show that OPNa splice variant is overexpressed in cPTCs 
when compared to other thyroid tissues. In an attempt to 
understand the expression pattern of OPN-SV in fvPTC 
cases, we separately analyzed well or poorly circumscribed 
fvPTC cases. We observed that poorly circumscribed fvPTC 
significantly overexpress tOPN, OPNb and OPNc variants, 
compared with well-circumscribed cases of fvPTC (p = 0.02, 
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p = 0.002 and p = 0.01; respectively). Also a higher expression 
of OPNa in poorly circumscribed fvPTC was noted, although 
not reaching statistical significance (p = 0.07) (Figure 2E). 
The median transcript expression levels of tOPN were 
significantly higher in cPTC tumors larger than 2 cm (Table 3). 
tOPN and OPNa median expression levels were significantly 
Figure 1: Total OPN (tOPN) IHC staining in cPTC samples. Representative sections of cPTC samples showing tOPN staining 
in thyroid tumor cells (20x and 60x magnification, respectively at the left and right images are shown A-H. Scale bar: 50 µm). A and B 
represent cPTC samples with staining score 0; C and D, staining score 3; E and F, staining score 5; G and H staining score 7. Black arrows 
points to membrane tOPN staining (G and H); I and J: represent adjacent thyroid tissues negative for tOPN staining.
Table 1: Staining intensity, proportion of positive stained cells and staining score of tOPN IHC in cPTC samples
Staining 
intensity
n % Proportion of positive 
stained cells %
n % OPN Staining 
Score*
%
Absent 17 38.6 <5% 22 50 0 38.6
1 2.3
Faint 14 31.8 5-25% 6 13.6 2 15.9
3 11.4
Moderate 9 20.5 25-50% 4 9.1 4 4.5
5 13.6
Strong 4 9.1 50-75% 1 2.3 6 11.4
7 2.3
75-100% 11 25
Total 44 100 44 100 44 100
* Staining intensity plus % of positive stained cells
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Table 2: tOPN protein expression evaluated by IHC and correlation with clinicopathological associations in 
formalin-fixed paraffin-embedded (FFPE)
Tissue Clinicopathological features (N) tOPN tissue expression (Average ± SD) p-value
cPTC Stroma
 Absent (n=17) 1.53 ± 2.18 p=0.01
 Hyaline (n=19) 3.37 ± 2.16
Vascular Invasion
 Absent (n=16) 1.44 ± 2.15 p=0.05
 Present (n=23) 2.91 ± 2.41
Extrathyroid Extension
 Absent (n=21) 0.67 ± 1.98 p=0.07
 Present (n=18) 3.00 ± 2.56
Figure 2: Transcript expression levels of tOPN, OPNa, OPNb and OPNc in thyroid tissue samples and in thyroid cell 
lines. A. tOPN, B. OPNa, C. OPNb and D. OPNc mRNA expression levels has been measured by real time PCR in the distinct thyroid 
tissue samples (symbols: adjacent thyroid -•; follicular adenomas -■; FTC -▲; fvPTC -▼; cPTC -♦); E. mRNA expression levels have 
been measured by real time PCR in well and poorly circumscribed fvPTC tissue samples (symbols: tOPN expression in well circumscribed 
fvPTC -•; tOPN expression in poorly circumscribed fvPTC -■; OPNa expression in well circumscribed fvPTC -▲; OPNa expression in 
poorly circumscribed fvPTC -▼; OPNb expression in well circumscribed fvPTC -♦; OPNb expression in poorly circumscribed fvPTC -○; 
OPNc expression in well circumscribed fvPTC - •; OPNc expression in poorly circumscribed fvPTC -Δ) F. OPN-SV transcript expression 
levels have been also evaluated in distinct thyroid tumor cell lines (TPC1, KAT4, Hth74, XTC1, 8505c, K1, BCPAP and c643). * p < 0,05; 
** p < 0,01; **** p < 0,0001. Results are representative of at least two independent assays with triplicates.
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higher in cPTC samples with extrathyroid extension and 
vascular invasion than in those without such features 
(Table 3). cPTC harboring BRAFV600E gene mutation exhibited 
higher tOPN, OPNa and OPNb transcript expression levels 
than those presenting wild type BRAF gene (p < 0.03) 
(Table 3). In fvPTC, older patients presented higher tOPN and 
OPNa expression levels (p < 0.04). No statistical significant 
differences have been observed between tOPN and OPN-SV 
transcript expression levels and other clinicopathological or 
molecular features in fvPTC.
Regarding OPN-SV expression patterns in TC cell 
lines, we found that OPNa variant is also overexpressed 
when compared to OPNb and OPNc variants in all the 
tested TC cell lines, except XTC1 (Figure 2F).
OPNa overexpression modulates proliferation 
and migration in c643 and 8505c cell lines
c643 and 8505c cells transfected with each OPN-
SV express higher transcript levels of the corresponding 
ectopically expressed OPN-SV in relation to EV control 
cells (Figure 3A and 3B) and were used for further 
functional assays, as depicted below. The overexpression 
of OPN protein in c643 and 8505c cell lines transfected 
with tOPN and each OPN-SV was validated using 
immunocytochemistry (Figure 3C and 3D).
c643 and 8505c OPNa overexpressing cells 
displayed higher proliferation rates than OPNb, OPNc and 
EV control at 48 h (p < 0.01) (Figure 4A, 4B; p < 0.05).
In order to investigate the effect of OPN-SV 
overexpression on c643 and 8505c cell migration, these 
cells were subjected to in vitro wound closure assays (Fig. 
4C, 4D, 4E and 4F). c643 clones overexpressing OPNa have 
higher migration rates, as depicted by wounding area, than 
OPNb, OPNc or EV clones. At 6h after cell scratch, c643-
OPNa overexpressing cells completely closed the wound 
edges, at variance with OPNb, OPNc or EV clones. The 
same migration behavior was observed for 8505c-OPNa 
overexpressing cells, although the wound closure has only 
been achieved at 12h after cell scratch. In order to further 
validate these motility properties, we used time-lapse 
video microscopy, monitoring the distance travelled by 
the cells during 12h. As shown in Figure 4G, c643-OPNa 
overexpressing clones showed higher motility rates than the 
remaining OPN-SV clones and EV controls. Similar higher 
motility behavior pattern has been observed for 8505c-OPNa 
overexpressing cells (Figure 4H) (Representative videos are 
shown in Supplemental Material).
TC cells overexpressing OPNa induces MMP2 
and MMP9 activity
We then investigated the impact of OPNa 
overexpression in invasion-related enzymes secreted 
at the extracellular conditioned medium (CM). CM 
secreted from c643 and 8505c cells overexpressing 
OPNa, OPNb, OPNc or EV control were tested for 
MMP2 and MMP9 metalloproteinase activity. We found 
Table 3: Correlation between tOPN and OPN-SV transcript expression levels with clinicopathological and molecular 
features in cPTC and fvPTC samples
Tissue Variable tOPN mRNA 
expression 
(Median)
p-value OPNa mRNA 
expression 
(Median)
p-value OPNb mRNA 
expression 
(Median)
p-value
cPTC Tumor size (cm)
  <2 (n=18) 0.14 p=0.02 0.12 p=0.27 0.10 p=0.89
  ≥ 2 (n=38) 0.17 0.13 0.10
Extrathyroid Extension
  Absent (n=20) 0.15 p=0.04 0.12 p=0.02 0.09 p=0.09
  Present (n=21) 0.18 0.13 0.11
fvPTC
 
Vascular Invasion
  Absent (n=22) 0.15 p=0.04 0.12 p=0.03 0.10 p=0.45
  Present (n=28) 0.17 0.13 0.10
BRAFV600E Mutation
  Absent (n=26) 0.14 p=0.03 0.12 p=0.01 0.09 p=0.01
  Present (n=30) 0.18 0.13 0.11
Age (yr)
  <45 (n=13) 0.11 p=0.03 0.09 p=0.04 0.08 p=0.07
  ≥45 (n=9) 0.17 0.14 0.11
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that the levels of matrix MMP2, mainly the active form, 
were increased in the CM secreted from c643-OPNa 
overexpressing cells, compared to CM secreted from 
the corresponding c643-OPNb and c643-OPNc clones 
(Figure 5A). No MMP9 expression was detected 
in c643 cells, regardless of the expressed OPN-SV. 
We observed an increase in the activity of MMP2 
and MMP9 in the CM secreted from 8505c-OPNa 
overexpressing cells (Figure 5B). 8505c-OPNa 
overexpressing cells present higher levels of active 
MMP2 and MMP9 than 8505c-OPNb and 8505c-OPNc 
overexpressing cells.
Overexpression of OPNa increases the invasive 
potential of TC cells in the CAM assay
In vivo CAM assays were conducted to evaluate the 
effect of ectopic OPNa overexpression on the angiogenic, 
tumorigenic and invasive behavior of c643 cells. To 
achieve this, the c643 clones overexpressing OPNa and 
EV were injected in the chick embryo CAM.
Tumors formed by cells overexpressing OPNa exhibited 
an invasive pattern (Figure 6A, left). In contrast, xenograft 
tumors formed by c643-EV cells were compact, with 
encapsulated-like borders (Figure 6A, right), as evaluated by HE 
staining (Figure 6A, upper panel) and IHC for tOPN staining 
(Figure 6A, lower panel). We used a score system to semi-
quantify the property of TC cells to spread inside the CAM. 
We observed that c643 cells overexpressing OPNa exhibited 
higher invasive capacity (p = 0.003) than c643-EV cells. This 
higher invasiveness was characterized by the presence of tumor 
cells oriented towards the invasion front and the presence of 
isolated cells and small clusters at distance from the tumor 
bulk (Figure 6B). Similar angiogenic (p > 0.05; Figure 6C) 
and tumorigenic responses (p > 0.05; Figure 6D) were observed 
in c643-OPNa when compared with c643-EV control.
DISCUSSION
We characterize for the first time the transcript and 
protein expression patterns of tOPN and OPN-SV in DTC 
Figure 3: Stable overexpression of each OPN-SV in c643 and 8505c transfected cells. The expression levels of each OPN-
SV were analyzed by qRT-PCR, when compared to control cells transfected with EV plasmid, which was used as the reference sample. 
The relative expression levels of each OPN-SV were calculated using the delta-delta CT method (pcR3.1/OPNa, pcR3.1/OPNb or pcR3.1/
OPNc relative to pcR3.1/EV). Each OPN-SV is represented by a different bar graph, as indicated. A. OPN-SV mRNA overexpression in 
c643 cells; B. OPN-SV mRNA overexpression in 8505c cells. C. Immunocytochemistry analyses of OPN expression in control cells (c643 
cells with EV: pcR3.1/EV) and in c643 cells overexpressing OPNa (pcR3.1/OPNa), OPNb (pcR3.1/OPNb) and OPNc (pcR3.1/OPNc) have 
been performed using the anti-tOPN antibody; D. Immunocytochemistry analyses of OPN expression in control cells (8505c cells with 
EV: pcR3.1/EV) and in 8505c cells overexpressing OPNa (pcR3.1/OPNa), OPNb (pcR3.1/OPNb) and OPNc (pcR3.1/OPNc). NOTE: Cell 
isolated clones used for these assays were named EV2, a3, b3 and c1 for each OPN-SV.
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and TC cells. Then, we also showed their association 
to TC prognosis and progression features, especially in 
cPTC samples. Our data further demonstrated that OPNa 
transcript is the dominant overexpressed splice variant in 
DTC tissues and in distinct thyroid cell lines, notably in 
cPTC. Remarkably, high transcript expression levels of 
tOPN and OPNa, but not OPNb and OPNc, were associated 
with aggressive cPTC clinicopathological features (tumor 
size, vascular and extrathyroid invasion). Moreover, we 
demonstrated using in vitro and in vivo approaches that 
ectopically overexpressed OPNa promotes cell growth, 
migration and invasion in TC-derived cell lines.
We have shown that tOPN is predominantly expressed 
(both at transcript and protein level) in cPTC and in fvPTC, 
when compared to FTC and adjacent non-tumoral thyroid 
tissues. In fvPTC samples, we observed higher expression 
of tOPN, OPNa and OPNb variant in poorly circumscribed 
cases. This result is very interesting for several reasons: a) 
first, it is in accordance with the increased expression of 
OPN and the respective spliced forms in cases presenting 
invasive features; b) second, it corroborates our in vitro and 
in vivo results showing an increased invasiveness in cells 
overexpressing tOPN and OPN-SV; c) finally, it shows the 
different biological characteristics of the well and poorly 
Figure 4: Cells overexpressing OPNa stimulate cell growth, migration and motility. DNA synthesis and proliferation rates have 
been evaluated by BrdU incorporation assays; A. c643 and B. 8505c cell clones (overexpressing EV, OPNa, OPNb, OPNc, respectively). 
Effect of each OPN-SV overexpression in c643 C. and in 8505c D. cells on migration rates using wound-healing assays. Representative images 
are shown for cell migration in c643 E. and 8505c F. OPN-SV overexpressing cells, which were monitored by time-lapse microscopy for 0, 
3, 6, 9 and 12 hours after cell scratch. The % wound closure in the graphs represents the wound measured area. For motility assays, OPNa, 
OPNb, OPNc and EV cell clones were cultured in µ-Slide 4 Well Ph+ and monitored by time-lapse microscopy for 12 hours. Four microscope 
fields were averaged for each c643 G. and of 8505c H. OPN-SV overexpression clones and controls containing 10 cells/field (Representative 
videos are available in Online Supplemental Material). Graph data corresponds to motility rates from two independent experiments and values 
are expressed as mean ± se. *p < 0,05; ** p < 0,01; **** p < 0,0001. All the experiments were done in triplicated.
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circumscribed fvPTC. In this last point it is also worth to 
mention that our results in OPN expression fits with the 
recent proposal for the reclassification of encapsulated 
fvPTC as NIFT (“noninvasive follicular thyroid neoplasm 
with papillary-like nuclear features”) due to the very low 
risk of adverse outcome of these patients [27].
Further, we found that high levels of tOPN expression 
in cPTC are associated with increased tumor size, presence 
of extrathyroid extension, vascular invasion and BRAFV600E 
mutation. Our results regarding tOPN are in accordance with 
previous studies demonstrating tOPN overexpression in PTC 
samples [15]. Our results also corroborates previous studies 
which showed that tOPN overexpression (transcript and/
or protein) are significantly associated with poor prognostic 
factors, such as presence of lymph node metastasis, tumor size 
and poor disease free survival in PTC samples [13, 14, 16, 17].
We also observed that tOPN protein overexpression 
in cPTC is significantly associated with hyaline stroma. 
These data are in accordance with OPN as a glycoprotein 
secreted in the extracellular matrix, both in tumor and non-
Figure 5: MMP2 and MMP9 activity in cells overexpressing OPN-SV. Gelatin zymography assay was used to analyze the 
levels of active MMP2 and MMP9 in conditioned medium from A. c643 (overexpressing OPNa, OPNb, OPNc and EV) and from B. 8505c 
(overexpressing OPNa, OPNb, OPNc and EV) cell clones. Representative images are shown. On the left are depicted molecular weights 
of standard markers; on the right are shown the variants of metalloproteinases (MMPs) observed in the gels. C. The intensity of gelatin-
digested bands by pro- MMP2, MMP2 and MMP9 were measured by densitometry and are represented by the diagram bar. Percentage (%) 
of proteolytic activity from 8505c and c643 cells overexpressing OPNa, OPNb or OPNc was compared with the activity present in culture 
medium from 8505c and c643 control cells (EV). Data correspond to mean values of two independent experiments.
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tumoral tissues [28]. OPN is also known to be upregulated 
in the tissue stroma in different conditions, such as 
salivary pleomorphic adenomas [29] and intrahepatic 
cholangiocarcinoma [30]. It is well known that the interplay 
between epithelial cells and the microenvironment may 
contribute to keep the epithelial polarity and to modulate 
growth inhibition [31]. On the other hand, the stromal 
compartments undergo changes in response to emerging 
epithelial lesions that can have a key role in cancer initiation 
and progression [31, 32]. Accordingly, our observed data 
regarding the correlation of tOPN and the presence of a 
hyaline stroma support the assumption that either tOPN 
expression alone or tOPN in association to hyaline stroma 
may play a role in cPTC tumor aggressiveness.
Our data show that OPNa variant is overexpressed 
and specifically associated with poor prognostic features 
in PTC. In particular, OPNa variant was significantly 
associated with presence of extrathyroid extension, 
vascular invasion and BRAFV600E mutation. In contrast 
to this, OPNb was only significantly associated with 
BRAFV600E mutation. In the fvPTC, the only significant 
association observed was between high tOPN and OPNa 
expression levels and older patients. Based on these 
findings, we postulate that elevated OPNa expression 
in TC may occur during tumor progression, facilitating 
more aggressive phenotypes. Some authors have 
shown that OPN-SV expression and its associations to 
clinicopathological features seem to be tissue specific. 
For instance, it has been reported that high OPNb and 
OPNc expression levels in breast cancer [33] and in 
gastric tumors [34] is correlated with more aggressive 
clinicopathological features. In a combined expression 
analysis, OPNc, ER and HER2 can reliably predict grade 
2-3 in breast cancer samples [35]. Moreover, in a prostate 
tumor model, our group has also observed that OPNc 
overexpression is correlated to poor prognostic features 
[36]. Conversely, our data show that OPNa has a more 
relevant prognostic role in PTC than the other OPN-SV.
To assess the possible impact of OPN-SV in TC 
cell properties we ectopically overexpressed OPNa, 
OPNb or OPNc in c643 and 8505c cell lines with 
plasmid constructs containing each of the three OPN-
SV. We observed that TC cells overexpressing OPNa 
displayed significantly increased cell growth, migration 
and motility, whereas OPNb and OPNc overexpression 
in TC cells did not induce similar effects. Other reports 
have demonstrated that OPN-SV play an important role 
in tumor progression by regulating cell growth, adhesion, 
migration and tumor formation. As reported by Lin J and 
co-workers [37], OPNb overexpressing cells derived from 
esophageal adenocarcinoma also evoked enhanced cell 
proliferation, migration and invasion. Additionally, our 
Figure 6: Overexpression of OPNa increases the invasive potential of TC cells in the CAM assay. A. Invasive capacity of inoculated 
cells was evaluated by HE and IHC using an anti-tOPN antibody in xenograft CAM tumor sections. Positive human tOPN immunostaining 
demonstrating effective overexpression of OPN in CAM tumors originated from OPNa clones. c643-EV cells forming compacted tumors (score 1; 
full lines surrounding the tumor bulk, right panels). OPNa tumors exhibiting loosen structures and single cells invading the xenograft CAM tumor 
mesenchyme (arrow heads; score 3, left panels); B. Invasion score analysis demonstrating c643-OPNa overexpressing cells and their corresponding 
invasive score, when compared to EV control clones (p = 0.003) C. CAM angiogenic assay, as demonstrated by the number of formed vessels in c643-
OPNa and EV control clones D. CAM xenograft tumors areas measured in mm2 indicating tumorigenesis in c643-OPNa and EV clones.
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group also previously demonstrated that OPNc activates 
invasion and adhesion properties, as well as metastatic 
potential and angiogenesis in a prostate and an ovarian 
carcinoma model [26, 38]. In prostate cancer cells, 
OPNc can activate AR signaling [39] and resistance to 
docetaxel [40]. Furthermore, other groups demonstrated 
that in hepatocellular carcinoma cells, OPNa and OPNb 
can induce cell migration [25]. Our findings highlight the 
importance of OPNa in TC cell growth and migratory and 
invasive phenotype.
To further explore OPNa roles on modulating TC 
invasive properties, we also explored the role of OPNa 
in the activation of matrix metalloproteinases (MMPs). 
MMPs are important enzymes in the metastatic cell 
arsenal. These proteins can degrade both cell adhesion 
molecules and extracellular matrix molecules, enabling 
tumor cells both to migrate from the tumor bulk and to 
invade adjacent tissues [41]. Previous data from our group 
in prostate and ovarian tumor models showed that cells 
overexpressing the OPNc variant induce expression of 
MMP2 and MMP9, highlighting the functional tissue 
specificity of OPN-SV [38]. Thyroid carcinomas produce 
elevated levels of MMP2, which has been correlated with 
the presence of lymph node metastasis [51]. Herein, we 
have found that CM collected from cells overexpressing 
OPNa have increased activity of MMP2 in c643 cells 
and MMP2 and MMP9 in 8505c cell lines. These results 
evidence that OPNa may promote TC cell invasion 
through inducing MMP2 and MMP9 secretion. The 
detailed mechanism by which this event occurs still needs 
further characterization. Nonetheless, it has been described 
that OPN can regulate MMPs activity by binding to pro-
MMP9, thus promoting its activation [42]. Additionally, 
OPN can induce NFkB-mediated pro-MMP2 and MMP9 
activation through IkBa/IKK signaling pathway [43].
Since MMPs expression and cancer cell migration 
are fundamental features for tumor invasion [44], we 
further investigated the contribution of OPNa variant for 
a TC cell line invasiveness using an in vivo experimental 
model. Using the CAM assay approach, we observed 
that tumors formed by these cell clones present a loosen 
structure, in which the cells were oriented towards the 
invasion front while single cells and cell clusters invading 
the CAM mesenchyme could also be observed. In contrast 
to this, EV clones formed compact tumors, with clear 
defined boarders lacking invading cells. Similarly to 
our data, overexpression of OPNa has been previously 
associated with the cancer cell invasion modulation 
in mesothelioma, breast cancer and hepatocellular 
carcinomas [25, 45, 46]. Although activating cell invasion, 
OPNa overexpression does not significantly modulated 
angiogenesis and tumorigenesis in this in vivo tumor 
model. Some oncogenic proteins can activate some 
specific steps in tumor progression, but not others. As 
evidenced by our data OPNa overexpression in vivo may 
predominantly modulate signaling pathways that stimulate 
migration and invasion, possibly through stimulating 
extracellular matrix degradation by MMP2 and MMP9. In 
light of our results, we may hypothesize that the increased 
invasive capacity of c643 cells overexpressing OPNa (in 
comparison to c643-EV cells) allows the cells to reach the 
blood vessels, and have no effect in the recruitment of new 
vessels.
In conclusion, our data demonstrated that OPNa 
is the prevalent OPN-SV in DTC tissues and cell lines, 
and that overexpression of OPNa is associated with poor 
prognostic and invasive features in cPTC. Moreover, 
OPNa overexpression in TC cell lines strongly increases 
cell migration, invasion and MMPs activity, evidencing 
a major role for OPNa in TC progression features. Taken 
together, these features provide early evidence that OPNa 
can potentially mediate invasive and metastatic potential 
in cPTCs.
MATERIALS AND METHODS
Tumor specimens
We evaluated adjacent thyroid tissues (n = 20), 
thyroid adenomas (n = 6), follicular thyroid carcinoma 
(FTC) (n = 12), follicular variant of papillary thyroid 
carcinoma (fvPTC) (n = 22) and classic papillary thyroid 
carcinoma (cPTC) (n = 69). All the analyzed specimens 
were collected from primary tumors, surgically resected 
at the Centro Hospitalar São João, Porto, Portugal. After 
surgery, samples were immediately snap-frozen and stored 
at -80°C until use. Additional fragments were fixed in 
10% buffered formalin and embedded in paraffin (FFPE). 
The histologic diagnosis of all cases were reviewed by 
three thyroid pathologists (CE, ER, MSS) according to 
the WHO classification [47]. Clinicopathological and 
molecular features are summarized in Supplementary 
Table S2. All the procedures described in this study were 
approved by the respective ethical boards and are in 
accordance with national and institutional standards.
Immunohistochemistry
OPN IHC analysis was performed in representative 
tumor tissue sections of 44 cPTC, 16 fvPTC and 10 
FTC samples using an antibody that recognize all three 
OPN-SV (anti-total OPN- tOPN) (polyclonal, goat, 
1:500, R&D Systems). Normal gallbladder was used as 
a positive control, once it has been previously reported 
to overexpress tOPN [48, 49]. IHC procedure was done 
according to [49]. Semi-quantitative IHC evaluation was 
independently performed by two observers (CE and LBF). 
Total OPN staining was scored in the range 0-7, which 
corresponds to the sum of the staining intensity (absent 
= 0, faint = 1, moderate = 2 and strong = 3) plus the 
proportion of positively stained cells (<5% = 0; 5-25% 
= 1; 25–50% = 2, 50–75% = 3 and >75% = 4) (Table 1).
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RNA extraction, reverse transcription and real 
time PCR
Total RNA was extracted from cell lines and tumor 
tissues using Trizol reagent (Life Technologies, GIBCO 
BRL). For cDNA preparation, 1 μg of total RNA was 
reverse transcribed using the RevertAid first-strand cDNA 
synthesis kit (Fermentas, Burlington, ON, Canada).
Each OPN-SV transcript region was amplified 
with specific oligonucleotide pairs (Supplementary Table 
S3 and Supplementary Figure S1A). Quantitative PCR 
reactions were conducted using SYBR Green detection 
system (Applied Biosystems, Warrington WA1 4SR, UK). 
Conditions for OPN-SV amplification were 50º C for 2 
minutes, 94º C for 5 minutes followed by 40 cycles of 94º 
C for 30 seconds, 60º C for 30 seconds, and 72º C for 45 
seconds. Relative gene expression was calculated using 
the Delta-Delta CT method. GAPDH gene was used as the 
constitutive control.
Cell culture, OPN plasmids and transfections
We analyzed eight TC cell lines: TPC1, KAT4, 
Hth74, XTC1, 8505c, K1, BCPAP and c643, from which 
two were selected for stable transfection. All cell lines 
were authenticated using DNA profile analysis, obtained 
with the PowerPlex 16 system (Promega, Madison, USA), 
according to ATCC and HSRRB available DNA profiles 
[50]. All the cell lines were cultured in standard culture 
medium, supplemented with 10% fetal bovine serum 
(FBS), 100 IU/ml penicillin and 100 mg/ml streptomycin 
in a humidified environment containing 5% CO2 at 37˚C. 
The open reading frame of OPN-SV, was cloned into 
pCR3.1 mammalian expression vector, as previously 
described [51]. OPN-SV expression vectors (kindly 
provided by Dr. George Weber (Cincinnati University)) 
were used to transfect c643 and 8505c cell lines (the 
ones with lower OPN expression; Figure 2F) in order 
to overexpress each OPN-SV. These cells were also 
transfected with the pCR3.1 control empty vector (EV). 
Transfections were performed using LipofectamineTM 
2000 (Invitrogen, CA). Expression plasmids were 
transfected into c643 and 8505c cells and the stably 
overexpressing cell clones were selected using 600 μg/ml 
of G418 for c643 and 800 μg/ml for 8505c cell lines.
Immunocytochemistry
Cells plated on coverslips were fixed in 4% 
paraformaldehyde for 20 min at room temperature (RT). 
Cells were emerged in NH4Cl 50 mM in PBS during 10 
min, and then, cells were permeabilized in 0.2% Triton 
X-100 and blocked in 5% BSA in PBS for 30 min at RT. 
Primary antibodies were diluted in PBS containing 5% 
BSA and incubated overnight at 4ºC as follows: rabbit 
polyclonal against OPN (Rockland, Limerick, PA, USA, 
diluted 1:500). Coverslips were washed in 0.1% Triton 
X-100 prepared in PBS (PBT) and incubated with goat 
anti-rabbit IgG secondary antibodies conjugated with 
Alexa Fluor 594 (Invitrogen; diluted 1:300 in 5% BSA–
PBT) for 1h at RT. Nuclei were stained with 0.1 mg/ml 
diamino phenylindole (DAPI; Sigma–Aldrich). Images 
were taken by a Zeiss fluorescence microscope with 
ApoTome attachment (Axio Imager Z1 stand).
Cell proliferation
Proliferation was measured by evaluating 
bromodeoxy uridine (BrdU) incorporation in c643 and 
8505c OPN-SV transfected cells as previously described 
[52]. Quantification of BrdU positive cells was performed 
using ImageJ software, by counting the percentage of 
BrdU-positive nuclei on a total of 1500 cells.
Cell migration and motility assays
For cell migration assays, c643 and 8505c 
(overexpressing OPNa, OPNb, OPNc or EV) clones were 
seeded until forming a confluent monolayer. The cell 
wound was created by scraping the cell monolayer with 
a pipette tip. After scratch, cell migration was monitored 
by time-lapse microscopy and images were taken every 
10 minutes for 24 hours.
For motility assays, 3,0 x 105 cells of c643 and 
8505c OPNa, OPNb, OPNc or EV transfected cells were 
plated in μ-Slide 4 Well Ph+ and monitored by time-lapse 
video microscopy to evaluate cell motility. Migratory 
tracks were measured for individual cells overexpressing 
each OPN-SV or EV cells using ImageJ software. Four 
microscope fields containing around 10 cells per field were 
monitored for each cell line.
Gelatin zymography
2.5 x 105 cells from c643 and 8505c (overexpressing 
OPNa, OPNb, OPNc or EV) were seeded to generate 
conditioned medium (CM). Matrix metalloproteases 
(MMPs), namely MMP2 and MMP9, activity was assessed 
in the CM of each condition by gelatin zymography, as 
previously described [53].
In vivo chicken embryo chorioallantoic 
membrane (CAM) angiogenesis, tumorigenesis 
and invasion assays
In vivo angiogenic activity of c643 cells 
overexpressing OPNa and the EV controls were assessed 
by chicken chorioallantoic membrane (CAM) assay, as 
previously described [54]. According to the European 
Directive 2010/63/EU, ethical approval is not required for 
experiments using embryonic chicken. Correspondingly, 
the Portuguese law on animal welfare does not restrict the 
use of chicken eggs.
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CAMs bearing the tumors were fixed in 10% neutral-
buffered formalin and paraffin-embedded for slide sections. 
Sections were HE stained for histological examination or 
processed for anti-tOPN IHC analysis to validate OPN 
overexpression in CAM-xenografted tumor cells. These 
xenograft tissue sections were also used to evaluate cell 
invasion. The analysis was performed in a blind fashion 
manner by two independent observers and slides were 
scored as follows: score 1- Tumor cells are tight together 
forming a compact mass. The invasion front (area where 
tumor cells touch the CAM mesenchyme) is clearly defined 
as an encapsulated -like structure; score 2- Tumor cells are 
more loosen at the core of the tumor and in some cases, 
matrigel can be detected. Cells are oriented towards the 
invasion front; score 3- Tumor cells are oriented towards 
the invasion front and it is possible to observe single cells or 
small clusters of cells disconnected from the invasive front.
Data and statistical analysis
Statistical analyses were performed using 
22.0 SPSS statistical package (IBM, 2014). X2 and 
independent samples t-test were performed to verify if 
there was any association(s) between OPN expression 
and clinicopathological data. GraphPad was used for 
the construction of the graphs. ANOVA test was used 
to calculate significance in the CAM angiogenic and 
tumorigenic assays. A ChiSquare test was used to calculate 
significance in the CAM invasion assay. All results are 
presented as mean ± standard error. Values of p ≤ 0.05 
were considered to be statistically significant.
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Osteopontin-a splice variant is overexpressed in papillary 
thyroid carcinoma and modulates invasive behavior
SUPPLEMENTARY FIGURE, TABLES AND VIDEOS
Supplementary Figure S1: Schematic representation of three OPN splice variants (OPNa, OPNb and OPNc). Figure 
depicts oligonucleotide primers annealing sites for amplification of each specific OPN splice variant and tOPN. OPNa (full-length splice 
variant), OPNb (lacks exon 5) and OPNc (lacks exon 4). Green: primers used for tOPN amplification (forward and reverse primers, located 
at exon 6) and the corresponding green tOPN amplification product; Orange: primers used for OPNa amplification (forward primer located 
at exon 4-5 splice junction; reverse primer located at exon 6) and the corresponding OPNa orange amplification product; Red: primers used 
for OPNb amplification (forward primer, located at exon 4-6 splice junction; reverse primer, located at exon 6) and the corresponding red 
OPNb amplification product; Blue: primers used for OPNc amplification (forward primer – exon 3-5 junction; reverse primer - exon 6) and 
the corresponding blue OPNc amplification product. Numbers in the boxes represent the coding exons. B. OPN-SV transcript expression 
levels (symbols: tOPN -•; OPNa -■; OPNb -▲, OPNc -▼) in adjacent thyroid, follicular adenomas, FTC, fvPTC and cPTC samples.
Supplementary Table S1: Analyses of total OPN (tOPN) IHC staining in well and poorly circumscribed fvPTC 
samples
fvPTC N Score Mean
Well circumscribed 13 (81.25%) 1
Poorly circumscribed 3 (18.75 %) 2.33 p=0.27
Total 16 (100%)
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Supplementary Table S2: Summary of the clinical, pathological and molecular data of the FTC, fvPTC and cPTC 
cases
Variable FTC fvPTC cPTC
Gender
 Female 4 (66.7%) 20 (90.1%) 54 (84.4%)
 Male 2 (33.3%) 2 (9%) 10 (15.6%)
Age (yr) (mean ±S.D.) 54.7 (±15.8) 40.1 (±13.1) 41.5 (±15.4)
Stroma
 Absent - - 17 (47.2%)
 Present - - 19 (52.8%)
Tumor size (cm)
 (mean ±S.D.) 4.1 (±1.2) 2.6 (±1.5) 2.6 (±1.4)
Extrathyroid Extension
 Absent - 10 (83.3%) 24 (51%)
 Present - 2 (16.7%) 23 (49%)
Invasion (vascular and/or capsular)
 Absent 0 13 (68.4%) 24 (42.8%)
 Present 6 (100%) 6 (31.6%) 32 (57.2%)
Lymph Node Metastasis
 Absent - 12 (75%) 25 (53.2%)
 Present - 4 (25%) 22 (46.8%)
Thyroiditis
 Absent - - 2 (20%)
 Present - - 8 (80%)
RET/PTC1 translocation
 Absent 11 (100%) 21 (95.5%) 45 (83.3%)
 Present 0 1 (4.5%) 9 (16.7%)
BRAFV600E mutation
 Absent (n=26) 11 (100%) 20 (91%) 25 (43.1%)
 Present (n=30) 0 2 (9%) 33 (56.9%)
TERT mutation
 Absent 7 (87.5%) 22 (100%) 51 (96.2%)
 Present 1 (12.5%) 0 2 (3.8%)
RAS mutation
 Absent 11 (91.7%) 18 (81.8%) 50 (92.6%)
 Present 1 (8.3%) 4 (18.2%) 4 (7.4%)
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Supplementary Table S3: Forward and reverse oligonucleotide sequences used for tOPN, OPN-SV and GAPDH 
specific amplification
Gene Oligonucleotide Name Sequence 5’ – 3’
tOPN tOPNF CCA ACG AAA GCC ATG ACC AC
tOPNR CTG TGG GGA CAA CTG GAG TG
OPNa OPNaF ATC TCC TAG CCC CAC AGA AT
OPNaR CAT CAG ACT GGT GAG AAT CAT C
OPNb OPNbF CTC CTA GCC CCA CAG ACC CT
OPNbR TAT CAC CTC GGC CAT CAT ATG
OPNc OPNcF CTG AGG AAA AGC AGA ATG
OPNcR AAT GGA GTC CTG GCT GT
GAPDH GAPDH-F TGA CCC CTT CAT TGA CCT CA
GAPDH-R AGT CCT TCC ACG ATA CCA AA
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Supplementary Video S2: Motility 8505c-EV: Representative video of motility assay used to evaluate the motility of 
8505c cells overexpressing empty vector (EV) control.
Supplementary Video S1: Motility 8505c-OPNa: Representative video of motility assay used to evaluate the motility of 
8505c cells overexpressing OPNa splice variant.
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Chapter	 4	 –	 Paper	 II	 -	 OPNa	 expression	 is	 associated	 with	 the	
formation	of	psammoma	bodies	in	papillary	thyroid	cancer:	in	vivo	
and	in	vitro	evidence	
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ABSTRACT 
Background: Osteopontin (OPN) and its three spliced variants (OPN-SV: OPNa, 
OPNb and OPNc) are overexpressed in several tumours and frequently associated with 
cancer progression. This holds true for papillary thyroid carcinoma (PTC) which is the 
most common variety of thyroid cancer (TC) being the histologic type which often 
presents desmoplasia (collagen deposition) and dystrophic calcification, including a fairly 
typical features, the psammoma bodies (PB). 
Objective: The aim of this study was to investigate the role of OPN-SV expression 
in the development of PB in classical variant of PTC (cPTC). 
Methods: Total OPN and OPN-SV expression was analysed by 
immunohistochemistry and real time PCR in a series of 48 cPTC cases and three diffuse 
sclerosing PTCs. The association of OPN expression and the presence of PB as well as 
between PB in cPTC and the clinicopathological features of the tumours were evaluated. 
TPC-1 and c643 TC cell lines overexpressing OPN-SV were tested for the ability to 
promote calcification and to synthesize collagen in vitro. 
Results: Overexpression of OPNa transcripts was significantly associated with the 
presence of PB in cPTC samples. The presence of PB in cPTC was associated with 
younger patients and lymph node metastasis. Moreover, OPNa overexpression displayed 
a strong capacity to promote calcification and substantial collagen synthesis in the thyroid 
cancer cell lines. 
Conclusion: Our data suggest that OPNa plays a role in the formation of PB often 
associated with cPTC. Basic research on the interactions between OPNa overexpression 
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by tumour cells and the surrounding microenvironment can give clues for a better 
understanding of cPTC biology and phenotype.    
 68 
	
4.1	Introduction	
 
 
Thyroid cancer (TC) is the most prevalent endocrine malignancy, being papillary 
thyroid carcinoma (PTC) the most common histologic type, accounting for approximately 
80% – 90% of human TCs [1, 2]. The rising incidence of TC is almost entirely attributed 
to the increased incidence of PTC cases [2, 3]. PTC display genetic alterations such as 
BRAFV600E mutations, RET/PTC rearrangements and RAS mutations. However, the 
etiopathogenesis of these carcinomas is not completely understood [4].  
Previous reports have shown that clinicopathological features, such as patient age, 
sex, tumour size, histological grouping, extrathyroid extension and lymph node status are 
useful prognostic factors in PTC patients [5-7]. Calcification, which is a frequent 
histological feature in several cancers, is not generally valued in PTC, although being 
usually detected by ultrasonography in the preoperative evaluation of thyroid nodules [8, 
9]. Despite the fact that calcification may be present in both benign and malignant thyroid 
lesions, its association with malignancy has been consistently verified in a few reports 
[10, 11].  
Based on histological characteristics, TC calcification can consist in dystrophic 
calcification or in formation of psammoma bodies (PB). PB are defined as spherical (50–
70 mm round) calcified foci with concentric laminations, presenting a glassy appearance 
[12-14]. The genesis of PB in PTC is not completely understood. Some authors proposed 
that PB may be formed by (i) thickening of the base lamina of the vascular stalk of the 
neoplastic papillae, followed by vascular thrombosis, calcification, and tumour cell 
necrosis and/or (ii) necrosis and calcification in intralymphatic tumour thrombi in the 
thyroid adjacent to the tumour or in the opposite thyroid lobe [13]. The presence of PB is 
easily detected in cytological or histologic specimens. In fine-needle aspiration (FNA) 
 69 
biopsies, it has been correlated to malignancy, and to PTC in particular [10]. In PTC, PB 
are almost exclusively observed in classical variants of PTC (cPTC) but also in some 
other variants of PTC (such as diffuse sclerosing variant and tall cell) [15], and have been 
considered as a feature that supports PCT diagnosis [10, 12, 15].  
OPN is recognised as a multifunctional phosphoglycoprotein, with roles which 
include bone remodelling and mineralization. In normal bone tissue, OPN is expressed 
by osteoclasts and osteoblasts, which are responsible for bone remodelling. This protein 
has calcium-binding properties and hydroxyapatite affinity. It has been proposed that the 
OPN phosphate groups steric arrangements are needed for calcium binding and further 
apatite crystal formation during bone matrix mineralization [16].  
Earlier reports showed that total OPN (tOPN) overexpression seems to plays a 
role on the formation of PB in PTC samples. Tunio et al. [17] observed that OPN 
overexpression in PTC cells was found around PB and that OPN transcript-expressing 
cells were identified as CD68-positive macrophages. In a more recent study, OPN 
expression in PTC samples was significantly associated with the presence of PB [18]. 
Recently, we demonstrated that among the different spliced variant of osteopontin 
(OPN-SV) primary transcripts, OPNa (which contains the full length coding sequence) is 
overexpressed in cPTC samples. This overexpression was associated with aggressive 
clinicopathological features of PTC. Additionally, we showed that OPNa overexpression 
induced cell proliferation, migration, motility and invasion rates in TC cell lines [19].  
Despite the aforementioned studies, little is known about the molecular 
interactions that result from PB in cPTC and OPN overexpression and the relative 
relevance of the different OPN-SV in the process. The goal of this study was to evaluate 
the putative associations between the expression of tOPN and its variants with PB and 
the involvement of OPN on PTC calcification.  
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4.2	Material	and	Methods	
	
 
Tumour specimens 
 
Tissue specimens were collected from primary tumours, surgically resected at the 
Centro Hospitalar São João (CHSJ), Porto, Portugal. This series is composed by three 
cases of diffuse sclerosing variant of PTC and 48 cases of cPTC. After surgery, samples 
were immediately snap-frozen and stored at -80°C until use. Additional fragments were 
fixed in 10% buffered formalin and embedded in paraffin (FFPE). The histologic 
diagnosis of all cases were reviewed by pathologists specialized in thyroid cancer 
according to the WHO classification criteria [20]. Clinicopathological and molecular 
features are summarized in Table 1. All the procedures described in this study are in 
accordance with national and institutional ethical standards.  
 
Cell culture 
 
The expression levels of tOPN and OPN-SV have been established in TC cell lines 
in a previous study from our group [19]. For this study, the TPC1 and c643 cell lines 
(presenting respectively the highest and lowest tOPN and OPN-SV levels) have been 
selected for experimental approaches. 
c643 cells stably overexpressing OPN-SV were used, as described in Ferreira LB 
et al. [19]. Briefly, the open reading frame of OPNa, OPNb and OPNc were cloned into 
pCR3.1 mammalian expression vector as previously described by He B et al. [21]. These 
plasmid constructs were used for transfection of c643 cells. Transfections were carried 
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out using Lipofectamine 2000 (Invitrogen). The OPN variants/pCR3.1 plasmids or the 
vector alone (Empty Vector) were transfected into c643 cells and the stably expressing 
cells were selected with 600 µg/mL of G418 in the culture medium. All the cell lines were 
cultured in RPMI 1640 cell culture medium with ultraglutamine, supplemented with 10% 
fetal bovine serum (FBS), 100 IU/ml penicillin and 100 mg/ml streptomycin in a 
humidified environment containing 5% CO2 at 37˚C.  
 
Immunohistochemistry 
 
OPN immunohistochemistry (IHC) analysis was performed in representative 
tumour tissue sections using an anti-total OPN antibody (anti- tOPN) (polyclonal, goat, 
1:500, R&D Systems) that recognize all three OPN-SV. Normal gallbladder tissue 
samples previously reported to overexpress tOPN [22], was used as a positive control. 
IHC procedures were done according to Ferreira LB et al. [22]. Semi-quantitative IHC 
evaluation was independently performed by two observers (CE and LBF). Total OPN 
staining was scored in the range 0-7, corresponding to the sum of the staining intensity 
(absent = 0, faint = 1, moderate = 2 and strong = 3) plus the proportion of positively 
stained cells (<5% = 0; 5-25% = 1; 25–50% = 2, 50–75% = 3 and >75% = 4).  
 
RNA extraction, reverse transcription and Real time PCR  
 
Total RNA was extracted from cell lines and tumour tissues using Trizol reagent 
(Life Technologies, GIBCO BRL). For cDNA preparation, 1 µg of total RNA was reverse 
transcribed using the RevertAid first-strand cDNA synthesis kit (Fermentas, Burlington, 
ON, Canada).  
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Real time PCR analysis was carried out for each OPN-SV transcript region with 
a SYBR Green detection system (Applied Biosystems, Warrington WA1 4SR, UK) using 
the previously described primers [19] and the following conditions: 50º C for 2 minutes, 
94º C for 5 minutes followed by 40 cycles of 94º C for 30 seconds, 60º C for 30 seconds, 
and 72º C for 45 seconds. Relative gene expression was calculated using the Delta-Delta 
CT method. GAPDH gene was used as the housekeeping control.  
 
Matrix mineralisation assessment  
 
In order to evaluate matrix calcification, c643 overexpressing OPN-SV and TPC1 
cell lines were cultured in 24 well plates (1.5 x105 cells/well) for 31 days. Following 10, 
17, 24 or 31 days  in culture, cells were fixed with 4% paraformaldehyde (PFA) in PBS 
and evaluated for calcium deposits production by staining with 1 % Alizarin Red solution 
in 2% ethanol. Cells were then washed with water three times and representative images 
for each culture condition were captured with NIKON microscope and NIKON Digital 
DLS Camera. 
 
Matrix collagen production assay 
 
c643 overexpressing OPN-SV and TPC1 cell lines were cultured in 24 well plates 
(1.5 x105 cells/well) for 31 days. Following 10, 17, 24 or 31 days  in culture, cells  were 
fixed with 4% paraformaldehyde (PFA) in PBS and evaluated for collagen fibbers 
production by Masson’s trichrome staining. Briefly, cells were immersed in Richard-
Allan Scientific® Bouin’s Fluid (Thermo Scientific) solution for 5 minutes at room 
temperature, washed with water followed by incubation in Celestin Blue (Thermo 
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Scientific) for 6 minutes and then in Gil’s hematoxylin staining solution (Sigma-Aldrich, 
St. Louis, MO) for 5 min. Cells were washed with 1% acid alcohol, three times and with 
water for further three times. Cells were then immersed in Biebrich scarlet-acid fuchsin 
(Thermo Scientific) for 5 min, placed in phosphotungstic and phosphomolybdic acid 
solution (Thermo Scientific) for 5 min, moved to Aniline Blue solution (Thermo 
Scientific) for 5 min and then placed in 1 % acetic acid solution for 2 min. Finally, cells 
were rinsed in deionized water and representative images for each culture condition were 
captured with NIKON microscope and NIKON Digital DLS Camera. 
 
Statistical analysis 
 
Statistical analysis was performed using 22.0 SPSS statistical package (IBM, 
2014). Independent-samples t-test test was performed to verify if there were any 
association(s) between OPN expression and the presence of PB. The significance of any 
correlation between the presence of PB and the clinicopathological features was 
determined by either the X2 test or Fisher’s exact test (two-sided). The predictive value 
of PB and other factors (sex, age, presence of stroma, tumour size, absence of capsule, 
extrathyroid extension, invasion, lymph node metastases, RET/PTC rearrangement, 
BRAFV600E and RAS mutations) were assessed using univariated and multivariated logistic 
regression models. For in vitro experiments, data are represented as mean ± standard error 
and analysed using Mann-Whitney test. Values of p < 0.05 were considered statistically 
significant. 
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4.3	Results	
 
PB are strongly stained by anti-tOPN in cPTC samples 
 
IHC staining for tOPN was performed in three cases of diffuse sclerosing PTC 
samples and 48 cases of cPTC, following a score criteria based on our previous report 
[22]. Total OPN expression was observed in 60.4% of the cPTC cases (29 out of 48). The 
three diffuse sclerosing PTC samples were virtually negative for tOPN staining. (Table 
2). The samples were also carefully analysed for the presence of PB according to HE and 
anti-tOPN antibody staining. As shown in Figure 1, right panel, PB were strongly stained 
by tOPN antibody, allowing a much clearer view of PB in the cPTC cases, when 
compared to HE staining. PB were present in 53% (24 out of 45) of the cPTC cases 
according to anti-tOPN staining. No statistically significant association was found 
between the presence of PB and tOPN expression (p = 0.71) (Table 3). Similarly, no 
association was found between tOPN protein expression and sex, age, tumour size, 
extrathyroid extension, lymphovascular and/or capsular invasion, lymph node metastases, 
RET/PTC rearrangements, BRAFV600E or RAS mutations. On the other hand, high levels 
of tOPN protein expression was associated with the presence of stroma in cPTC samples 
(p = 0.01) (Table 4).  
 
The presence of PB is correlated with cPTC clinicopathological features  
 
We evaluated the correlation between the presence of PB and cPTC 
clinicopatological features. An association was found between the presence of PB and 
cPTC in younger patients (p = 0.005) and those presenting lymph node metastases (p = 
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0.03) (Table 5). No significant associations were observed between the occurrence of PB 
and patients’ sex, stroma, tumour size, extrathyroid extension, lymphovascular and/or 
capsular invasion, RET/PTC translocation, BRAFV600E and RAS mutations.  
Regression model was performed to evaluate factors associated with lymph node 
metastases in cPTCs (Table 6). A total of 14 patients (40%) had lymph node metastases. 
Younger age (odds ratio (OR) 4.4; p = 0.05) and the presence of PB (OR 7.3; p = 0.02) 
were associated with lymph node metastases. However, when introducing features 
significantly associated with lymph node metastases (using the univariate model) in the 
multivariate regression analysis, only PB was found to be significant (OR 5.6; p= 0.05). 
 
OPNa transcript overexpression is associated with presence of PB in cPTC samples  
 
Since we found a higher tOPN protein expression in cPTC samples containing PB 
(although not attaining statistically significant association (Table 3)), we then evaluated 
transcript expression levels of each OPN-SV (OPNa, OPNb or OPNc) and of tOPN to 
analyse their relative contributions to PB formation. Of note, tOPN expression 
corresponds to the sum of all OPN-SV. In this study, we have found that cPTC cases that 
present PB also have higher tOPN, OPNa, OPNb and OPNc transcript levels than those 
cases lacking PB. Interestingly, only OPNa and OPNb levels were significantly higher (p 
<0.05) (Figure 2 and Table 7). In the three diffuse sclerosing PTC cases, we found that 
OPNa is expressed in higher levels than OPNb and OPNc variants (Figure 2). 
 
 
 
 
 76 
OPNa overexpression induce the formation of calcium deposits in c643 thyroid cells 
 
The ability of c643 thyroid cells overexpressing each OPN-SV to produce 
calcified extracellular matrix (ECM) was evaluated by Alizarin Red staining following 
31 days in culture (Figure 3). We found that c643 cells overexpressing OPNa variant 
presented higher Alizarin Red staining intensity, when compared to those overexpressing 
OPNb and OPNc variants. These results showed that OPNa-overexpressing cells were 
able to produce higher rates of calcified ECM (Figure 3, left panel). 
 
OPNa promotes collagen synthesis in thyroid cell line 
 
Since PB formation is described to rely on calcium deposition, in association with 
some ECM component, such as collagen [23], we decided to analyse if the OPN-SV 
differently contribute to induce collagen deposition in c643 cells. For this, c643 OPN-SV 
overexpressing cells were maintained in culture for 31 days and stained with Masson 
trichrome. We observed that OPNa overexpression prompted substantial collagen 
synthesis, when compared with the other variants (OPNb and OPNc), as shown by the 
Masson trichrome dark purple-red staining (Figure 3, right panel).  
 
TPC1 thyroid cell line produce calcium deposits and collagen synthesis   
 
Since our previous study had shown that from the nine thyroid cancer cell lines 
for OPN expression [19], TPC1 was the one presenting the highest endogenous levels of 
OPNa variant we decided to analyse if this cell line was also able to deposit calcium and 
to promote collagen synthesis, without exogenous OPN-SV overexpression. Our results 
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showed that TPC1 cells are also able to promote calcification and collagen synthesis in 
the ECM forming PB-like structures (Figure 3, upper).  
 
4.4	Discussion	
 
 
In this study, we investigated the association between the expression of the 
matricellular protein OPN and its splice variants in cPTC cases and their correlations with 
the presence of PB in such cases. We observed that cPTC tumour cases presenting PB are 
associated with younger age and the presence of lymph node metastasis. We also found 
that higher OPNa transcript expression is correlated with the presence of PB in cPTC 
cases. Noteworthy, OPNa variant overexpression strongly induced calcified collagen-rich 
matrix deposition, forming PB-like structures in thyroid cancer cell lines in vitro.  
 We have shown that tOPN protein expression has been observed in cPTC samples 
that present PB. Of note, in the immunohistochemistry analysis of the cases stained for 
tOPN, PB are much clearer than in HE staining, particularly since the staining of PB with 
anti-OPN antibody is stronger. To date, only two studies reported an association between 
OPN expression and the occurrence of PB in PTC samples [17, 18]. Both studies showed 
that the expression of tOPN protein associates with the occurrence of PB in PTC samples, 
suggesting a role for OPN in calcification of PTC [17]. Another association between OPN 
and calcification in cancer was reported by Hirota et al. [24], who described OPN protein 
co-localization with calcium phosphate in meningioma tissues, further evidencing a role 
for OPN on the PB formation in this context.  
We further showed that cPTC cases that presented PB also had higher expression 
levels of tOPN, OPNa, OPNb and OPNc transcripts, although only OPNa and OPNb 
levels demonstrated statistically significant differences (OPNa > OPNb). In a previous 
work, we demonstrated that among the three OPN-SV, OPNa had the highest expression 
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levels in cPTC, when compared with other thyroid tissues [19]. Therefore, the current 
results are in accordance with our earlier observations, raising a possible relation between 
OPNa variant overexpression and the formation of PB in cPTC. Regarding the small 
series of diffuse sclerosing PTC samples analysed in this study, no expression of tOPN 
protein was observed. On the other hand, when we evaluated the three OPN-SV in these 
cases, high OPNa levels have been detected. In addition to the cPTC, the diffuse 
sclerosing PTC is the variant that frequently presents numerous PB [25], as also 
confirmed in the 3 cases analysed here. Notably, diffuse sclerosing PTC have been 
described to have a higher incidence of lymph node metastasis when compared to cPTCs 
[26].  
Regarding the analysis of cPTC clinicopathological features, we found a 
correlation between cPTC cases presenting PB and presence of lymph node metastasis 
and younger patients. PB is a diagnostic indicator for cPTC, and its presence strongly 
suggest tumour malignancy in preoperative diagnosis. Bai et al. [12] also reported that 
the presence of PB in PTC cases was associated with gross lymph node metastasis and 
high-stage cancer (stage IVa). Conversely, Pyo et al. [27] found an association between 
PB and tumour multifocality, extrathyroid extension, and lymph node metastasis. The 
higher expression of OPNa in cPTC containing PB and the association of PB with lymph 
node metastases is in accordance with our previous data, in which we showed that OPNa 
overexpression contributes to cPTC progression features [19]. Bai et al. [12] found an 
association between stromal calcification and advanced age of patients (> 60 years). 
However, in that study authors only considered calcification in the stroma. Stromal 
calcification frequently arises in benign lesions, whereas PB are suggestive of 
malignancy. Herein, we evaluated only PB in cPTC cases, excluding other dystrophic or 
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stromal calcifications, as well as bone formation. In fact, when we consider dystrophic 
calcification, no correlation was found with OPNa expression (data not shown). 
In our previous work, we also reported an association between tOPN protein 
expression and presence of stromal tissue areas in cPTC cases, suggesting that this may 
be correlated with tumour aggressiveness in cPTCs [19]. Herein, we further investigated 
this point and presented in vitro and in vivo evidence of an association particularly 
between OPNa expression and the presence of PB and stromal collagen. 
In order to establish putative impacts of OPN-SV regarding the calcification 
process, OPNa, OPNb and OPNc (and an empty vector as a control) were overexpressed 
in c643 TC cells. We then analysed the effects of OPN-SV overexpression in the 
formation of calcium deposits in the ECM produced by the cells and found that OPNa 
overexpressing cells strongly induced calcium deposits in the ECM. Calcification within 
the thyroid gland is a common finding both on thyroid imaging and thyroid 
histopathologic findings [28]. Although PB are a highly specific sign of malignancy 
frequently detected in cPTC [27], the mechanisms by which PB are formed in thyroid 
tumours is still controversial. Several reports have revealed that calcification is more 
common in malignant than in benign thyroid nodules [29, 30]. Other authors reported that 
intrathyroidal calcification was noted in 26.1% (29 out of 111) of the malignant thyroid 
nodules and in only 8.0% (20 out of 250) of benign thyroid samples [28]. Nonetheless, it 
is important to mention that many authors have been stressing that the presence of 
intrathyroidal calcification per se cannot be used to distinguish between benign and 
malignant thyroid disease [29-32].  
We also observed that, among the overexpressing OPN-SV c643 cells, OPNa 
overexpressing cells induced more efficiently collagen synthesis in the ECM. This data 
indicates that among the three variants, OPNa remarkably promoted these effects. These 
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results are in accordance with our previous observations, whereby OPNa (among all 
OPN-SV) seemed to be the key OPN variant associated with the presence of stroma [19]. 
 The roles of OPN in the tumour ECM microenvironment has been investigated. 
For instance, Liaw et al. [33] showed that OPN knockout mice exhibit defective repair of 
incisional skin wounds with abnormal collagen fibrillogenesis. Additionally, it is known 
that depending on the ECM stiffness, collagen fibbers potentiate cell migration, especially 
in the presence of MMPs activity [34]. Accordingly, our previous work demonstrated that 
OPNa activates MMP2 and MMP9 activities in thyroid cell lines, besides promoting cell 
migration and invasion in the in vivo CAM model [19]. Being the most abundant ECM 
components, collagens constitute up to 90% of the ECM and 30% of the total proteins in 
humans, also providing the structural integrity and the tensile strength of human tissues 
and organs [35]. Furthermore, the increased collagen deposition is the most well-
recognized ECM alteration in tumour tissue [36-38]. In the context of cancer biology, it 
has also been shown that collagens regulate the physical and the biochemical properties 
of tumour microenvironment, modulating cancer cell polarity, migration and signalling 
[39-41].  
In order to evaluate OPNa properties on inducing calcium deposit and collagen 
synthesis in the ECM, we selected TPC1 among nine thyroid cell lines, due to its highest 
levels of endogen OPNa expression. Similarly to what has been observed for c643 cells 
overexpressing OPNa variant, TPC1 cells also exhibited calcium deposits and production 
of collagen fibbers. TPC1 cell line is recognized as presenting the RET/PTC 
rearrangements [42]. This molecular alteration was demonstrated to induce OPN 
expression in thyroid cell lines, such as PCCl3 [43], reinforcing the hypothesis that OPN 
plays a role in such processes. Although our results also provide evidence in the same 
direction, in particular giving some early evidence that OPNa plays a role in such 
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mechanism, further studies are needed to better understand how OPNa modulates 
collagen synthesis and the calcification process. In addition, it is imperative to better 
comprehend the underlying molecular mechanisms that dictate the lymphovascular 
invasion, thus contributing to the pathophysiology knowledge of cPTCs.    
In conclusion, our results show that the presence of PB is associated with lymph 
node metastases in cPTC samples. Additionally, OPNa overexpression and its association 
with the occurrence of PB in cPTC samples, together with its strong capacity to promote 
calcium deposit and to synthesize collagen in the ECM in thyroid cells in vitro, supports 
an important role for OPNa in the etiopathogenesis of the cPTC.    
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4.6	Figures/Figure	Legends	
 
 
Figure 1: Total OPN staining at PB in cPTC cases. Two different representative cPTC 
cases (upper and lower panel) showing psammoma bodies (PB) appearing rounded, 
sometimes fused with each other, or even fragmented, with concentric lamination, as 
shown by the black arrow heads. Left panel: PB stained by HE, 40 x. Right panel: PB 
stained for tOPN antibody, 40 x.  
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Figure 2: Expression levels of tOPN, OPNa, OPNb and OPNc transcripts in cPTC 
samples concerning presence or absence of PB. (A) tOPN, (B) OPNa, (C) OPNb and 
(D) OPNc mRNA expression levels measured by real time PCR in the cPTC samples. (E) 
OPNa, OPNb, OPNc and tOPN mRNA expression levels measured by real time PCR in 
the three diffuse sclerosing PTC samples. * p < 0.05. Results are from at least two 
independent assays with triplicates. 
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Figure 3: c643 cells overexpressing OPNa and TPC1 cells present higher 
calcification and collagen ECM production levels. Left panel: Matrix calcification 
detected with Alizarin Red staining. Dark orange areas correspond to extracellular matrix 
rich in calcium deposits. Representative photomicrographs of 2 independent experiments 
are shown. Right panel: Collagen ECM production was determined by Masson trichrome 
staining. Dark purple areas correspond to extracellular matrix rich in collagen. Scale bar: 
100 µM. Representative photomicrographs of 2 independent experiments at 24 days of 
culture are shown.  
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Tables: 
 
Table 1: Summary of the clinical, pathological and molecular data of the cPTC cases 
 
    Variable cPTC n (%) 
Sex*  
    Male 6 (15) 
    Female  41 (85) 
Age (yr) (mean ±S.D.)* 39.87 (±16.42) 
    <45 26 (56.5) 
    ≥45 20 (43.4) 
Stroma  
    Absent 21 (44) 
    Present 27 (56) 
Tumour size (cm)*  
    (mean ±S.D.)  2.4 (±1.1) 
    <2 17 (37) 
    ≥2 29 (63) 
Capsule*  
    Absent 24 (56) 
    Present 19 (44) 
Psammoma Bodies*  
    Absent 21 (47) 
    Present 24 (53) 
Extrathyroid Extension*  
    Absent   24 (57) 
    Present  18 (43) 
Invasion Lympho (vascular 
and/or capsular)* 
 
    Absent  15 (35) 
    Present  28 (65) 
Lymph Node Metastases*  
    Absent 21 (60) 
    Present 14 (40) 
RET/PTC1 translocation*  
    Absent 37 (84) 
    Present 7 (16) 
BRAFV600E mutation*  
    Absent  22 (48) 
    Present  24 (52) 
RAS mutation*  
    Absent 44 (96) 
    Present 2 (4) 
 
*Clinicopathological data from all the cases included in the series was impossible to 
obtain 
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Table 2: Staining score of tOPN IHC in cPTC samples. 
 
OPN Staining 
Score* 
n  
% 
0 
1 
19 
1 
39.6 
2.1 
2 
3 
7 
6 
14.6 
12.5 
4 
5 
2 
7 
4.2 
14.6 
6 
7 
5 
1 
10.4 
2.1 
                    * Staining intensity plus % of positive stained cells 
 
 
 
 
Table 3. tOPN protein expression evaluated by IHC and correlation with presence of PB 
in formalin-fixed paraffin-embedded (FFPE) cPTC samples 
 
 
Psammoma bodies (PB) N % Score Mean  
    
p=0.71 
No     21  (47) 2.29 
Yes     24  (53) 2.54 
Total     45  (100)  
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Table 4: Correlation between tOPN protein expression and the clinicopathological 
characteristics in cPTC 
  
Variable N (%) OPN Score 
Mean 
 
p value 
Sex*    
Male 6  (13) 1.50 0.34 
Female 41 (87) 2.49  
Age ( years)*    
             <45 26 (55) 2.15 0.48 
             ≥45 20 (45) 2.65  
Stroma    
            Absent 21 (43) 1.48 0.01 
            Present 27 (57) 3.04  
Tumour Size (cm)*    
           < 2 17 (37) 2.94 0.22 
           ≥2 29 (63) 2.07  
Extrathyroid Extension*    
          Absent 24 (57) 1.79 0.09 
          Present 18 (43) 3.00  
Invasion Lympho 
(capsular and/or 
vascular)* 
   
          Absent 15 (35) 1.93 0.49 
          Present 28 (65) 2.46  
Lymph Node 
Metastasis* 
 
Absent 
Present 
 
 
21 (60) 
14 (40) 
 
 
2.33 
2.64 
 
 
0.71 
RET/PTC 
rearrangement* 
   
Absent 37 (84) 2.57 0.88 
Present 7 (16) 2.43  
BRAFV600E mutation*    
Absent 22 (48) 2.64 0.62 
Present 24 (52) 2.29  
RAS mutation*    
Absent 44 (96) 2.57 0.11 
Present 2 (4) 0  
*Clinicopathological data from all the cases included in the series was impossible to 
obtain 
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Table 5: Correlation between the presence of PB and the clinicopathological 
characteristics in cPTC 
 Psammoma Bodies (PB)  
Total n = 45 Absent n =  21 (%) Present n = 24 (%) p value 
Sex    
Male 2 (9.5) 2 (8.3) NS (1.0) 
Female 19 (90.5) 22 (91.7)  
Age (years)    
<45 7 (33.3) 18 (75) 0.005 
≥45 14 (66.7) 6 (25)  
Stroma    
Absent 11 (52.4) 8 (33.3) NS (0.1) 
Present 10 (47.6) 16 (66.7)  
Tumour size (cm)    
<2 10 (47.6) 8 (34.8) NS (0.3) 
≥2 11 (52.4) 15 (65.2)  
Capsule    
Absent 9 (47.4) 14 (63.6) NS (0.2) 
Present 10 (52.6) 8 (36.4)  
Extrathyroid Extension 
 
 
   
Absent 10 (58.8) 13 (56.5) NS (0.8) 
Present 7 (41.2) 10 (43.5)  
Invasion Lympho (Vascular 
and/or capsular) 
capsular) 
 
 capsular 
 
 
 
 
 Capsular) 
   
Absent 9 (47.4) 
 
4 (19) NS (0.1) 
Present 10 (52.6) 17 (81)  
Lymph node metastases    
Absent 11 (84.6) 9 (42.9) 0.030 
Present 2 (15.4) 12 (57.1)  
RET/PTC translocation    
Absent 18 (90) 17 (77.3) NS (0.4) 
Present 2 (10) 5 (22.7)  
BRAFV600E mutation    
Absent 9 (42.9) 12 (52.2) NS (0.5) 
Present 12 (57.1) 11 (47.8)  
RAS mutation    
Absent 20 (95.2) 22 (95.7) NS (1.0) 
Present 1 (4.8) 1 (4.3)  
Abbreviations: NS, not significant. Numbers in parentheses represent percentages within 
each category. Bold values indicate the result was statistically significant. 
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Table 6: Predictive factors for lymph node metastases in papillary thyroid carcinomas 
 
  Lymph Node Metastases (n = 34) 
Presence 
(%) 
Univariate Analysis  Multivariate Analysis 
OR (95% CI) P value  OR (95% CI) P value 
Total 14 (41)      
Sex       
Male 1 (7.1) 1 (Referent)     
Female 13 (92.9) 1.4 (0.8 – 25) NS (0.8)    
Age, years       
< 45 11 (78.6) 4.4 (0.9 – 21) 0.05  3.1 (0.5 – 16) NS (0.1)   
≥ 45 3 (21.4) 1     
Stroma       
Absent 4 (28.6) 1     
Present 10 (71.4) 1.5 (0.3 – 6.5) NS (0.5)    
Tumour size (cm)       
< 2 5 (35.7) 1     
≥ 2 9 (64.3) 1.3 (0.3 – 5.4) NS (0.6)    
PB       
Absent 2 (14.3) 1     
Present 12 (85.7) 7.3 (1.2 – 41) 0.02  5.6 (0.9 – 34)  0.05 
Capsule       
Absent 8 (61.5) 2.1 (0.5 – 8.7) 0.2    
Present 5 (38.5) 1     
Extrathyroid 
extrension 
      
Absent 6 (46.2) 1     
Present 7 (53.8) 2.0 (0.4 – 8.3) NS (0.3)    
Invasion Lympho 
(Vascular and/or 
Capsular) 
      
Absent 2 (14.3) 1     
Present 12 (85.7) 4.3 (0.7 – 25) NS (0.09)    
BRAFV600E mutation       
Absent 8 (61.5) 1     
Present 5 (38.5) 2.1 (0.5 – 8.7) NS (0.2)    
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Table 7: Correlation between tOPN and OPN-SV transcript expression levels with the 
presence of PB in cPTC samples 
 
 
    Variable 
tOPN  
mRNA expression 
(Median) 
p-value 
OPNa mRNA 
expression 
(Median) 
p-value 
OPNb mRNA 
expression 
      (Median) 
p-value 
OPNc mRNA 
expression 
      (Median) 
p-value 
Psammoma Bodies         
    Absent (n=19) 0.15  p=0.73 0.12  p=0.01 0.10  p=0.04 0.052 p=0.07 
    Present (n=26) 0.18          0.14  0.11           0.055  
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Chapter	5	–	Paper	III	-	Osteopontin	expression	is	correlated	with	
differentiation	 and	 good	 prognosis	 in	 medullary	 thyroid	
carcinoma		
 
 
This	chapter	appears	as	an	article	with	the	same	title	published	in	the	“European	Journal	
of	Endocrinology”	Ferreira	LB	et	al.	(2016)	174,	551–561		
	
	
	
	
	
	
	
	
	 	
 96 
	
	
	
	
	
	
	
	 	
 97 
	
	
	
	 	
AUTHOR COPY ONLY
Osteopontin expression is correlated with
differentiation and good prognosis in medullary
thyroid carcinoma
Luciana Bueno Ferreira1,2,3, Catarina Eloy2, Ana Pestana2, Joana Lyra2,
Margarida Moura4, Hugo Prazeres1,2,5, Catarina Tavares1,2,3,
Manuel Sobrinho-Simo˜es1,2,3,6, Etel Gimba7,8 and Paula Soares1,2,3
1Instituto de Investigac¸a˜o e Inovaca˜o em Sau´de, Universidade do Porto, 4200-135 Porto, Portugal,
2Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup) – Cancer Biology,
Rua Dr Roberto Frias, s/n, 4200-465 Porto, Portugal, 3Medical Faculty, University of Porto, Al. Professor Hernaˆni
Monteiro, P-4200 Porto, Portugal, 4Unidade de Investigac¸a˜o em Patobiologia Molecular (UIPM), Instituto Portugueˆs
de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal,
5Molecular Pathology Service of the Portuguese Institute of Oncology of Coimbra FG, EPE, Avenue. Bissaya Barreto,
98, 3000-075 Coimbra, Portugal, 6Department of Pathology, Hospital de S. Joa˜o, Al. Professor Hernaˆni Monteiro,
P-4200 Porto, Portugal, 7Research Coordination, National Institute of Cancer, Rio de Janeiro 22743-051, Brazil and
8Natural Sciences Department, Health and Humanities Institute, Fluminense Federal University,
Rio das Ostras, Rio de Janeiro 28895-532, Brazil
Correspondence
should be addressed
to P Soares
Email
psoares@ipatimup.pt
Abstract
Background: Osteopontin (OPN) or secreted phosphoprotein 1 (SPP1) is a matricellular glycoprotein whose expression
is elevated in various types of cancer and has been shown to be involved in tumourigenesis and metastasis in many
malignancies, including follicular cell-derived thyroid carcinomas. Its role in C-cell-derived thyroid lesions and tumours
remains to be established.
Objective: The objective of this study is to clarify the role of OPN expression in the development of medullary thyroid
carcinoma (MTC).
Methods: OPN expression was analysed in a series of 116 MTCs by immunohistochemistry and by qPCR mRNA quantification
of the 3 OPN isoforms (OPNa, OPNb and OPNc) in six cases from which fresh frozen tissue was available. Statistical tests were
used to evaluate the relationship of OPN expression and the clinicopathological and molecular characteristics of patients
and tumours.
Results: OPN expression was detected in 91 of 116 (78.4%) of the MTC. We also observed high OPN expression in C-cell
hyperplasia as well as in C-cells scattered in the thyroid parenchyma adjacent to the tumours. OPN expression was
significantly associated with smaller tumour size, PTEN nuclear expression and RAS status, and suggestively associated with
non-invasive tumours. OPNa isoform was expressed significantly at higher levels in tumours than in non-tumour samples.
OPNb and OPNc presented similar levels of expression in all samples. Furthermore, OPNa isoform overexpression was
significantly associated with reduced growth and viability in the MTC-derived cell line (TT).
Conclusion: The expression of OPN in normal C-cells and C-cell hyperplasia suggests that OPN is a differentiation marker of
C-cells, rather than a marker of biological aggressiveness in this setting. At variance with other cancers, OPN expression is
associated with good prognostic features in MTC.
European Journal of
Endocrinology
(2016) 174, 551–561
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Introduction
Thyroid tumours are the most common malignancies of
the endocrine system. About 1% of the thyroid cells
correspond to (parafollicular) C-cells that are located in
the basal layer of thyroid follicles (1). Medullary thyroid
carcinoma (MTC) is the thyroid tumour that arises from
the neural crest-derived C-cells of the thyroid gland. MTCs
account for 5–10% of the clinically evident thyroid
cancers and are associated to a higher incidence of distant
metastases and poorer prognosis, when compared with
follicular cell-derived well-differentiated thyroid carci-
nomas (2, 3). In total, 70–80% of MTCs are sporadic and
the remaining 20–30% are hereditary (1).
C-cells are dispersed as individual cells or in small
groups in the spaces among thyroid follicles, and their
function is to secret a whole series of regulatory peptides
and growth factors (4). Hyperplasia of C-cells corresponds
to an abnormal increase in the number of these cells and
is recognised as a precursor of medullary carcinoma
(especially in the setting of multiple endocrine neoplasia
types IIA and IIB) and associates with a number of other
conditions, including advanced age, hypercalcemia,
hypergastrinemia due to Zollinger–Ellison syndrome,
Hashimoto disease and chronic lymphocytic thyroiditis,
follicular and papillary thyroid neoplasms, exogenous
estrogen administration and cimetidine treatment. Yet,
patients with germ-line mutations of the RET oncogene
present age-related progression ofC-cell lesions fromC-cell
hyperplasia (CCH) towards MTC (5). In sporadic cases, the
putative role of CCH in carcinogenesis is controversial.
Thyroid carcinomas frequently present aberrant
expression of different gene products (6, 7, 8), and it was
advanced that such overexpression can be related to
cancer progression. Castellone et al. (9) demonstrated
that OPN is one of the most overexpressed molecules in
papillary thyroid carcinoma (PTC) and showed that its
up-regulation promoted proliferation, migration and
spreading of thyroid cancer-derived cell lines (9).
OPN is a secreted multifunctional phosphorylated
glycoprotein constitutively expressed in epithelial cells of
the gastrointestinal, reproductive and urinary tracts, sweat
ducts, lung bronchi, pancreas, lactating breast, salivary
glands and, notably, in the gallbladder (10). OPN mRNA
and/or protein expression levels were reported to be
increased in several types of human cancers, such as
prostate carcinoma (11); melanoma (12); and ovary (13),
lung and gastric carcinoma (14). OPN overexpression was
associated with poor prognosis in some malignancies,
namely, in PTC (15). The overexpression of OPN in many
types of tumours and its frequent association with
invasive properties and aggressive clinicopathological
features (16, 17) suggest that OPN may be involved in
tumourigenesis, tumour progression and in metastasis
formation (18, 19). In contrast to this, OPN expression has
been related with better prognostic clinical features in
osteosarcoma (20). To date, it has not been described the
expression of OPN in neuroendocrine tumours if one
excludes a case report of Kuroda et al. (21) showing the
expression of OPN in neoplastic cells of a large-cell
neuroendocrine carcinoma (LCNEC) of the lung. Kuroda
et al. (21) observed that part of the LCNEC neoplastic cells
as well as the calcified foci were positive for OPN,
suggesting that in addition to dystrophic calcification,
OPN may be involved in the mechanism of calcification
within necrotic areas of LCNEC.
OPN mRNA is subjected to alternative splicing that
generates three protein variant isoforms, designated as
OPNa, OPNb and OPNc (22). The three OPN isoforms have
been shown to play specific roles in different types of
tumours; for example, in breast and ovarian cancer cells,
OPNc isoform activates invasion and adhesion properties
(13, 23). In prostate cancer cells, OPNb and OPNc
stimulate proliferation, migration and invasion (11), and
in hepatocellular carcinoma cells, OPNa and OPNb
promote migration (24).
To the best of our knowledge, expression of total OPN
and of OPN splicing variants has not been systematically
assessed so far in MTC samples. The objective of this study
was therefore to evaluate the expression profile of OPN in
MTC and to relate such expression with molecular and
clinicopathological data.
Subjects and methods
Human MTC tissue samples
The study involved 116 cases of MTC (diagnosed in three
Institutes from 1974 to 2011). Formalin-fixed, paraffin-
embedded tissue and clinical data were retrieved from the
files of Centro Hospitalar Sa˜o Joa˜o (CHSJ)/Medical Faculty
of Porto (FMUP)/Ipatimup (56 cases), Portuguese Institute
of Oncology, Coimbra (IPO-C) (19 cases), and Portuguese
Institute of Oncology, Lisboa (IPO-L) (41 cases). The
diagnosis of MTC was revised by two pathologists (CE
and MSS) and confirmed by calcitonin immunostaining.
Clinicopathological and follow-up data were obtained
from the surgical pathology reports and patients’ records
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of the Department of Pathology and Oncology of CHSJ
and from IPO databases (Table 1). RET and RAS genetic
characterisation of the series had been done previously
and reported in two publications (25, 26). The study was
approved by the Hospital Ethical Committees, and
National Ethical rules were followed in every procedure.
Immunohistochemistry
Semi-quantitative immunohistochemistry (IHC) analysis
of OPN expression was performed in representative 116
MTC tumour tissue sections using an antibody that
recognises all OPN isoforms (anti-total OPN). To demon-
strate specificity of the antibody to human OPN, we used
normal gallbladder as positive control, because it has been
previously reported to strongly express OPN in both
supranuclear and luminal contents (10) (Fig. 1A). The
following was the IHC procedure: briefly, deparaffinised
and rehydrated sections were subjected to microwave
treatment in 10 mM sodium citrate buffer, pH 6.0, for anti-
gen retrieval. After blocking, the sections were incubated
overnight at 4 8C in a humidified chamber with a primary
antibody anti-OPN (polyclonal, goat, 1:500; R&D Systems,
Figure 1
OPN cytoplasmic intracellular immunoexpression. (A) Staining in
normal gallbladder used as positive control. (B) Normal thyroid
gland showing no OPN staining. (C) Normal thyroid tissue
showing OPN staining in scattered C-cells. (D) ‘Normal’ thyroid
tissueadjacent toMTC;note theOPNpositive scatteredC-cells (in
the inset calcitonin staining of the same area). (E) C-cell
hyperplasia showing OPN staining (F) The same area of C-cell
hyperplasia stained for calcitonin. (G) A case of MTC showing
OPN staining in many neoplastic cells, classified as score: 6
(proportion of positive cells: 50–75%C staining intensity: 3C).
(H) The same case stained for calcitonin showing positivity of
almost every neoplastic cells. A full colour version of this figure is
available at http://dx.doi.org/10.1530/EJE-15-0577.
Table 1 Summary of the clinical, pathological and molecular
data of the MTC cases.
MTC
Gender (nZ97)*
Female 53 (54.6%)
Male 44 (45.4%)
Tumour size (cm)* (nZ80; meanGS.D.) 3.00 (G2.24)
Stroma (nZ112)*
Absent 31 (27.7%)
Present (hyaline) 81 (72.3%)
Amyloid deposits (nZ42)*
Absent 16 (38.1%)
Present 26 (61.9%)
Extrathyroidal extension (nZ64)*
Absent 28 (43.8%)
Present 36 (56.3%)
Metastasis (lymph node and/or distance)
(nZ73)*
Absent 27 (36.9%)
Present 46 (63.1%)
Invasion (vascular and/or capsular) (nZ34)*
Absent 6 (17.6%)
Present 28 (82.4%)
RET mutation (nZ116)
Absent 49 (42.2%)
Present 67 (57.8%)
RAS mutation (nZ116)
Absent 97 (83.6%)
Present 19 (16.4%)
PTEN nuclear score (nZ75)*
Low 48 (64.0%)
High 27 (36.0%)
PTEN cytoplasmic score (nZ75)*
Low 14 (18.7%)
High 61 (81.3%)
pS6 intensity score (nZ75)*
Low 33 (44.0%)
High 42 (56.0%)
*Clinicopathological data from all the cases included in the series was
impossible to obtain.
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Minneapolis, MN, USA). The detection was performed with
a labelled streptavidin–biotin immunoperoxidase detection
system (Thermo Scientific/ Lab Vision, Fremont, USA),
and the IHC staining was developed with 3,30-diamino-
benzidine substrate. Negative control consisted in the
omission of the primary antibody incubation. Semi-
quantitative OPN expression was evaluated using a
staining score, which has been independently established
by two observers (CE and LF). Proportion of positive-stained
cells was scored as !5%Z0, 5–25%Z1, 25–50%Z2,
50–75%Z3 and O75%Z4, while staining intensity values
were classified as absentZ0, faintZ1, moderateZ2 or
strongZ3 (Table 2). The OPN staining score (range from
0 to 7) corresponds to the sum of staining intensity and
the proportion of positive-stained cells (Table 3). OPN
staining score was correlated with data previously obtained
by our group in this tumour series with regards to PTEN and
pS6 IHC expression (25).
Cell culture and generation of medullary cancer cells
overexpressing OPN isoforms
As a model to examine the putative roles of OPN isoforms
in MTC, we used a MTC-derived cell line (TT). TT cell line
was cultured in RPMI 1640 supplemented with 20% of
foetal bovine serum, 100 IU/ml penicillin and 100 mg/ml
streptomycin in a humidified environment containing 5%
CO2 at 37 8C. The open reading frame of OPN splicing
variants, OPNa, OPNb and OPNc, were cloned into pCR3.1
mammalian expression vector as previously described (23),
and the DNA constructs were used for transfection into TT
cells. Transfections were carried out using Lipofectamine
2000 (Invitrogen). The OPN isoforms/pCR3.1 plasmids or
the vector alone (empty vector (EV)) were transfected into
TT cells, and the stably expressing cells were selected with
600 mg/ml of G418 in the culture medium. The cells
overexpressing each OPN isoform were tested individually
on functional assays, as indicated below.
RNA extraction and reverse transcription
Total RNA was extracted from frozen specimens of MTC
(nZ6), adjacent normal tissue specimens (nZ6), two
MTC-derived cell lines (TT and MZ-CRC-1) and from TT
cells overexpressing OPNa, OPNb, OPNc and EV using a
Trizol commercial kit (Life Technologies, GIBCO BRL),
according to the manufacturer’s protocol. RNA was
quantified by spectrophotometry, and its quality was
checked by analysis of 260/280 and 260/230 nm ratios.
For cDNA preparation, 1 mg of total RNA was reverse
transcribed using the RevertAid first-strand cDNA
synthesis kit (Fermentas, Burlington, ON, Canada).
Real-time PCR
The amplification of fragments corresponding to each
OPN isoform was performed using the following oligonu-
cleotide pairs: OPNa: 5 0-ATC TCC TAG CCC CAC AGA AT-
3 0 (forward) and 5 0-TTC TCC ATG GTG GTG AAG ACG
CCA-3 0 (reverse); OPNb: 5 0-CTC CTA GCC CCA CAG ACC
CT-3 0 (forward) and 5 0-TAT CAC CTC GGC CAT CAT ATG-
3 0 (reverse); OPNc: 5 0-CTG AGG AAA AGC AGA ATG-3 0
(forward) and 5 0-AAT GGA GTC CTG GCT GT-3 0 (reverse).
GAPDH was amplified with primers 5 0-TCC CAT CAC CAT
CTT CCA GGA GCG-3 0(forward) and 5 0- TGG CGT CTT
CAC CAC CAT GGA GAA-3 0(reverse) and was used as an
internal control to normalise the expression and to verify
integrity of the cDNA. All qRT-PCRs were conducted using
SYBR Green (Applied Biosystems). Gene expression of the
target gene was calculated by using the DCT method.
Table 3 Staining score of OPN IHC in 116 MTC cases.
OPN staining score* Frequency (n) Percentage (%)
0 25 21.6
1 1 0.9
2 3 2.6
3 14 12.1
4 16 13.8
5 27 23.3
6 18 15.5
7 12 10.3
Total 116 100%
*Staining intensityCproportion of positive-stained cells.
Table 2 Staining intensity and proportion of positive stained
cells of OPN IHC in 116 MTC cases.
Frequency (n) Percentage (%)
Staining intensity
Absent 25 21.6
Faint 31 26.7
Moderate 25 21.6
Strong 35 30.1
Total 116 100
Proportion of positive stained cells
!5% 31 26.7
5–25% 12 10.3
25–50% 19 16.4
50–75% 12 10.3
75–100% 42 36.2
Total 116 100
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Immunocytochemistry
Upon being plated on coverslips, cells were fixed in 4%
paraformaldehyde for20 minat roomtemperature (RT).Cells
were emerged in NH4Cl 50 mM in PBS during 10 min, and
then, cells were permeabilised in 0.2% Triton X-100 and
blocked in5%BSAinPBSfor30 minatRT.Primaryantibodies
were diluted in PBS containing 5% BSA and incubated
overnight at 4 8C as follows: rabbit polyclonal against OPN
(Rockland, Limerick, PA,USA,diluted1:500).Coverslipswere
washed in 0.1% Triton X-100 prepared in PBS (PBT) and
incubated with goat anti-rabbit IgG secondary antibodies
conjugated with Alexa Fluor 594 (Invitrogen; diluted 1:300
in 5% BSA–PBT) for 1 h at RT. Nuclei were stained with
0.1 mg/ml diamino phenylindole (DAPI; Sigma–Aldrich).
Images were taken by a Zeiss fluorescence microscope with
ApoTome attachment (Axio Imager Z1 stand).
Cell growth and viability assays
Cell growth was analysed by MTT assay. Cells over-
expressing OPNa, OPNb, OPNc and EV were seeded in
96-well plates at 5!104 cells density per well. After 48 h for
adherence of the cells, 5 mg/ml of MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) were
added to each well. Cells stayed in the incubator at 37 8C,
5% CO2 for 4 h, and then dimethyl sulphoxide was
added in the cells for solubilisation of MTT. Absorbance
was measured at 570 nm. Viability assay was performed
by Trypan blue exclusion after 48 h of plating the cells.
Three independent experiments were carried out using
triplicates in each experiment. Data are expressed as
meanGS.E.M. and analysed using Mann–Whitney test.
Significance level was fixed in 0.05.
Statistical analysis
Statistical analysis was performed using 22.0 SPSS statisti-
cal package (IBM, 2014). c2 and independent samples
t-test were performed to verify if there was any associ-
ation(s) between OPN expression and clinicopathological
data. For in vitro experiments, data are expressed as
meanGS.E.M. and analysed using Mann–Whitney test.
Values of P%0.05 were considered statistically significant.
Results
OPN immunoexpression in MTC, C-cell hyperplasia
and C-cells
IHC studies were performed in samples of the 116 MTC
cases. Stromal areas of MTC, when present, were virtually
negative for OPN staining (Fig. 1B). OPN protein
expression was found in 91 of 116 MTCs (78.4%). In the
positive cases, the staining intensity was faint in 26.7%,
moderate in 21.6% and strong in 30.1% of the cases
(Table 2); on average, more than 50% of the cells were
positive (Table 2). Among the positive cases, staining
score was 1 in 0.9%, 2 in 2.6%, 3 in 12.1%, 4 in 13.8%, 5 in
23.3%, 6 in 15.5% and 7 in 10.3% of the cases (Table 3).
OPN staining was mainly localised in the cytoplasm,
i.e. intracellular. Representative regions of OPN and
calcitonin staining are depicted in Fig. 1G and H. We
also observed strong OPN staining in dispersed C-cells
(Fig. 1C and 1D), as well as in C-cell hyperplasia foci
detected in the adjacent thyroid tissue of some samples
(Fig. 1E), which was confirmed by calcitonin positive
staining (Fig. 1F).
Association of OPN immunoexpression with
clinicopathological and molecular features of MTC
We observed significant differences of OPN staining score
with regards to tumour size, PTEN nuclear expression and
RAS status. Tumours larger than 2 cm presented a lower
average OPN staining score than tumours smaller than
2 cm (2.8 vs 4.6 respectively; PZ0.001). Tumours display-
ing PTEN nuclear expression showed a higher average of
OPN staining score than tumours without PTEN nuclear
expression (5.3 vs 3.9 respectively; PZ0.003). Finally,
tumours WT for RAS presented a higher average staining
score for OPN than tumours harbouring a RAS mutation
(4.0 vs 2.6 respectively; PZ0.043). There was a sugges-
tively significant association with invasion (capsular
and/or vascular): tumours without evidence of invasion
presented a higher OPN staining score than tumours
presenting invasion (4.8 vs 3.5 respectively; PZ0.083). No
significant or suggestive associations were observed
between OPN staining score and gender or age of the
patients, presence of stroma, lymph node and/or distant
metastasis, presence of amyloid, extrathyroidal extension,
RET mutation, PTEN cytoplasmic expression and pS6
expression (Table 4).
Expression of OPN isoforms in MTC
In order to further investigate the OPN expression profile
in MTC samples, we advanced that determining OPN
splicing isoform expression could provide evidence
regarding the contribution of each OPN variant within
the total OPN expression evaluation. To achieve this
objective, we evaluated mRNA levels of OPNa, OPNb and
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OPNc splice variants in six MTC cases with their
corresponding matched non-tumoural tissues, from
which frozen samples were available. OPNa isoform
expression is significantly higher in the MTC tumour
samples than in non-tumoural specimens (PZ0.032).
Conversely, OPNb and OPNc isoforms have similar
expression levels in tumour and in non-tumour tissue
samples (Fig. 2A). In addition, the expressions of these
three splice variants were also analysed in two MTC-
derived cell lines (TT and MZ-CRC-1). Both MTC cell lines
expressed the three OPN splicing isoforms. Similarly to
tumour tissue specimens, OPNa expression levels are
higher than OPNb and OPNc expression levels (OPNa O
OPNbOOPNc), being the expression higher in TT cell line
than in MZ-CRC-1 (Fig. 2B).
Overexpression of OPN isoforms in TT cell line,
decrease cell growth and viability
To examine the contributions of each OPN isoform in
medullary thyroid cancer, we used in vitro gain-of-function
experiments. We chose the approach to stable overexpress
each of these splicing isoforms in TT cells once this cell
line is a well-established model for medullary thyroid
cancer functional studies (27). Analysis by real-time PCR
demonstrated the overexpression of OPN isoforms in TT
cell lines transfected by OPN isoforms, showing higher
mRNA levels of the corresponding isoform in relation to
their levels in EV-transfected cells (Fig. 3A). The over-
expression of OPN protein in TT cell lines transfected with
OPNa, OPNb and OPNc isoforms was confirmed through
immunocytochemistry analyses using OPN antibody
(Fig. 3B). By contrast, OPN protein expression was poorly
identified in control cells (EV) (Fig. 3B). Additionally, we
evaluated cell proliferation byMTT assay, and we observed
that TT cells overexpressing OPNa, OPNb and OPNc
significantly reduced growth when compared with control
cells (EV) (Fig. 3C). We also confirmed the viability of
these cells using Trypan blue exclusion, and we found that
OPNa isoform is able to significantly reduce the viability
when compared with the control (EV) (Fig. 3D).
Discussion
In this study, we investigated the expression pattern of the
glycoprotein OPN in 116 MTCs and correlated it with
clinicopathological features of the cases. We observed that
OPN expression is a potential marker of good prognosis
for MTCs, and we gathered suggestive evidence that total
OPN can be a newly identified differentiation marker of
(parafollicular) C-cells.
Besides the aforementioned studies (15, 28) in thyroid
cancer, OPN expression has been investigated by other
groups (29, 30, 31, 32, 33, 34), but only one study
evaluated MTC; in this study, Briese et al. (31) observed
an up-regulation of OPN in three of the four MTCs of their
series (75%). Our results, obtained in a much large series,
confirm such percentage and demonstrate that 78.4%
(91/116) of MTCs express OPN. We have also found that
OPN expression is significantly associated with smaller,
usually non-invasive cancers. In other words, at variance
with PTC, in MTCs, the expression of OPN is associated
with features of good prognosis and is reduced during
tumour progression.
Interestingly, we observed that isolated C-cells scat-
tered in adjacent normal thyroid parenchyma show strong
Table 4 Clinicopathological and molecular associations with
OPN expression. Data is presented as meanGS.D.
Clinicopathological n OPN immunoexpression P value
Gender 0.196
Female 53 (3.9G2.3)
Male 44 (3.3G2.4)
Tumour size (cm) 0.001
!2 30 (4.6G1.8)
R2 50 (2.8G2.4)
Stroma 0.492
Absent 31 (3.6G2.4)
Present (hyaline) 81 (4.0G2.2)
Amyloid deposits 0.239
Absent 16 (4.8G2.0)
Present 26 (4.0G2.2)
Extrathyroidal extension 0.620
Absent 28 (3.4G2.2)
Present 36 (3.1G2.5)
Metastasis 0.434
Absent 27 (3.0G2.3)
Present 46 (3.4G2.5)
Invasion (vascular and/or capsular) 0.083
Absent 6 (3.5G2.4)
Present 28 (4.8G1.3)
RET 0.883
Normal 49 (3.7G2.3)
Mutated 67 (3.8G2.3)
RAS 0.043
Normal 97 (4.0G2.2)
Mutated 19 (2.6G2.5)
PTEN nuclear score 0.003
Low 48 (3.9G2.2)
High 27 (5.3G1.4)
PTEN cytoplasmic score 0.716
Low 14 (4.2G2.4)
High 61 (4.4G2.0)
pS6 intensity score 0.744
Low 33 (4.5G1.8)
High 42 (4.3G2.3)
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OPN expression. A strong expression of OPN was also
observed in clusters of C-cell hyperplasia (both in cases
with and without germinal RET mutation – data not
shown), indicating that this multifunctional protein may
be a differentiation marker for C-cells. This assumption is
supported by the observation, using serial sections, of
strong calcitonin staining in the C-cells displaying OPN
expression (Fig. 1F). In contrast to the strong expression
in C-cells, we did not observe any OPN expression in
follicular cells of the adjacent ‘normal’ thyroid tissue. Our
results suggest that OPN immunostaining may be a useful
marker in the study of the physiology and physiopathol-
ogy of C-cells, C-cell hyperplasia and MTC, but further
studies with an in-depth analysis of C-cell characteristics
are needed to confirm this assumption.
Often OPN up-regulation in tumours has been
associated with poor prognosis (34), but due to its
versatility, this protein is also able to play roles that may
be related to protective factors and cell differentiation. For
instance, OPN expression usually correlates with the
intermediate and later stages of osteoblast differentiation
from mesenchymal stem cells (35, 36, 37). Furthermore,
recent studies support the requirement of OPN expression
in maintaining macrophage differentiation and function
(38), and Chang et al. (39) reported that OPN is implicated
in keratinocyte differentiation. Taken together, these
findings and our observations suggest the potential role
of OPN in differentiation of specific cell types and, in
particular, as we are herein advancing, in C-cells.
Using IHC, OPN staining pattern in MTC is consistent
with a predominant intracellular localisation of OPN
(iOPN). OPN is usually known as an extracellular protein.
There is increasing knowledge that extracellular OPN
(eOPN) binds to its main receptors, integrins and CD44,
activating their corresponding signalling pathways and
mediating different OPN functions in cancer cells (40).
However, other reports have also described iOPN, both in
the cytoplasm and in the nucleus, in distinct cell contexts
(41, 42). Similarly to eOPN, iOPN isoforms have also been
associated to intracellular CD44 complex (43) and related
to cellular processes such as cytoskeletal relocation and
cell motility (42, 44). Some authors have suggested
furthermore that iOPN and eOPN can act in concert (41,
42). Our results disclose the predominant intracellular
expression of OPN in MTC cells. We cannot rule out that
an unbalanced proportion of iOPN and eOPN can be
present in C-cells and MTC, and that the aforementioned
proportion may also modulate tumour- and tissue-specific
OPN functional roles (41, 45). Additional studies should
be performed to determine the putative regulation and
functional roles of both iOPN and eOPN in C-cells and
MTC cells.
Although nuclear PTEN function remains poorly
understood, it has been shown that acting as a tumour
suppressor, nuclear PTEN might lead to cell cycle arrest
and decreased tumour growth (46, 47). It was also recently
described the maintenance of chromosomal stability as
another function of nuclear PTEN (48). PTEN has been
related with OPN regulation, and it was reported that
PTEN overexpression suppresses cellular migration stimu-
lated by OPN (49). As higher levels of OPN were
significantly associated with higher levels of nuclear
PTEN in MTCs, these two molecules can probably act
together in the maintenance of the differentiation of
C-cells, thus contributing to prevent tumour progression.
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Figure 2
Expression of OPNmRNA splicing isoforms in thyroid tissues and
in MTC cell lines. (A) Expression of OPNa, OPNb and OPNc
splicing isoforms by qRT-PCR in MTC specimens and in the
adjacent thyroid. (B) Expression of OPNa, OPNb and OPNc
splicing isoforms in TT and in MZ-CRC-1 cell lines by qRT-PCR.
Expression of OPN isoforms is presented relative toGAPDH gene
expression. A full colour version of this figure is available at
http://dx.doi.org/10.1530/EJE-15-0577.
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In sporadic MTC, RASmutations are often detected in
HRAS and KRAS genes (25), representing an alternative
genetic event to RET mutation. Casson et al. (50) showed
that RAS mutation induces expression of OPN in human
esophageal cancer, and other authors reported that OPN
promoter have target sequences for RAS binding, inducing
OPN expression in both human (51) and mouse (52). At
variance with the presence of RET mutations that were
not associated with OPN expression, we observed that
RAS-mutated MTC cases display a significantly lower
expression of OPN. Although in apparent contradiction
with the results obtained in other tissue models cited
previously (50, 51), our results fit in with the hypothesis
that OPN expression is associated with normal differen-
tiation of C-cells. Many studies have demonstrated loss of
thyroid-specific gene expression in thyroid cells following
the introduction of a variety of transforming oncogenes,
in particular of the RAS gene family (53). This issue, as far
as we are aware, has not been assessed to date concerning
C-cell differentiation.
Another interesting result of the present study relies in
the demonstration of the differential expression of the
three OPN isoforms in MTC. It is known that OPN splicing
variants present different and specific roles depending on
the tissue and the tumour type (for a thorough review,
see reference (54)). While in some tumour models, an
individual OPN splicing isoform can act as a tumour-
stimulating factor, in other tumour types, the same
variant may present the opposite effect, acting against
tumour progression (24, 54, 55, 56). We observed that
total OPN, detected by IHC with an antibody that
recognises all three OPN isoforms, is expressed in MTCs.
Unfortunately, the expression of the different isoforms in
paraffin sections could not be evaluated for technical
reasons. We were able to evaluate the mRNA expression of
OPN isoforms, by real-time PCR, using distinct primers to
recognise three different isoforms, in six pairs of tumours
and respective adjacent thyroid parenchyma. To the best
of our knowledge, this is the first study reporting the
mRNA expression of OPN isoforms in MTCs. OPNa mRNA
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Figure 3
Proliferation and viability in TT cells overexpressing OPNa,
OPNb, OPNc and EV. (A) Real-time PCR showing relative
expression in TT cells overexpressing OPNa, OPNb, OPNc and EV.
(B) Immunocytochemistry analyses of OPN expression in control
cells (TTcells with EV) and in TTcells overexpressing OPNa, OPNb
and OPNc. (C) MTT and (D) Trypan blue assays showing
significantly decreased proliferation levels in TT cells over-
expressing OPNa, OPNb, OPNc and EV (nR3; *P!0.05;
**P!0.005). A full colour version of this figure is available at
http://dx.doi.org/10.1530/EJE-15-0577.
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was expressed at significantly higher levels in tumour
samples than in non-tumour samples (PZ0.032), while
OPNb and OPNc presented similar levels of mRNA
expression in tumours and respective adjacent tissues.
We realised that when analysing the so-called ‘normal
adjacent thyroid’, we were evaluating mainly follicular
cells and comparing the expression of the isoforms
between follicular cells and MTC. Only by analysing
isolated C-cells we were able to compare “normal”
C-cells and neoplastic MTC cells. Nevertheless, as we
observed that OPNb and OPNc had similar expression
levels in ‘normal’ adjacent tissue and in MTC, whereas
OPNa showed significantly higher levels in MTC, we can
conclude that OPNa mRNA is the isoform more expressed
in MTC. This conclusion fits with our observation of
higher levels of OPNa mRNA in the two MTC-derived cell
lines. It remains to be clarified whether the same is true
regarding normal and hyperplastic C-cells, i.e. if OPNa
mRNA high expression is also present in normal and
hyperplastic C-cells, or if it is tumour specific.
Additionally, we examined the functional roles of each
OPN splicing isoform in medullary thyroid cancer pro-
gression by using an in vitro model. Here we show that
TT cells overexpressing OPNa, OPNb and OPNc show a
significant decrease in proliferation and viability, being
OPNa isoformhaving themost prominent effect. Although
OPN is widely known as implicated in promoting invasive
and metastatic progression in many carcinomas (11, 57),
in medullary thyroid cancer, the overexpression of OPN
isoforms seems to be related with a protective role, as
reported in pancreatic adenocarcinoma (58). These results
indicate that in MTC, OPN contributes to impair tumour
growth, corroborating the hypothesis that OPN can act in
the maintenance of the differentiation of C-cells. Further
studies, including evaluation of adhesion, invasion and
migration, would allow a view of the whole picture and
the complete understanding of the role of OPN in C-cell
biology and disease.
In summary, the present study shows for the first time
that OPN is expressed in MTCs and that such expression is
associated with smaller tumour size, less invasive features
and overexpression of nuclear PTEN. Yet, our study reports
the first description of OPN expression in the specialised
neuroendocrine cells of the thyroid, indicating a role for
this multifunctional protein in C-cell differentiation.
Furthermore, we showed that TT cells overexpressing
OPNa isoform show reduced proliferation and viability,
indicating that OPN contributes to prevent tumour
progression.
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Chapter	6	–	General	Discussion	and	Conclusions	
 
 
 
Our study on the role of OPN and its variants revealed the broad spectrum of 
functions that this protein can have inside a tissue. This study shows that in thyroid, in 
different kind of cells, OPN can have diverse effects, acting as a promoter of tumour 
aggressiveness in follicular-tumours derived cells, and as a differentiation marker in 
parafollicular cells.  
OPN has been widely studied since its discovery in 1979 [1]. Early works reported 
it as a phosphoprotein in osteoblasts secreted to the bone extracellular matrix [3]. Then 
many functions have been attributed to this molecule, involved in both physiological and 
pathologic events, such as biomineralization, bone resorption, cell adhesion, migration 
and cell survival, angiogenesis, apoptosis, inflammation and wound healing [45].   
When we analysed the OPN protein expression in tumours derived from follicular 
cells, we found that tOPN is predominantly expressed in cPTC, when compared to 
adjacent non-tumoural thyroid tissues, and significantly associates with hyaline stroma 
and vascular invasion. These data are in accordance with OPN as a glycoprotein secreted 
in the ECM, both in tumour and non-tumoural tissues [45]. OPN is also known to be 
upregulated in the tissue stroma in different conditions, such as salivary pleomorphic 
adenomas [199] and intrahepatic cholangiocarcinoma [200]. It is well known that the 
interplay between epithelial cells and the microenvironment may contribute to keep the 
epithelial polarity and to modulate growth inhibition [201]. On the other hand, the stromal 
compartments undergo changes in response to emerging epithelial lesions that can have 
a key role in cancer initiation and progression [201, 202]. Accordingly, our data regarding 
the correlation of tOPN and the presence of a hyaline stroma support the assumption that 
either tOPN expression alone or tOPN in association to hyaline stroma may play a role in 
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cPTC tumour aggressiveness. Of note, cPTC samples displaying vascular invasion 
exhibited higher tOPN staining scores than tumours without vascular invasion. Such 
results also corroborate previous studies which showed that tOPN overexpression is 
significantly associated with poor prognostic factors, such as presence of lymph node 
metastasis, tumour size and poor disease free survival in PTC samples [100, 102, 103, 
203].  
At variance with the aforementioned results, and the majority of published papers 
which OPN functions are related to malignancy and tumour progression, we described 
OPN as a differentiation marker for normal C-cells in thyroid, whereas in medullary 
thyroid cancer, OPN appear associated with good prognosis. Parafollicular cells are cells 
with neuronal differentiation, and in this cells OPN is expressed and appear as a 
differentiation marker. Similarly, Melen-Mucha et al. [204] reported that OPN levels 
were decreased in Gastro-entero-pancreatic/neuroendocrine (NET) tumours, when 
compared with healthy controls. Moreover, a recent study showed that OPN deficient 
mouse (OPN-/-) crossed with TRansgenic Adenocarcinoma of the Mouse Prostate 
(TRAMP), developed aggressive human-like neuroendocrine cancer, instead of prostate 
carcinoma [205]. These data shed light to the role of OPN in the different cancer types, 
thus its expression seems to protect against the development of aggressive 
neuroendocrine tumours.  
Regarding expression of OPN in MTC, our series represents the largest reported 
to date. We demonstrate that 78.4% (91/116) of MTCs express OPN and such expression 
is significantly associated with smaller, usually non-invasive tumours. Therefore, on the 
contrary of what is frequently found, the expression of OPN in MTC is associated with 
features of good prognosis and is reduced during tumour progression. During evaluation 
of the slides, we also observed strong OPN expression in isolated C-cells scattered in 
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adjacent normal thyroid parenchyma, and strong OPN expression was also observed in 
clusters of C-cell hyperplasia. Together, these results indicate that OPN may be a 
differentiation marker for C-cells. This assumption is supported by the observation of 
strong OPN expression in C-cells, confirmed by strong calcitonin staining in the same 
tissues (see paper III, Fig. 1F). In contrast to the strong expression in C-cells, we did not 
observe any OPN expression in follicular cells of the adjacent ‘normal’ thyroid tissue.  
Additionally, we also found that high levels of OPN protein expression in MTC 
was correlated with high levels of nuclear PTEN expression. Although nuclear PTEN 
function remains poorly understood, it has been shown that acting as a tumour suppressor, 
nuclear PTEN might lead to cell cycle arrest and decreased tumour growth [206, 207]. It 
was also recently described the maintenance of chromosomal stability as another function 
of nuclear PTEN [208]. PTEN has been related with OPN regulation, and it was reported 
that PTEN overexpression suppresses cellular migration stimulated by OPN [209]. As 
higher levels of OPN were significantly associated with higher levels of nuclear PTEN in 
MTCs, these two molecules can probably act together in the maintenance of the 
differentiation of C-cells, thus contributing to prevent tumour progression.  
At variance with the presence of RET mutations that were not associated with 
OPN expression, we observed that RAS-mutated MTC cases display a significantly lower 
expression of OPN. Although in apparent contradiction with the results obtained in other 
tissue models cited previously [119, 210], our results fit in with the hypothesis that OPN 
expression is associated with normal differentiation of C-cells. Many studies have 
demonstrated loss of thyroid-specific gene expression in thyroid cells following the 
introduction of a variety of transforming oncogenes, in particular of the RAS gene family 
[211]. This issue, as far as we are aware, has not been assessed to date concerning C-cell 
differentiation.  
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Therefore, concerning tOPN protein expression in the tumour types derived from 
different cells in thyroid, and its association with clinicopathological data, we found 
opposite results thus leading to opposite consequences when we analyse follicular and 
parafollicular cells in thyroid.     
We then evaluated the transcript expression of tOPN and the three OPN-SV in 
both models (follicular and parafollicular -derived cells in thyroid). Regarding the 
follicular-derived cells, we found that among the three OPN-SV, OPNa is also 
overexpressed in all thyroid tissues (adjacent thyroid tissue, adenoma, FTC, fvPTC and 
cPTC), and that among such different tissues, OPNa is overexpressed in cPTC. 
Furthermore, we found that the OPNa overexpression is specifically associated with poor 
prognostic features in cPTC. In particular, OPNa variant was significantly associated with 
presence of extrathyroid extension, vascular invasion and BRAFV600E mutation. In the 
fvPTC, the only significant association observed was between high tOPN and OPNa 
expression levels and older patients. Based on these findings, we postulate that elevated 
OPNa expression in TC may occur during tumour progression, facilitating more 
aggressive phenotypes. Other studies have shown that OPN-SV expression and its 
associations to clinicopathological features seem to be tissue specific. For instance, it has 
been reported that high OPNb and OPNc expression levels in breast cancer [212] and in 
gastric tumours [213] is correlated with more aggressive clinicopathological features. 
In parafollicular-derived cells, we investigated the expression in 6 MTC cases and 
in 2 cell lines (TT and MZ-CRC1). OPNa mRNA was expressed at significantly higher 
levels in tumour samples than in non-tumour samples (P = 0.032), while OPNb and OPNc 
presented similar levels of mRNA expression in tumours and respective adjacent tissues. 
We realised that when analysing the so-called ‘normal adjacent thyroid’, we were 
evaluating mainly follicular cells and comparing the expression of the variants between 
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follicular cells and MTC. Only by analysing isolated C-cells we were able to compare 
“normal” C-cells and neoplastic MTC cells. Nevertheless, as we observed that OPNb and 
OPNc had similar expression levels in ‘normal’ adjacent tissue and in MTC, whereas 
OPNa showed significantly higher levels in MTC, we can conclude that OPNa mRNA is 
the variant more expressed in MTC. This conclusion fits with our observation of higher 
levels of OPNa mRNA in the two MTC-derived cell lines. It remains to be clarified 
whether the same is true regarding normal and hyperplastic C-cells, i.e. if OPNa mRNA 
high expression is also present in normal and hyperplastic C-cells, or if it is tumour 
specific.  
In order to disclose the possible roles of OPNa and/or the two other OPN-SV, we 
chose three thyroid tumour-derived cell lines (two from follicular cells, c643 and 8505c; 
and one from parafollicular MTC, TT). We overexpressed OPNa, OPNb or OPNc in c643 
and 8505c cell lines (follicular-derived TC cells) with plasmid constructs containing each 
of the three OPN- SV. Then, we observed that follicular-derived TC cells overexpressing 
OPNa displayed significantly increased cell growth, migration and motility, whereas 
OPNb and OPNc overexpression in TC cells did not induce similar effects. Other reports 
have demonstrated that different OPN-SV play important roles in tumour progression by 
regulating cell growth, adhesion, migration and tumour formation. Our group as 
previously demonstrated in prostate and ovarian carcinoma model that OPNc activates 
invasion and adhesion properties, as well as metastatic potential and angiogenesis [30, 
31]. Others demonstrated that in hepatocellular carcinoma cells, OPNa and OPNb can 
induce cell migration [37]. Lin J and co-workers in cells derived from esophageal 
adenocarcinoma [214], observed that OPNb overexpression evoked enhanced cell 
proliferation, migration and invasion. Our findings highlight the specific importance of 
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OPNa in follicular cells derived-TC promoting cell growth and migratory and invasive 
phenotype.  
Hence, to further explore OPNa roles on modulating TC invasive properties in 
such TC follicular derived cell lines, we also explored the role of OPNa in the activation 
of MMPs. MMPs are important enzymes in the metastatic cell arsenal. These proteins can 
degrade both cell adhesion molecules and extracellular matrix molecules, enabling 
tumour cells to migrate from the tumour bulk and to invade adjacent tissues [215]. 
Previous data from our group in prostate and ovarian tumour models showed that cells 
overexpressing the OPNc variant induce expression of MMP2 and MMP9, highlighting 
the functional tissue specificity of OPN-SV [31]. Thyroid carcinomas produce elevated 
levels of MMP2, which has been correlated with the presence of lymph node metastasis 
[29]. Herein, we have found that CM collected from cells overexpressing OPNa have 
increased activity of MMP2 in c643 cells and MMP2 and MMP9 in 8505c cell lines. 
These results evidence that OPNa may promote TC cell invasion through inducing MMP2 
and MMP9 secretion. The detailed mechanism by which this event occurs still needs 
further characterization. Nonetheless, it has been described that OPN can regulate MMPs 
activity by binding to pro- MMP9, thus promoting its activation [216]. Additionally, OPN 
can induce NFkB-mediated pro-MMP2 and MMP9 activation through IkBa/IKK 
signalling pathway [217].  
Taking in consideration that MMPs expression and cancer cell migration are 
fundamental features for tumour invasion [218], we further investigated the contribution 
of OPNa variant for a TC cell line invasiveness using an in vivo experimental model. 
Using the CAM assay approach, we observed that tumours formed by the overexpressing 
OPNa cells present a loosen structure, in which the cells were oriented towards the 
invasion front while single cells and cell clusters invading the CAM mesenchyme could 
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also be observed. In contrast to this, EV clones formed compact tumours, with clear de 
ned boarders lacking invading cells. Similarly to our data, overexpression of OPNa has 
been previously associated with modulation of cancer cell invasion in mesothelioma, 
breast cancer and hepatocellular carcinomas [33, 37, 219]. Although activating cell 
invasion, OPNa overexpression does not significantly modulated angiogenesis and 
tumorigenesis in this in vivo tumour model. Some oncogenic proteins can activate some 
specific steps in tumour progression, but not others. As evidenced by our data OPNa 
overexpression in vivo may predominantly modulate signalling pathways that stimulate 
migration and invasion, possibly through stimulating ECM degradation by MMP2 and 
MMP9. In light of our results, we may hypothesize that the increased invasive capacity 
of c643 cells overexpressing OPNa (in comparison to c643-EV cells) allows the cells to 
reach the blood vessels, and have no effect in the recruitment of new vessels.  
Respecting to the parafollicular-derived cells, and in contrast of what we observed 
for follicular-derived cells, we show that TT cells overexpressing OPNa, OPNb and 
OPNc show a significant decrease in proliferation and viability, having OPNa variant the 
most prominent effect. Although OPN is widely known as implicated in promoting 
invasive and metastatic progression in many carcinomas [31, 220], in MTC, the 
overexpression of OPN variants seems to be related with a protective role, as reported in 
pancreatic adenocarcinoma [221]. These results indicate that in MTC, OPN contributes 
to impair tumour growth, corroborating our hypothesis that OPN can act in the 
maintenance of the differentiation of C-cells. Further studies, including evaluation of 
adhesion, invasion and migration, would allow a view of the whole picture and the 
complete understanding of the role of OPN in C-cell biology and disease. 
Although is widely established the deep relationship between OPN and 
calcification, little is known regarding the OPN expression and the psammoma bodies 
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(PB) formation in cPTC cases. Thus, to better comprehension of such process, we 
intended to explore this issue. For that, we investigate the relationship between the 
expression pattern of the OPN and OPN-SV in cPTC cases and correlated it with the 
occurrence of PB in such cases. Moreover, we analyse if the presence of PB in cPTC 
cases is related with its clinicopathological data. We observed that high expression of 
OPNa transcript is correlated with PB in cPTC cases. We also found that cPTC cases 
having PB are associated with younger patients and presence of lymph node metastasis. 
Moreover, OPNa overexpression displayed a strong capacity to promote calcification and 
substantial collagen synthesis in the thyroid cancer cell lines. 
We have shown that tOPN protein expression has been observed in cPTC samples 
that present PB. Of note, in the immunohistochemistry analysis of the cases stained for 
tOPN, PB are much clearer than in HE staining, particularly since the staining of PB with 
anti-OPN antibody is stronger. To date, only two studies reported an association between 
OPN expression and the occurrence of PB in PTC samples [85, 86]. Both studies showed 
that the expression of tOPN protein associates with the occurrence of PB in PTC samples, 
suggesting a role for OPN in calcification of PTC [85]. Another association between OPN 
and calcification in cancer was reported by Hirota et al. [222], who described OPN protein 
co-localization with calcium phosphate in meningioma tissues, further evidencing a role 
for OPN on the PB formation in this context.  
We further showed that cPTC cases that presented PB also had higher expression 
levels of tOPN, OPNa, OPNb and OPNc transcripts, although only OPNa and OPNb 
levels demonstrated statistically significant differences (OPNa > OPNb). In a previous 
work, we demonstrated that among the three OPN-SV, OPNa had the highest expression 
levels in cPTC, when compared with other thyroid tissues [223]. Therefore, the current 
results are in accordance with our earlier observations, raising a possible relation between 
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OPNa variant overexpression and the formation of PB in cPTC. Regarding the small 
series of diffuse sclerosing PTC samples analysed in this study, no expression of tOPN 
protein was observed. On the other hand, when we evaluated the three OPN-SV in these 
cases, high OPNa levels have been detected. In addition to the cPTC, the diffuse 
sclerosing PTC is the variant that frequently presents numerous PB [224], as also 
confirmed in the 3 cases analysed here. Notably, diffuse sclerosing PTC have been 
described to have a higher incidence of lymph node metastasis when compared to cPTCs 
[225].  
Regarding the analysis of cPTC clinicopathological features, we found a 
correlation between cPTC cases presenting PB and presence of lymph node metastasis 
and younger patients. PB is a diagnostic indicator for cPTC, and its presence strongly 
suggest tumour malignancy in preoperative diagnosis. Bai et al. [226] also reported that 
the presence of PB in PTC cases was associated with gross lymph node metastasis and 
high-stage cancer (stage IVa). Conversely, Pyo et al. [227] found an association between 
PB and tumour multifocality, extrathyroid extension, and lymph node metastasis. The 
higher expression of OPNa in cPTC containing PB and the association of PB with lymph 
node metastases is in accordance with our previous data, in which we showed that OPNa 
overexpression contributes to cPTC progression features [223]. Bai et al. [226] found an 
association between stromal calcification and advanced age of patients (> 60 years). 
However, in that study authors only considered calcification in the stroma. Stromal 
calcification frequently arises in benign lesions, whereas PB are suggestive of 
malignancy. Herein, we evaluated only PB in cPTC cases, excluding other dystrophic or 
stromal calcifications, as well as bone formation. In fact, when we consider dystrophic 
calcification, no correlation was found with OPNa expression (data not shown). 
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In our previous work, we also reported an association between tOPN protein 
expression and presence of stromal tissue areas in cPTC cases, suggesting that this may 
be correlated with tumour aggressiveness in cPTCs [223]. Herein, we further investigated 
this point and presented in vitro and in vivo evidence of an association particularly 
between OPNa expression and the presence of PB and stromal collagen. 
In order to establish putative impacts of OPN-SV regarding the calcification 
process, OPNa, OPNb and OPNc (and an empty vector as a control) were overexpressed 
in c643 TC cells. We then analysed the effects of OPN-SV overexpression in the 
formation of calcium deposits in the ECM produced by the cells and found that OPNa 
overexpressing cells strongly induced calcium deposits in the ECM. Calcification within 
the thyroid gland is a common finding both on thyroid imaging and thyroid 
histopathologic findings [228]. Although PB are a highly specific sign of malignancy 
frequently detected in cPTC [227], the mechanisms by which PB are formed in thyroid 
tumours is still controversial. Several reports have revealed that calcification is more 
common in malignant than in benign thyroid nodules [229, 230]. Other authors reported 
that intrathyroidal calcification was noted in 26.1% (29 out of 111) of the malignant 
thyroid nodules and in only 8.0% (20 out of 250) of benign thyroid samples [228]. 
Nonetheless, it is important to mention that many authors have been stressing that the 
presence of intrathyroidal calcification per se cannot be used to distinguish between 
benign and malignant thyroid disease [229-232].  
We also observed that, among the overexpressing OPN-SV c643 cells, OPNa 
overexpressing cells induced more efficiently collagen synthesis in the ECM. This data 
indicates that among the three variants, OPNa remarkably promoted these effects. These 
results are in accordance with our previous observations, whereby OPNa (among all 
OPN-SV) seemed to be the key OPN variant associated with the presence of stroma [223]. 
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 The roles of OPN in the tumour ECM microenvironment has been investigated. 
For instance, Liaw et al. [233] showed that OPN knockout mice exhibit defective repair 
of incisional skin wounds with abnormal collagen fibrillogenesis. Additionally, it is 
known that depending on the ECM stiffness, collagen fibbers potentiate cell migration, 
especially in the presence of MMPs activity [234]. Accordingly, our previous work 
demonstrated that OPNa activates MMP2 and MMP9 activities in thyroid cell lines, 
besides promoting cell migration and invasion in the in vivo CAM model [223]. Being 
the most abundant ECM components, collagens constitute up to 90% of the ECM and 
30% of the total proteins in humans, also providing the structural integrity and the tensile 
strength of human tissues and organs [235]. Furthermore, the increased collagen 
deposition is the most well-recognized ECM alteration in tumour tissue [236-238]. In the 
context of cancer biology, it has also been shown that collagens regulate the physical and 
the biochemical properties of tumour microenvironment, modulating cancer cell polarity, 
migration and signalling [239-241].  
In order to evaluate OPNa properties on inducing calcium deposit and collagen 
synthesis in the ECM, we selected TPC1 among nine thyroid cell lines, due to its highest 
levels of endogen OPNa expression. Similarly to what has been observed for c643 cells 
overexpressing OPNa variant, TPC1 cells also exhibited calcium deposits and production 
of collagen fibbers. TPC1 cell line is recognized as presenting the RET/PTC 
rearrangements [242]. This molecular alteration was demonstrated to induce OPN 
expression in thyroid cell lines, such as PCCl3 [99], reinforcing the hypothesis that OPN 
plays a role in such processes. Although our results also provide evidence in the same 
direction, in particular giving some early evidence that OPNa plays a role in such 
mechanism, further studies are needed to better understand how OPNa modulates 
collagen synthesis and the calcification process. In addition, it is imperative to better 
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comprehend the underlying molecular mechanisms that dictate the lymphovascular 
invasion, thus contributing to the pathophysiology knowledge of cPTCs.    
Our results show that the presence of PB is associated with lymph node metastases 
in cPTC samples. Additionally, OPNa overexpression and its association with the 
occurrence of PB in cPTC samples, together with its strong capacity to promote calcium 
deposit and to synthesize collagen in the ECM in thyroid cells in vitro, supports an 
important role for OPNa in the etiopathogenesis of the cPTC.      
In summary, our data demonstrated that OPNa is the prevalent OPN-SV in DTC 
tissues and cell lines, and that overexpression of OPNa is associated with poor prognostic 
and invasive features in PTC. Yet, OPNa overexpression in TC cell lines strongly 
increases cell migration, invasion and MMPs activity, evidencing a major role for OPNa 
in TC progression features.  
The present study also showed the overexpression of OPNa and its association 
with the occurrence of PB in cPTC samples, together with its strong capacity to induce 
calcium deposit and to synthesize collagen in ECM in thyroid cells in vitro, suggest a role 
for this molecule on the physiopathology of the cPTC. 
Finally, this Thesis demonstrated for the first time that OPN is expressed in MTCs 
and that such expression is associated with smaller tumour size, less invasive features and 
overexpression of nuclear PTEN. Yet, our study reports the first description of OPN 
expression in the specialised neuroendocrine cells of the thyroid, indicating a role for this 
multifunctional protein in C-cell differentiation. Furthermore, we showed that TT cells 
overexpressing OPNa variant show reduced proliferation and viability, indicating that 
OPN contributes to prevent tumour progression. These data suggest that OPN 
immunostaining may be a useful marker in the study of the physiology and 
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physiopathology of C-cells, C-cell hyperplasia and MTC, although further studies with 
an in-depth analysis of C-cell characteristics are needed to confirm this assumption. 
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Chapter	7	–	Appendix	
	
7.1	–	Additional	publications	in	the	PhD	time	course	
	
7.1.1	Paper	I	-	Poorly	differentiated	and	undifferentiated	thyroid	carcinomas		
	
	
	
 
 
 
  
 138 
 
 
 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
 139 
 
doi: 10.5146/tjpath.2015.01314Review
48
Received : 29.05.2015   Accepted : 03.06.2015
Correspondence: Manuel SOBRINHO-SIMÕES 
IPATIMUP, Rua Roberto Frias s/n 4200-465 
PORTO, PORTUGAL
E-mail: ssimoes@ipatimup.pt   Phone: +351 225570700 
(Turk Patoloji Derg 2015, 31(Suppl):48-59)
ABSTRACT
Thyroid cancer is the most common endocrine malignancy and its incidence goes on increasing worldwide. The majority of thyroid tumours 
comprise well-differentiated (papillary and follicular) thyroid carcinomas that usually carry an excellent prognosis, while a minority progress to 
poorly differentiated carcinoma (PDTC) and, ultimately, to the highly aggressive and lethal undifferentiated carcinoma (UTC). Recently, some 
major advances have been made on the histologic and imunohistochemical identification, as well as on the molecular characterization of PDTC 
and UTC. In this review we summarize the most recent immunohistochemical and molecular findings in PDTC and UTC, giving a particular 
emphasis to the diagnostic and prognostic meaning of the genetic alterations.
Key Words: Anaplastic thyroid carcinoma, Non-medullary thyroid carcinoma, Molecular medicine, Small cell carcinomas, Poorly differentiated 
thyroid carcinoma
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INTRODUCTION
The most important difference between the classifications 
of thyroid tumours in the WHO books of 1988 and 2004 
concerns the individualization in the latter of the group of 
poorly differentiated carcinomas (PDTC) (1, 2). It was also 
recognized that all sorts of benign and malignant thyroid 
tumours may be composed by the individualization of 
oncocytic (oxyphilic or Hürthle) cells, thus leading to 
oncocytic/Hürthle cell variants of adenoma and of follicular 
papillary and poorly differentiated thyroid carcinoma (1). 
It is usually advanced that the absence of an oncocytic/
Hürthle cell variant of undifferentiated carcinoma (UTC) 
reflects the high mitotic ratio of such tumours (the cells of 
undifferentiated/anaplastic carcinoma divide too fast to allow 
the accumulation of mitochondria in their cytoplasm) (3).
The immunohistochemical and molecular characteristics of 
poorly differentiated and undifferentiated carcinomas were 
thoroughly addressed in the 2004 edition of the WHO book, 
as well as in a number of review papers by Garcia-Rostan et 
al., Nikiforov et al. (4-6) and Soares et al. (7) (Tables 1, 2).
Most of the problems found in the stratification of such 
immunohistochemical and/or molecular markers reflect 
differential diagnostic difficulties – it is not easy, for 
instance, to separate a poorly differentiated carcinoma from 
a widely invasive follicular carcinoma with a trabecular/
solid growth pattern – and the intrinsic heterogeneity of 
both groups of carcinoma.
Another problem regards the existence of several clinico-
pathological entities in thyroid oncology that may be 
considered as a sort of poorly differentiated carcinoma [e.g. 
(sclerosing) mucoepidermoid carcinoma and mucinous 
carcinoma)]. Such entities have been recently described 
and discussed in the 2014 - AFIP book on Thyroid and 
Parathyroid Tumours (8) and will not be addressed in the 
present review. The only exception concerns the group of 
Small cell carcinomas/Carcinoma of the thyroid with Ewing 
Family Tumour Elements (CEFTE) because it represents a 
particularly interesting end result of new developments in 
the immunohistochemical and molecular study of peculiar 
thyroid tumour that raise difficult differential diagnostic 
problems (9-12).
POORLY DIFFERENTIATED CARCINOMA  
The histological description should follow the 2004 WHO 
book and the AFIP book of Rosai et al. (1, 8) (Figure 1A-
E). The diagnostic guidelines and the histological pictures 
in the latter are excellent and review thoroughly the steps 
used in the diagnosis of PDTC following the algorithmic 
approach advanced by Volante et al. (13).
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Table I: Poorly differentiated carcinoma
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Antibodies usually expressed Antibodies variably expressed Antibodies usually not expressed
Cytokeratins
TTF1
Thyroglobulin (focal)
Ki-67 (labelling index is higher than 
in well differentiated carcinomas)
Cyclin D1
Synaptophysin
p53
E-cadherin
Calcitonin
Chromogranin
M
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ec
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Molecular alterations Prevalence (%) References
RAS 20-50 (7); (4)
TP53 15-40 (7); (4)
BRAF 5-20 (7); (4); (31)
CTNNB1 5-25 (31); (28)
PIK3CA 5-14 (7); (4); (31)
PTEN 20 (31)
AKT1 5-10 (4)
TERT 20-50 (7); (36)
STRN/ALK 9 (42)
PDTC: Immunohistochemical and molecular features (poorly differentiated carcinomas).
Table II: Undifferentiated thyroid carcinoma
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Antibodies usually expressed Antibodies variably expressed Antibodies usually not expressed
Cytokeratins (usually focal)
Ki-67 (labelling index is higher than 
in PDTC)
p53
Vimentin
Cyclin D1
TTF1
PAX8
E-cadherin
EMA
P63
CEA
Calcitonin
Chromogranin
Thyroglobulin
Synaptophysin
Bcl-2
CD31
CD34
M
ol
ec
ul
ar
 fe
at
ur
es
Molecular alterations Prevalence (%) References
TP53 50-80 (19); (4)
TERT promoter mutation 30-50 (19);(56)
RAS 4-60 (49)
BRAF 10-50 (19);(4)
CTNNB1 5-66 (29)
PI3KCA 5-25 (19)
PTEN 5-15 (19); (4)
AKT1 5-10 (19); (4)
ALK 0-10 (19)
UTC: Immunohistochemical and molecular features (undifferentiated carcinoma).
The most difficult diagnostic problems occur in the 
border between well differentiated (WDTC) and poorly 
differentiated carcinoma. The separation between papillary 
thyroid carcinoma (PTC) and PDTC is based upon the 
nuclear features of the neoplastic cells. In case the nuclei 
are of the PTC type the tumour is classified as a solid or 
trabecular variant of PTC regardless of the existence of 
necrotic foci and/or high mitotic number (6, 14, 15). 
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The separation between widely invasive follicular thyroid 
carcinomas (FTC) with foci of necrosis and/or high mitotic 
index and PDTC is almost impossible to establish in many 
situations (15). Molecular data did not provide so far any 
diagnostic clue and the pathology reports are written 
assuming the aforementioned limitations. This does not 
constitute a major drawback since the prognosis and 
treatments are similar in both situations (1, 8, 15).
In different fields of well differentiated thyroid carcinomas 
there are reports of tumours displaying poorly differentiated 
features [e.g. cribriform morular variant of PTC (16)]. These 
cases should not be lumped together with common PDTC.
The differential diagnosis between PDTC and UTC/
anaplastic carcinoma may be difficult in intermediate cases 
but is based upon a very precise immunohistochemical 
feature: PDTC exhibits diffuse nuclear positivity for TTF1 
and focal positivity, frequently with a dot-like pattern, for 
thyroglobulin, and UTC by definition are thyroglobulin 
negative and almost always TTF1 negative.
The hottest topic in the world of PDTC regards the 
diagnosis of PDTC, which do not exhibit unequivocal 
signs of capsular and/or vascular invasion. The question is 
simple but the answer is difficult. Which are the criteria for 
diagnosing a PDTC in an apparently non-invasive thyroid 
tumour? There are anecdotic reports in the literature 
claiming that such cases exist and have given rise to 
metastases (17). Ghossein et al. (18) did not find evidence 
supporting this claim and we must confess we do not know 
how to solve the problem. In real life, and whenever the 
Figure 1: Poorly Differentiated Thyroid Carcinoma (PDTC): A) Tumour with expansive growth pattern, invasion of the capsule and 
images of vascular invasion, B) Macroscopic appearance of an apparently well circumscribed PDTC whose histological characteristics 
are documented below, C, D) Nested pattern area with foci of necrosis (H&E, 40x), E) Focus with numerous mitoses and without PTC 
type nuclei (H&E, 400x).
A
C D E
B
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tumour displays (very) aggressive histological features 
without showing concomitant signs of invasion, we sample 
the capsule completely and look at deeper sections of the 
tumour in an attempt to find such signs. The only molecular 
feature which might be used for making a diagnosis of 
noninvasive PDTC would be the demonstration of clonal 
TP53 mutations or diffuse nuclear immunoreactivity for 
p53, but even then the classification of noninvasive PDTC 
is questionable (we must confess we have never made such 
diagnosis).
In the future, there will hopefully exist drugs that can be 
efficiently used to treat patients with thyroid carcinomas 
not responding to radioactive iodine, in these settings the 
focus will rest on the identification of specific molecular 
targets rather than on the histological classification of the 
carcinomas.
The molecular features of PDTC are summarized in Table 1. 
Activating point mutations of the RAS gene typically affect 
codons 12, 13 and 61. At variance with differentiated thyroid 
cancer where NRAS codon 61 mutations are the most 
frequent, HRAS and KRAS codon 12 and 13 are also found 
mutated in PDTC (4, 7, 19). Volante et al. reported RAS 
mutations as the most common genetic alteration in PDTC 
(20). Moreover, the detection of RAS mutations appears to 
be clinically relevant in terms of prognosis, identifying a 
subset of more aggressive tumours (20). It was shown that 
PDTC cases with mutated NRAS are significantly associated 
with the appearance of haematogenous (particularly bone) 
metastases (19). Due to the association found between 
RAS mutations and guarded prognosis in PDTC and UTC, 
Wang et al. proposed that a particular attention should also 
be paid to WDTC, namely FTC, harbouring RAS mutations 
(7, 21). 
TP53 gene, encoding a nuclear transcription factor that 
is typically involved in the negative regulation of the cell 
cycle and in promoting apoptosis, is a frequently impaired 
gene during thyroid tumour dedifferentiation (22-24). 
In thyroid, TP53 shows a mutational pattern located in 
known hotspots (exons 5-9) in 15-40% of cases. Moreover, 
there is a relatively good correlation between mutations 
and p53 immunohistochemical reactivity: aberrant p53 
immunoreactivity is detectable in 40-50% of PDTC (1, 7, 19). 
TP53 mutation seems to be (one of) the dedifferentiation 
switches necessary for progression and dedifferentiation in 
thyroid tumours (7).
BRAFV600E mutation occurs in 5-20% of PDTC (25, 26). 
Many of these carcinomas also reveal areas of PTC, and 
BRAFV600E is present in both tumour components, thus 
suggesting that this mutation is an early event that do 
not impair tumour dedifferentiation (4). In accordance 
with a stepwise progression model, BRAF mutations are 
almost exclusively found in PDTC arising from PTC, being 
extremely rare in PDTC associated with FTC (7). Ricarte-
Filho et al. (27) reported that 39% of PDTC, FDG-PET 
positive tumours refractory to radioactive iodine (RAI) 
treatment harbouring BRAF mutations, whereas non-RAI-
refractory PDTCs display a significantly lower prevalence 
of BRAF mutations (12%) (27). These results indicate that 
BRAF mutated PDTC are more often refractory to RAI 
treatment than BRAF wild type PDTC.
Two of the most common rearrangements in WDTC 
are RET/PTC and PAX8/PPARγ (4); however, these 
specific rearrangements are only rarely detected in PDTC 
(19). This finding suggests that WDTC harbouring 
such rearrangements do not usually evolve toward less 
differentiated carcinomas, thus reinforcing the assumption 
that the majority of “rearranged” PTC and FTC cases do 
not tend to progress towards further advanced steps of 
neoplastic development (19).
Another gene reported as frequently mutated in PDTC and 
UTC is CTNNB1, which encodes βcatenin that is involved 
in cell adhesion and WNT signalling (4). The seminal 
paper of Garcia-Rostan et al. (28) showed a frequency 
of 25% of CTNNB1 mutations in PDTC. The activating 
mutations cluster in exon 3 at the phosphorylation sites 
for ubiquitination and degradation of β-catenin and 
are associated with aberrant nuclear immunoreactivity, 
suggesting WNT pathway activation (28, 29). In contrast 
Rocha et al. (30) did not find mutations in CTNNB1 nor in 
the CDH1 gene (encoding E-cadherin) in a series of PDTC. 
Rocha et al. observed alterations of protein expression, 
concluding that loss of E-cadherin rather than CTNNB1 
mutation appears to be the crucial event in determining the 
degree of differentiation of thyroid carcinomas (19, 30). In 
accordance with these latter results, Pita et al. (31) found 
CTNNB1 mutations in a minority (5%) of PDTCs.
Thyroid carcinoma dedifferentiation involves also the 
progressive accumulation of other mutations, particularly 
those in genes that encode effectors of the PI3K–AKT 
pathway, such as the PIK3CA (the gene that encodes PI3K), 
AKT1 and PTEN (4). Among PDTC carcinomas, 5-14% 
harbour mutations in PIK3CA, 20% in PTEN and 5–10% in 
AKT1 (4, 8, 31, 32).
Telomerase activation is known to be a hallmark of 
cancer being detected in up to 80% of malignant tumours 
(7). Normal thyroid tissue is thought to be telomerase 
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is illustrated in Figure 2A,B. The immunohistochemical 
and molecular data on the whole group are summarized in 
Table 2.
Undifferentiated thyroid carcinoma (UTC) corresponds to 
the most aggressive form of thyroid cancer, being the final 
step of the progression of thyroid epithelial neoplasms. The 
concept of stepwise progression from a pre-existing well-
differentiated thyroid carcinoma to poorly differentiated 
and undifferentiated carcinoma is supported by clinical, 
epidemiologic, pathologic and molecular evidence 
(studies of loss of heterozygosity, comparative genomic 
hybridization, genetic and epigenetic alterations), although 
anaplastic carcinoma may apparently also arise de novo (7, 
47, 48).
Thyroid tumours are part of the minority of those human 
cancer types that do not follow the classical Vogelstein 
model, in which mutational inactivation of TP53 is a 
crucial step in the first steps of progression (from adenoma 
negative, thus raising the possibility that the reactivation of 
telomerase may be a useful marker of tumour development 
(33, 34). TERT promoter mutations were found in 20-50% 
of PDTC (8, 33, 35, 36). These findings concur with the 
evidences that TERT promoter mutations associates with a 
more aggressive behaviour of thyroid tumours (37, 38). 
Some PDTC and every UTC constitute the majority of 
clinically aggressive tumours that cause the death of the 
patients. In an attempt to address this lethality, efforts have 
been made for identify other genetic alterations in less 
differentiated and undifferentiated thyroid carcinomas that 
could pinpoint new therapeutic targets. Analysis of miRNA 
expression in normal thyroid tissue and in major types 
of thyroid tumours revealed that the majority of known 
miRNAs were expressed in normal thyroid tissues, whereas 
in thyroid neoplasms 32% of miRNAs were found to be 
consistently upregulated, and 38% were downregulated 
with more than a 2-fold change as compared to normal 
tissue (39). The most highly upregulated miRNAs in PDTC 
were miR-187, -221, -129, -222, -146b, -339, -183 (39). 
The rearrangement involving the anaplastic lymphoma 
kinase (ALK) gene (40) and the striatin (STRN) gene (STRN/
ALK) leads to constitutive activation of ALK kinase via 
dimerization mediated by the coiled-coil domain of STRN 
and to a kinase-dependent, thyroid-stimulating hormone-
independent proliferation of thyroid cells. Expression of 
STRN/ALK transforms cells in vitro and induces tumour 
formation in nude mice. Kelly et al. (41) reported this 
gene arrangement in 9% of PDTC and demonstrated that 
STRN/ALK gene fusion occurs in a subset of patients 
with aggressive types of thyroid cancer, providing initial 
evidence that ALK inhibitors may represent a therapeutic 
option in these cases (41).
Other molecular alterations include downregulation of 
genes responsible for specialized thyroid function and in 
cell adhesion, upregulation of genes involved in motility and 
cell–cell interaction, and different patterns of deregulation 
of the expression of genes that encode cytokines and 
other proteins involved in inflammation and immune 
response. Although the list of specific deregulated genes 
varies substantially between different studies, a number 
of genes have been consistently found to be deregulated at 
the mRNA level: MET, TPO, TIMP1, DPP4, LGALS3 and 
KRT19 (42-46).
UNDIFFERENTIATED (ANAPLASTIC) CARCINOMA
For a thorough and extremely competent review on the 
macroscopic and histologic aspects of these tumours please 
see the respective AFIP chapter (8). A typical case of UTC 
Figure 2: Undifferentiated Thyroid Carcinoma: A) Large 
tumour that grows beyond the thyroid limits, B) The neoplastic 
cells are mitotically active, atypical and pleomorphic displaying 
epithelioid to spindle cell morphology and co-existing with giant 
cells (H&E, 400x).
A
B
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to carcinoma) (49). TP53 gene inactivation seems to 
play a major role in the progression from differentiated 
to undifferentiated carcinoma, being a late event in the 
carcinogenic process and occurring together with a marked 
increase of cell proliferation (7). At variance with well-
differentiated tumours in which TP53 gene mutations are 
rare, in UTC the loss of function mutations in different 
reports ranges from 50 to 80% (19, 27, 50-52). Many studies 
have shown that, when the same tumour contained well-
differentiated and undifferentiated components, TP53 
mutation was restricted to the anaplastic foci (50, 53, 54). 
No clear prognostic significance has been attributed to the 
presence of TP53 mutations in UTC.
The second most frequent genetic alteration in UTC is the 
recently described TERT promoter mutation. The -124 
and -146 mutations in TERT promoter are detected in up 
to 50% of UTC; this percentage is higher to the percentage 
found in PDTC, and much higher than that reported in 
well-differentiated thyroid carcinomas (8, 55). The -124 
mutation occurs more frequently, being the two mutations 
mutually exclusive. It was reported that -124 and -146 TERT 
promoter mutations coexist frequently with BRAFV600E 
mutation (33, 35, 36). In one report, Landa et al. (37) stated 
that TERT promoter mutations were collectively associated 
with BRAF and RAS mutations when UTC and PDTC were 
lumped together. Recently, Shi et al. (56) found that a-124 
TERT promoter mutation in UTC is typically associated 
with older age of the patients and with distant metastasis, 
thus suggesting that this mutation plays an important role 
in the pathogenesis and aggressiveness of UTC.
The prevalence of RAS mutations in UTC ranges from 4 to 
60% (13, 31, 57, 58). Activating point mutations typically 
affect codons 12, 13 and 61 of the NRAS gene. In vitro RAS 
activation leads to the rapid loss of differentiation markers, 
such as thyroglobulin, thyroid peroxidase, and thyrotropin 
receptor, and increased proliferation, but it is not sufficient 
to induce per se complete transformation of thyroid cells 
(59-61). Dedifferentiation is likely not driven by RAS 
mutations individually, but rather by the combined effect of 
multiple genetic alterations (62) including TP53 and TERT 
promoter gene mutations 
The BRAFV600E point mutation that constitutes about 98–
99% of all BRAF mutations found in thyroid cancer, and 
it is present in up to 40% of UTC (25, 27, 63). Nikiforov 
et al. (47) reported that BRAF mutation was detected 
in areas of PTC and of PDTC or UTC coexisting in the 
same tumours, providing molecular evidence for stepwise 
progression from PTC to PDTC and UTC. The results on 
the record also suggest that constitutive activation of BRAF 
may predispose to such a progression, although it appears 
that this mutation represents an early event and additional 
genetic alterations (namely TP53 mutation) are required to 
promote the process of dedifferentiation (47). 
Molecular alterations are progressively accumulated in 
thyroid cancer during the dedifferentiation process, and 
this occurs particularly in those genes that encode effectors 
of the PI3K-AKT pathway. Among UTC, 5–25% of the 
tumours harbour mutations in PIK3CA (8), 5–15% PTEN 
mutations and 5–10% AKT1 mutations (22, 27, 32, 64). 
Amplification of the PIK3CA genomic locus in 3q26.3 is 
found in about 40% of UTC suggesting that alteration of the 
PI3K-AKT pathway plays a pivotal role in the pathogenesis 
of UTC (55).  
The STRN/ALK gene rearrangement has been identified in 
a subset of UTC that appears to develop from PTC. This 
gene rearrangement was also reported in one of 24 UTC 
coexisting with a follicular variant of PTC component (41). 
Murugan et al. (65) identified activating point mutations in 
ALK (encoding the tyrosine kinase domain of the protein) 
in two tumours from a series containing 18 UTC.
Recently, a critical role for miRNAs in carcinomas has 
emerged with increasing evidence showing that they 
may drive and potentiate tumourigenesis and neoplastic 
progression. Some miRNAs appear to be reduced in 
thyroid cancer, such as the let-7 family, but other miRNAs, 
such as the miR-200 and miR-30 families, are exclusively 
downregulated in UTC, indicating that its loss may 
play a role in the acquisition of more aggressive tumour 
characteristics (i.e., enhanced cell invasion and migration 
or dedifferentiation) (66, 67). On the other hand, miRNAs 
such as miR-146, miR-221, miR-222, and miR-17-92 are 
upregulated in UTC and in well-differentiated thyroid 
cancer, indicating that reinforced expression of these 
miRNAs appears to play a role in the maintenance of the 
oncogenic process (66). 
The low-density lipoprotein receptor-related protein gene 
(LRP1B) originally isolated on the basis of homozygous 
deletions detected in human lung cancer cell lines (68) is 
among the top 10 most significantly deleted genes across 
3312 human cancer specimens (69). LRP1B localizes at 
2q21, a susceptibility locus for familial non-medullary 
thyroid cancer and encodes for a member of the endocytic 
low-density lipoprotein receptor superfamily (68). Our 
group reported that the LRP1B expression level in UTCs was 
significantly lower than in differentiated thyroid cancers, 
and that such reduced expression was due to frameshift 
mutation and genomic loss of LRP1B gene (68). Moreover, 
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UTC showed frequent methylation of the promoter region 
of the gene leading the loss of the expression of LRP1B in 
more than 80% of UTCs (68).
Among the proteins whose expression is altered in UTC, 
some appear as promising novel therapeutic targets namely 
Aurora kinases and transferrin receptor. In UTC, Aurora 
kinases are often found overexpressed (70). Aurora kinases 
are serine/threonine kinases that play an essential role in 
cell division. Their aberrant expression and/or function 
induce severe mitotic abnormalities resulting in either cell 
death or aneuploidy. Baldini et al. (71) reported the in vitro 
efficacy of Aurora kinase inhibitors (MLN8237 inhibitor 
for Aurora-A and AZD1152 inhibitor for Aurora-B) in 
restraining cell growth and survival of four human UTC cell 
lines (CAL-62, BHT-101, 8305C, 8505C). Baldini showed 
furthermore that Aurora A inhibition appears to be more 
effective than that of Aurora B in UTC cell lines (71). These 
data indicate that inhibitors for overexpressed proteins, 
such as Aurora kinases, alone or in combination with 
other drugs, including microtubule inhibitors, display an 
anticancer effect in preclinical models of UTCs suggesting 
that this approach may be used as an alternative therapeutic 
strategy for patients with UTC (72, 73).
The TfR1/CD71 is a cell membrane glycoprotein involved 
in iron homeostasis and cell growth. Parenti et al. (74) 
reported immunohistochemical data demonstrating the 
overexpression of TfR1/CD71 in UTC and discuss the 
possibility of targeting TfR1/CD71 by monoclonal or 
recombinant antibodies or transferrin-gallium-TfR1/
CD71 molecular complexes or even small interfering RNAs 
(siRNAs) (74).
Finally, aberrant methylation of gene promoter regions 
and histone modifications can alter the function of tumour 
suppressor genes and thus contribute to activation of 
signalling pathways, such as PI3K–AKT and MAPK 
cascades. Changes in the epigenetic regulation of oncogenic 
steps might also lead to downregulation of thyroid-specific 
genes during tumour progression and dedifferentiation 
(75).
SMALL CELL THYROID CARCINOMAS
In thyroid, the small cell phenotype has been observed mainly 
in poorly differentiated carcinoma and lymphoma (76). 
Other primary tumours that may exhibit small cell features 
include medullary thyroid carcinoma, undifferentiated 
carcinoma, squamous cell carcinoma, CASTLE, primary 
extra-skeletal Ewing family tumours (PEEFTs) (76-79) as 
well as other rare flowers such as neuroblastoma (80) and 
basaloid neoplasm with solid cell nest features (81). Until 
now, the rare reports of primary neuroendocrine and non-
neuroendocrine small cell carcinomas of the thyroid (82, 
83) have not provided enough evidence to support the 
recognition of a primary small cell carcinoma of the thyroid 
as an entity.
In 2011, our group reported the first case of carcinoma of 
the thyroid with Ewing family tumour elements (CEFTE) 
(9). CEFTE is a unique small cell epithelial tumour that 
showed neither C cell nor follicular cell differentiation. It 
occurs in young patients and presents as large lobulated 
thyroid nodules. Histologically, CEFTE are unencapsulated, 
predominantly expansive neoplasms, displaying vascular 
invasion and growing in a nested pattern consisting of 
well-defined, variable sized insulae with central necrosis, 
as well as trabeculae and solid areas (Figure 3A,B). The 
cells are small, uniform, with regular and fairly round 
nuclei disclosing fine chromatin and variable nucleoli. The 
Figure 3: Histological aspect of carcinoma of the thyroid with 
Ewing family tumour elements (CEFTE): A) Nested pattern area 
with foci of necrosis (H&E, 20x), B) The majority of the neoplastic 
cells are small, there are foci of squamous differentiation and some 
follicles composed by cells with papillary thyroid carcinoma-type 
nuclei (arrow) (H&E, 100x).
A
B
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cytoplasm is scant with ill-defined boundaries. Additionally, 
epidermoid-like areas and co-existing follicular foci with 
papillary-like nuclear features may be observed (9). Mitotic 
activity is variable. 
The neoplastic cells of CEFTE diffusely express 
cytokeratins, p63, E-cadherin and CD99 in the absence of 
vimentin expression (9-11). In Table 3 we summarized the 
immunohistochemical features of CEFTE. CEFTE should 
be distinguished from basaloid tumor with solid cell nests 
features that is a PTC related tumor composed by small cells 
that express p63, cytokeratin 5 and galectin3 in the absence 
of CD5 and CD99 expression (81).
CEFTE discloses the EWSR1-FLI1 rearrangement typical of 
PEEFTs (9-11) (Figure 4A,B). We do not know if CEFTE 
should be considered as a type of PEEFT with extensive 
carcinomatous differentiation, or true small cell non-
neuroendocrine carcinoma exhibiting the EWSR1-FLI1 
rearrangement. As in other locations, the diagnosis of 
thyroid PEEFT relies on the detection of the typical EWSR1-
FLI1 rearrangement (84). The EWSR1 rearrangements with 
other partners have been reported in other non-PEEFT 
tumours (85,86).
It is worthwhile stressing the apparent good prognosis 
of these tumours, despite their poorly differentiated 
appearance, vascular invasiveness and necrotic foci. 
The etiopathogenesis of such small cell carcinomas of 
the thyroid remains unknown: do they derive from 
“dedifferentiated” PTC cells that have acquired the EWSR1-
FLI1 rearrangement and entirely lost thyroid differentiation 
Figure 4: CD99 expression and EWSR1/FLI1 rearrangement in 
a case of carcinoma of the thyroid with Ewing family tumour 
elements (CEFTE): A) CD99 diffuse and membrane expression 
in the small cells (200x), B) EWSR1/FLI1 rearrangement detected 
by FISH dual color probe in the same case (break apart signs – 
arrow).
Table III: Immunohistochemical features of carcinoma of the 
thyroid with Ewing family tumour elements (CEFTE)
Antibody Expression
Pan-cytokeratins Present
Cytokeratin 5 Absent
Cytokeratin19 Present
Vimentin Absent
TTF1 Absent
Thyroglobulin Absent
Calcitonin Absent
p63 Present
Chromogranin Variable
Synaptophysin Variable
CD99 Present
Galectin3 Absent
Ki67 labeling index Variable
A
B
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(negativity for TTF-1 and thyroglobulin), or do they 
originate from thymic/branchial pouch remnants such as 
the main cells of solid cell nests? (10).
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Abstract. Androgen receptor (AR) signaling is a key pathway 
modulating prostate cancer (PCa) progression. Several steps 
in this pathway have been investigated in order to propose 
novel treatment strategies for advanced PCa. Total osteopontin 
(OPN) has been described as a biomarker for PCa, in addition 
to its role in activating the progression of this tumor. Based on 
the known effects of the OPNc splice variant on PCa progres-
sion, the present study investigated whether this isoform can 
also modulate AR signaling. In order to test this, an in vitro 
model was used in which LNCaP cells were cultured in the 
presence of conditioned medium (CM) secreted by PCa cells 
overexpressing OPNc (OPNc-CM). The activation of AR 
signaling was evaluated by measuring the expression levels of 
AR-responsive genes (ARGs) using quantitative polymerase 
chain reaction and specific oligonucleotides. The data demon-
strated that all nine tested ARGs (Fgf8, TMPRSS2, Greb1, 
Cdk2, Ndrg1, Cdk1, Pmepa1, Psa and Ar) are significantly 
upregulated in response to OPNc-CM compared with LNCaP 
cells cultured in CM secreted by control cells transfected with 
empty expression vector. The specific involvement of OPNc 
was demonstrated by depleting OPNc from OPNc-CM using 
an anti-OPNc neutralizing antibody. In addition, by using a 
phosphoinositide 3-kinase (PI3K)-specific inhibitor and AR 
antagonists, such as flutamide and bicalutamide, it was also 
observed that upregulation of ARGs in response to OPNc-CM 
involves PI3K signaling and depends on the AR. In conclu-
sion, these data indicated that OPNc is able to activate AR 
signaling through the PI3K pathway and the AR. These data 
further corroborate our previous data, revealing the OPNc 
splice variant to be a key molecule that is able to modulate key 
signaling pathways involved in PCa progression. 
Introduction
Osteopontin (OPN) is a matricellular glyco-phosphoprotein 
that is overexpressed in several tumor types (1). In prostate 
cancer (PCa) samples, OPN is upregulated and mediates tumor 
progression (2,3). Moreover, high circulating OPN levels 
have been found in PCa patients, thus highlighting a putative 
biomarker role for OPN in PCa. The OPN transcript can occur 
as three distinct splice variants, OPNa, OPNb and OPNc (4), 
with tissue- and tumor-specific roles (5). Nonetheless, the 
majority of studies have explored the function of the full-length 
OPN in PCa (6-9). Notably, we have previously demonstrated 
that the overexpression of OPNc, and to a lesser extent OPNb, 
promotes PCa progression (10). Indeed, OPNc upregulation in 
PCa cells, which correlates to the Gleason score, induces PCa 
cell proliferation, migration, invasion, metastasis and tumor 
formation in vivo, mainly mediated by the PI3K pathway. 
Overall, our studies have shed light on the potential use of 
OPNc as a diagnostic and prognostic biomarker for PCa (11). 
Disruption of androgen-mediated differentiation has been 
strongly linked to PCa development. Androgens, which bind 
to androgen receptors (AR) to elicit their cellular effects, 
are the primary sex hormones required for normal develop-
ment, maintenance and differentiation of the male phenotype. 
AR-regulated genomic events modulate cell differentiation 
and the development of tissues and organs (12). Further-
more, AR signaling has been indicated as a key step for PCa 
progression (13), in which circumstance there is crosstalk 
with multifunctional growth factor signaling pathways, such 
as EGF, FGF, IGF, TGF-β and VEGF (14), as well as with 
the PI3K/Akt/mTOR pathway (15). In addition, it has been 
proposed that castration-resistant PCa evolution may be the 
result of increased growth factor signaling activity associated 
with intratumoral testosterone production (16,17).
Despite the key importance of AR signaling on PCa 
progression, to date, there have been no studies demonstrating 
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the putative correlations among total OPN or its splice vari-
ants and AR signaling. The exception to this is a single study, 
which reported that upregulated Fgf-8, an androgen target 
gene, induces total OPN expression in PCa cells (18). 
The present study describes an in vitro model in which 
LNCaP androgen-responsive PCa cells are used to investigate 
the differential modulation of AR target genes by the condi-
tioned medium (CM) secreted by PCa cells overexpressing 
OPNc (OPNc-CM). 
Materials and methods 
Cell culture. The LNCaP cell line was used as an in vitro 
model to examine whether the AR pathway modulated by 
OPNc in PCa cells. The LNCaP cell line was obtained from 
the American Type Culture Collection (Rockville, MD, USA) 
and maintained in RPMI-1640 medium (Sigma-Aldrich, 
St. Louis, MO, USA) supplemented with 10% (v/v) heat-inacti-
vated fetal bovine serum (FBS; Invitrogen Life Technologies, 
Carlsbad, CA, USA), in the presence of 100 U/ml penicillin 
and 100 µg/ml streptomycin, at 37˚C in a 5% CO2 humidified 
incubator. The cells were maintained in medium containing 
charcoal/dextran-stripped FBS (CCS; Invitrogen Life Tech-
nologies) for three days prior to assaying the modulatory 
effect of OPNc-overexpressing secreted CM on LNCaP cell 
AR signaling. 
OPNc plasmid constructs, transfection and preparation of 
CM. In order to prepare the OPNc-CM, OPNc overexpres-
sion vector, which was kindly donated by Dr George Weber 
(Cincinnati University, Cincinnati, OH, USA), was used for 
transfections into a PC-3 prostate tumor cell line. The transfec-
tions were performed using Lipofectamine™ 2000, following 
the manufacturer's instructions (Invitrogen Life Technologies). 
Cell clones stably overexpressing OPNc and empty vector 
(EV) control clones were selected using G418 at 800 µg/ml. 
Data from our previous study demonstrated that PC-3 stably 
transfected cells contain high levels of the protein and RNA 
transcript of OPNc in relation to their endogenous levels in 
EV-transfected cells (10). In order to prepare the CM secreted 
from OPNc-overexpressing cells and those expressing EV, cell 
number was normalized by plating PC-3 cells at the same cell 
density (5x105 cells/well). Subsequent to reaching 80% cell 
confluence, the cells were washed twice with phosphate-buff-
ered saline and cultured with RPMI in serum-free conditions 
for 48 h. Collected CM was clarified by centrifugation at 
1,200 x g for 5 min. All assays were performed using freshly 
prepared CM. CM produced by OPNc-overexpressing cells 
or those transfected with EV controls, termed OPNc-CM and 
EV-CM, respectively, were used for the LNCaP assays over 
24 h.
LNCaP assays and AR signaling analysis. The LNCaP cells 
were plated in 2.0 ml RPMI without antibiotics at a density of 
1.5x105 cells/well, and maintained in medium containing CCS 
(Invitrogen) for three days prior to treatment with OPNc-CM 
or EV-CM, containing either anti-OPNc neutralizing anti-
body, LY294002, flutamide and bicalutamide, individually 
or in distinct combinations. LY294002, a PI3K inhibitor, 
was obtained from Cell Signaling Technology Inc. (Danvers, 
MA, USA). The LNCaP cells were cultured and treated with 
50 mM LY294002. For OPNc depletion in OPNc-CM, 4 mg/
ml of an anti-OPNc antibody (Gallus Immunotech, Cary, NC, 
USA) was used. This antibody was produced by immunizing 
a chicken with a peptide representing the splice junction of 
OPNc (Ac-SEEKQNAVSCCOOH). Specific binding to OPNc 
has been demonstrated by the manufacturers (Gallus Immuno-
tech), and we have previously demonstrated that this antibody 
blocks PC3 cell proliferation in response to OPNc-overex-
pression (10). OPNc-CM was pre-incubated with anti-OPNc 
antibody for 2 h prior to LNCaP cell treatment. Assays using 
AR antagonists were performed using OPNc-CM containing 
100 nM flutamide or 10 µM bicalutamide (Sigma-Aldrich). 
The LNCaP cells were allowed to grow for 24 h following the 
treatments, and then harvested for the analysis of gene expres-
sion. The mRNA expression levels of the androgen-responsive 
genes (ARGs), Ar, Psa, Tmprss2, Ndrg1, Greb1, Fgf8, Cdk1, 
Cdk2 and Pmepa1, were analyzed using quantitative reverse 
transcription polymerase chain reaction (RT-qPCR).
Total RNA isolation and RT. LNCaP total RNA was purified 
using the RNeasy Mini kit, using RNase-free DNase (Qiagen, 
Hilden, Germany) following the RNA purification process. 
Total RNA (1 µg) was reverse-transcribed into cDNA using 
a Superscript II First-Strand Synthesis System for RT-PCR 
(Invitrogen). The resulting cDNA was quantified using a 
NanoDrop™ 1000 spectrophotometer (Thermo Scientific, 
Waltham, MA, USA).
qPCR. qPCR was performed using a CFX96 Real-Time 
System with a C1000 Thermal Cycler (Bio-Rad, Hercules, CA, 
USA), and SYBR Green (Applied Biosystems, Foster City, CA, 
USA), according to the manufacturer's instructions. The oligo-
nucleotide primers used for the qPCR are listed in Table I. 
The expression levels of Ar, Psa, Tmprss2, Ndrg1, Greb1, Fgf8, 
Cdk1, Cdk2 and Pmepa1 were normalized based on the refer-
ence gene (18S rRNA), using the ΔΔCT relative quantification 
method. Conditions for PCR amplification were as follows: 
50˚C for 2 min and 94˚C for 5 min, followed by 40 cycles at 
94˚C for 30 sec, 50˚C for 30 sec and 72˚C for 45 sec, and a final 
extension at 72˚C for 15 min. To evaluate the specificity of the 
PCR products, a melting curve analysis was performed after 
each reaction.
Statistical analyses. All the statistical analyses were performed 
using SPSS software version 18.0 (SPSS, Inc., Chicago, IL, 
USA). Data were analyzed by comparison using a two-tailed 
t-test, and P<0.05 was considered to indicate a statistically 
significant difference.
Results and Discussion
An improved understanding of the molecular mechanisms 
triggering AR signaling in PCa cells strongly relies on 
dissecting gene products and factors able to stimulate this 
hormonal pathway. Moreover, novel therapeutic strategies 
against PCa, mainly in recurrent disease, may attempt to target 
AR pathway elements or its stimulatory mechanisms (17). 
We previously demonstrated that the OPNc splicing isoform 
stimulates several PCa tumor progression features, including 
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cell proliferation, migration, invasion, metastatic potential 
and tumor formation in vivo (10). Although other studies have 
shown that total OPN stimulates LNCaP cell proliferation in 
the presence of EGF (19), to date, information about the effect 
of distinct OPN splice variants on AR pathway modulation in 
PCa is lacking. We have previously shown that the majority of 
the OPNc-mediated PCa features are specifically modulated 
by OPNc-CM (10). In addition, we have demonstrated that 
OPNc-CM secreted by PC3 cells differentially modulates 
several cancer-related genes (20). 
The present study used OPNc-CM to investigate the modu-
lation of AR signaling, by evaluating the expression patterns 
of ARGs in LNCaP androgen-responsive cells. OPNc-CM, but 
not EV-CM, significantly increased the expression of all nine 
ARGs tested (Fig. 1). These data support our previous findings 
that OPNc stimulates several aspects of PCa progression (10), 
possibly through an AR signaling-mediated pathway. All tested 
ARGs have been described with regard to the modulation of 
PCa growth and progression (21); the Fgf8 (22), Cdk1 (23), 
Cdk2 (24) and Greb11 (25) gene products are classically 
involved in prostate cell growth and proliferation. Although 
Psa has been classically described as an oncogene in PCa, 
promoting tumor progression and metastasis, its function as 
a tumor suppressor molecule has been also documented (23). 
NDRG1-ERG fusions, which encode a chimeric protein, are 
also regulated by androgens and correspond to one of the 
recurrent erythroblast transformation-specific rearrangements 
observed in PCa. Presumably, Ndrg1 promotes angiogenesis, 
metastasis and drug resistance (26). Tmprss2, which is another 
component of typical androgen-regulated PCa translocations, 
is expressed in PCa cells and contributes to prostate tumorigen-
esis (27,28). By contrast, the Pmepa1 gene, although a direct 
target of the AR, has been described as negatively regulating 
prostate epithelium cell growth, in addition to the AR protein 
levels in a range of cell culture models (29,30).
In order to investigate the specificity of the effect of OPNc 
on the upregulation of tested ARGs, LNCaP cells were cultured 
with OPNc-CM pre-treated with an anti-OPNc polyclonal 
neutralizing antibody. The expression of seven out of nine 
of the ARGs (Fgf8, Tmprss2, Greb1, Cdk2, Ndrg1, Cdk1 and 
Pmepa1) was not increased when OPNc activity was abrogated 
by this anti-OPNc antibody. These data indicated the specific 
effect of OPNc on inducing the upregulation of these seven 
ARGs in response to OPNc-CM (Fig. 1A-G). Conversely, AR 
transcript upregulation was sustained regardless of the OPNc 
activity, therefore suggesting that secreted factors contained in 
OPNc-CM, other than OPNc, could mainly contribute to AR 
transcript expression in PCa cells. Lastly, abrogation of OPNc 
activity further stimulated PSA expression in the LNCaP 
cells (Fig. 1I), thus indicating that secreted OPNc is a partial 
inhibitor of PSA expression in the PCa cell line. These results 
indicate that direct or indirect OPNc-mediated mechanisms, 
either in the OPNc-CM or within the LNCaP cells, could 
suppress PSA transcript expression. It has previously been 
demonstrated that during PCa progression, intracellular PSA 
levels are lower in the malignant rather than the normal pros-
tatic epithelium, being further reduced in poorly-differentiated 
tumors, despite the high serum levels of PSA detected in 
Table I. Oligonucleotide primers used for analysis of RT-qPCR expression of androgen receptor-responsive genes.
Gene Accession number Primer (5'-3')
Pmepa1 NC_000020.11 F: CATGATCCCCGAG CTGCT
  R: TGATCTGAACAAACTCCAGCTCC
TMPRSS2 NC_000021.9 F: CTGGTGGCTGATAGGGGATA
  R: GGACAAGGGGTTAGGGAGAG
Ndrg1 NC_000008.11 F: CGAGACTTTACATGGCTCTG
  R: GCATTGATGAACAGGTGCAG
Greb1 NC_000002.12 F: AAGGAGGGCTGGAAACAAAT
  R: CATTGTGGCCATTGTCATCT
Psa NC_000019.10 F: TGCATCAGGAACAAAAGCGTGA
  R: CCTGAGGCGTAGCAGGTGGTCCCCAG
Ar NC_000023.11 F: GGTGAG CAGAGTGCCCTATC
  R: GAAGACCTTGCAGCTTCCAC
Fgf8 NC_000010.11 F: CAACTCTACAGCCGCACCAGC
  R: TGCTCTTGGCGATCAGCTTC
Cdk1 NC_000010.11 F: AAGTGAAGAGGAAGGGGTTCC
  R: CCAAAAGCTCTGGCAAGGCC
Cdk2 NC_000012.12 F: ATGGGTGTAAGTACGAACAGG
  R: TTCTGCCATTCTCATCGG
18S NT_167214.1 F: AACCCGTTGAACCCCATT
  R: CCATCCAATCGGTAGTAGCG
F, forward; R, reverse.
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patients with PCa. Moreover, PSA can function as a tumor 
suppressor by inhibiting tumor angiogenesis in PCa cells (31). 
In fact, regardless of the widespread use of PSA as a PCa 
marker, it has been established that the modulation of PSA 
expression and the proliferation of PCa cells are independently 
regulated during the development and progression of the 
disease. It is notable that multiple factors have been indicated 
to be involved in the transcriptional transactivation of PSA; 
mainly AR, but also various growth factors and extracellular 
matrix proteins (32,33). We hypothesize that this could be 
the case for OPNc. Hence, it is possible that OPNc or growth 
factors secreted in response to the overexpression of this splice 
Figure 1. Conditioned medium (CM) secreted by PCa cells overexpressing OPNc (OPNc-CM) significantly activates the expression of AR responsive genes in 
LNCaP cells. Graphs showing relative RNA quantification of (A) Fgf8, (B) Tmprss2, (C) Greb1, (D) Cdk2, (E) Ndrg1, (F) Cdk1, (G) Pmepa1, (H) Ar and (I) Psa, 
in LNCaP cells cultivated with OPNc-CM compared with cells cultivated with the empty-vector CM (EV-CM), as described in the Materials and methods 
section. In order to test OPNc-specific effects, anti-OPNc polyclonal neutralizing antibody (α-OPNc), flutamide (FL), bicalutamide (BL) and PI3K inhibitor 
(LY), were used. 18S RNA was used as a constitutive gene in all these assays. Data are represented as the mean ± standard deviation. All experiments were 
biological replicates repeated a minimum of three times. *P<0.0001 vs. OPNc-CM cultivated cells. **P<0.0001 vs. EV-CM cultivated cells. 
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variant could negatively modulate PSA expression in LNCaP 
cells, using androgen-dependent and/or independent mecha-
nisms, in order to favor PCa progression. 
The precise mechanisms responsible for the aberrant AR 
expression in PCa remain elusive (34). The data from our 
studies has shed light on the complexity of the phenomenon, 
indicating that not only secreted OPNc, but also other secreted 
factors in response to OPNc overexpression, positively modu-
late AR signaling in LNCaP cells. In this context, other studies 
have also described the stimulatory effects of extracellular 
and intracellular signaling molecules on AR-mediated tran-
scription, such as heparin-binding EGF-like growth factor, 
activin A, Smad2 and angiotensin II receptor type 1 (35). 
Further studies should be performed to determine the factors 
produced in response to OPNc overexpression, as well as the 
molecular mechanisms these molecules can induce in order to 
modulate AR-mediated signaling in PCa cells. 
Our previous studies recently demonstrated that OPNc 
modulates the PI3K pathway (10), as well as other key cancer 
pathways (20). As a consequence, we hypothesize that OPNc 
modulates the signaling of several growth factors in PCa 
cells, which in turn, induce ARG expression, exactly as previ-
ously reported for other oncoproteins, such as PLK1 (36), 
ETV1 (37) and ELK1 (38). It is possible that OPNc can also 
stimulate LNCaP endogenous androgen synthesis, similar to 
the role of interleukin-6 on the de novo synthesis of intracrine 
androgens (39). Indeed, our previous data have clearly shown 
that PI3K mediates several OPNc tumor progression features 
in PC3 cells overexpressing this splice variant (10). In the 
present study, it was demonstrated that the PI3K pathway was 
also involved with OPNc-mediated ARG expression in the 
LNCaP cells, with the exception of PSA, whose expression 
was not abrogated by the PI3K inhibitor LY294002 (Fig. 1). 
Altogether, these results shed light on the PI3K pathway as 
a key mechanism for OPNc-mediated effects on LNCaP 
cells (10,15). Upon further consideration of the crosstalk 
between the PI3K and AR pathways, we postulate that OPNc 
can modulate each pathway (15). In this context, we propose 
that the observed PSA upregulation, regardless of the PI3K 
pathway activity status, could be mainly due to the depletion 
of OPNc-activated signals as an inhibitor of PSA expression, 
similar to the experimental conditions in which the anti-OPNc 
antibody was used to abrogate OPNc activity in OPNc-CM. 
We finally propose that the tumor progression features modu-
lated by OPNc in PCa cells may be derived, at least in part, 
from the PI3K-activated upregulation of ARGs. 
Significantly, the present study demonstrated that AR 
mediates the OPNc-CM-activated upregulation of all ARGs 
tested, as the observed phenomena were significantly reversed 
when the LNCaP cells were pre-treated with the AR antago-
nists flutamide and bicalutamide (Fig. 1). The expression of the 
OPNc-CM-activated ARGs was also assessed in the LNCaP 
cells in the presence of LY294002 or bicalutamide. With the 
exception of AR, the expression of all other ARGs was signifi-
cantly reduced. Also, the combined treatment with LY294002 
and bicalutamide promoted a stronger effect on the inhibition 
of the OPNc-CM-mediated upregulation of the ARGs in the 
LNCaP cells, as compared to the individual bicalutamide or 
LY294002 treatments. Therefore, these data could provide 
support to strategies that could target the PI3K and AR signaling 
pathways as an efficient approach to inhibit PCa progression, 
as discussed in the study by Bitting and Armstrong (15).
In conclusion, to the best of our knowledge, the present 
study is the first to use PCa cells overexpressing OPNc and 
report that OPNc and/or other secreted factors are key 
elements modulating the AR signaling pathway. Briefly, the 
data indicate that OPNc-CM induces the expression of ARGs 
in LNCaP cells mainly through the activation of the PI3K 
and AR pathways; the latter being activated either by secreted 
OPNc-CM or LNCaP endogenously-produced AR ligands. 
This reinforces that these signaling pathways have key roles 
in mediating OPNc-related tumor progression features in 
PCa. Further studies should investigate the specific molecular 
pathways by which OPNc modulates the AR signaling and the 
secreted factors expressed in response to OPNc overexpression 
that could also contribute to AR signaling activation. Based 
on these results, therapeutic strategies trying to target OPNc 
and its downstream PI3K and AR pathways should also be 
considered in order to negatively modulate PCa progression.
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